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Inflammatory bowel disease and the need for non-invasive clinical tests
The course of inflammatory bowel disease (IBD) is characterised by a chronic pattern of 
relapse and remission of gastro-intestinal inflammation. IBD usually develops during the 
teenage years or young adulthood and consists of two phenotypes: Crohn’s disease (CD), 
which is characterised by segmental inflammation of the entire gastro-intestinal tract, and 
ulcerative colitis (UC) in which inflammation exclusively affects the colorectal area. Chronic 
(subclinical) mucosal inflammation is associated with a variety of severe complications and 
irreversible bowel damage leading to the need for bowel surgery and a lower quality of 
life[1]. Therefore, deep remission and continuous tight monitoring of patients is required.
In clinical practice, the diagnostic work up and follow-up of IBD patients includes endoscopic 
assessment, which is an invasive and costly procedure [2]. The burden is especially high 
in children, who usually need hospitalization for administration of laxatives by nasogastric 
tube prior to ileocolonoscopy, which is performed under general anaesthesia. As such, non-
invasive biomarkers have been proposed for the purpose of IBD detection and follow-up. 
Faecal calprotectin is the most commonly used non-invasive biomarker to diagnose and 
monitor of IBD. This marker is characterised by a high sensitivity for mucosal inflammation 
(0.98, 95% CI 0.95–0.99) but lacks specificity for IBD (0.68, 95% CI 0.50–0.86), consequently 
leading to the performance of unnecessary endoscopies[3]. In addition, early prediction of 
changes in disease state adds to the timely management and treatment adjustment for IBD 
patients, which improves disease outcome and prevents drug-related side effects[4]. No 
non-invasive biomarkers have yet been validated for purpose of disease course prediction. 
Colorectal neoplasia: opportunities and pitfalls of screening 
and surveillance programs
Colorectal cancer (CRC) ranks second in terms of cancer mortality world-wide[5, 6]. Its overall 
5-year survival rate is 64.4% for colon cancer and 66.6% for rectal cancer, depending on the 
cancer stage at diagnosis. Early detection and treatment are critical factors in the course 
and prognosis of CRC, as the survival rate decreases with disease progression[7]. Most of 
the CRC lesions develop from adenomas in the so-called adenoma-carcinoma sequence, 
in which it is thought that a series of mutations result in carcinogenic development. 
Identification and removal of high-risk adenomas (advanced adenomas) has been described 
to decrease CRC incidence and mortality [8, 9].
In the US, the CRC screening program is mainly performed by 10-yearly colonoscopy in 
which all adenomas are required to be removed, whereas in Europe, guidelines recommend 
a more cost-effective approach, using faecal immunochemical tests (FIT) to select high-risk 
individuals for endoscopic screening[10, 11]. However, based on FIT, CRC is missed in 1-47% 
of the cases, advanced adenomas in 43-61% of the cases and for non-advanced adenomas, 
this number is even higher[12]. In addition, specificity is suboptimal, as approximately 7% of 
the performed tests provide false-positive results leading to the performance of unneeded 
colonoscopies. After the first screening endoscopy, surveillance is recommended at set 
intervals, dependent on the characteristics and number of adenomas removes, as these 
patients remain at risk of recurrent adenoma growth[13]. The yield of pathology in this 
Chapter 1. General introduction and outline
12
surveillance program is low, while interval-cancer still occurs (for example, 1.8% CRC yield vs 
0.6% interval cancers)[14, 15]. No non-invasive markers have yet been validated to improve 
the currently used, FIT-based, CRC screening program and timing of the surveillance 
endoscopies.
The potential of omics platforms for disease detection and follow-up
Omics data analysis is a biological system approach aimed to characterize a medium 
(e.g. mucosal biopsy, urine, breath, stool) by selection and/or quantification of important 
biological features. This is mostly done based on statistical machine learning methods using 
high-throughput data after deep phenotyping of the material on these specific features. 
The biological features may exist of various omics branches, such as the genome (DNA), 
transcriptome (RNA), proteome (protein spectra), metabolome (metabolite composition) 
and microbiome (bacterial composition). By analysing and combining these omics platforms, 
new associations can be revealed between different layers of the human metabolism, 
leading to new insights into pathophysiological pathways and host-pathogen interaction. 
In addition, this type of ‘multi-omics’ analysis often allows for the selection of relevant 
biomarkers for disease detection and follow-up. This leads to a more personalised medical 
approach compared to current widely used screening markers like FIT and FCP, which hold 
less disease-specific characteristics.
A relatively new technique within the omics spectrum is the analysis of volatile organic 
compounds (VOC), the so-called volatolome. These gaseous carbon-based molecules 
originate from both physiological and pathophysiological processes in the human body 
and are considered to reflect the human metabolism, the gut microbiota, its function and 
interaction with the host [16, 17]. VOCs can be captured non-invasively from all conceivable 
bodily excrements, including urine, breath, blood and faeces. The use of VOC profiles, or so 
called ‘smell prints’, is increasingly considered to have potential as biomarker in the diagnostic 
work-up and monitoring of various gastrointestinal diseases. In Figure 1, an example 
of such a ‘smell print’ obtained by an advanced ‘electronic nose (eNose)’ is presented.
Figure 1. This figure originates from a study in which 
we aim to predict the disease course of inflammatory 
bowel disease, presented in chapter eight. Depicted 
is an example output of the gas chromatography 
– ion mobility spectrometry instrument. The Y-axis 
represents retention time from the gas chromatography 
column, the X-axis represents drift time through the 
ion mobility spectrometry column. Darkness intensity 
depicts the level of measured metabolite. In this 
figure, bullets mark the locations in the VOC profiles 
that discriminate cases from controls.
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1The majority of studies on faecal VOCs have been performed using gas chromatography-
mass spectrometry (GC-MS), allowing for identification of individual VOCs on molecular 
level. This technique is expensive, time-consuming and requires specialised personnel[18]. 
Pattern-recognition based eNose techniques, such as conducting polymers, field 
asymmetric ion mobility spectrometry (FAIMS), and gas chromatography – ion mobility 
spectrometry (GC-IMS) are examples of instruments that are lower in expense and allow 
for fast measurements, underlining their potential as non-invasive biomarkers for clinical 
practice. Though, there is little knowledge on robustness of these measurements. 
This thesis focuses on the potential of eNose measurements for clinical practice. In addition, 
this thesis describes the exploration of non-invasive biomarkers for the detection and follow-
up of inflammatory bowel disease and colorectal neoplasia using various ‘omics’ platforms. 
OUTLINE OF THE THESIS
This thesis is divided in four parts. In part I, we investigate factors of influence on faecal 
VOC composition and propose multiple methods to correct for these factors. In part II, we 
assess the diagnostic potential of faecal VOC compounds for the detection and follow-up 
of paediatric and adult IBD. In part III, we investigate whether the liquid faecal metabolome 
may serve as non-invasive diagnostic biomarker for paediatric IBD. In part IV, the potential 
of multiple omics platforms for the detection and surveillance of colorectal neoplastic 
laesions are described. 
The first part consists of three chapters, in which important confounding factors and effect-
modificating variables for faecal VOC analysis are described. In the second chapter, the 
effects of various sampling protocols on diagnostic accuracy of VOC analysis are assessed. 
We define a standard operating procedure which ensures maximum accuracy for disease 
detection. In the third chapter, we describe the influence of various demographical and 
lifestyle factors, such as age, body-mass index, gender, smoking habits, co-morbidity, 
medication use and diet. Correction methods for these variations are proposed. In chapter 
four, we evaluate the influence of sensor drift on diagnostic accuracy of faecal VOC profiles 
for the detection of IBD. In this chapter, the importance of correction for this drift is visualised 
and correction methods are proposed. 
The second part of this thesis consists of four chapters all focussing on detection of IBD 
based on faecal VOC profiles. In chapter five, we describe the diagnostic potential of the 
faecal smell patterns to differentiate between paediatric patients with IBD, symptomatic 
patients without IBD and asymptomatic healthy controls. In chapter six, we compare 
diagnostic accuracy of faecal and urinary VOC profiles for the detection of inflammatory 
bowel disease in a paediatric cohort. In chapter seven, the potential of faecal VOC profiles 
to detect IBD and IBD activity is presented in a large multi-centre cohort of adult patients. 
In chapter eight, a prospective follow-up of IBD patients is described in which we aim to 
predict IBD disease course based on faecal VOC profiles. 
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In the third part, we assess the potential of the liquid faecal amino acid profiles (aminogram) 
as diagnostic biomarker for paediatric IBD patients. In chapter nine, we describe the 
potential of faecal aminograms for the detection of de novo treatment-naïve IBD patients. 
In chapter ten, we hypothesize on the pathophysiology underlying the observed increase in 
faecal aminogram profiles in paediatric IBD patients. In chapter eleven, our previous study 
outcomes are validated by comparing both faecal and serum aminograms in an intention-
to-diagnose setting comparing paediatric IBD patients and patients presenting with IBD-
like symptoms, in whom IBD was excluded. 
The fourth part of this thesis consist of four chapters evaluating the potential of multiple 
omics platforms for the detection and surveillance of colonic neoplasia. The twelfth 
chapter provides an overview of the available literature on the evidence of faecal VOCs 
as biomarker for CRC and adenoma detection. In the thirteenth chapter, the potential 
of faecal scent patterns for the discrimination between patients with colorectal cancer, 
advanced adenomas, large adenomas, small adenomas and controls is assessed in a large 
multi-centre cohort. In chapter fourteen, we integrate data on the faecal microbiota, human 
faecal proteome and faecal amino acid profiles in a multi-centre cohort of patients with 
CRC, adenomas and controls. We present novel biomarker panels outperforming accuracy 
of the currently used CRC screening test for both CRC and adenomas and integrate these 
omics platforms to reveal associated pathologic pathways. In chapter fifteen, the regulation 
of adenoma-associated gut microbiota and faecal aminograms is assessed in a prospective 
cohort of adenoma patients, pre- and post-polypectomy, and control patients, pre- and-
post colonoscopy, to evaluate whether these techniques may serve as guidance for the 
timing of surveillance endoscopy. 
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Faecal volatile organic compounds (VOCs) are increasingly considered as 
potential non-invasive, diagnostic biomarkers for various gastrointestinal 
diseases. Knowledge of influence of sampling conditions on VOC outcomes 
is limited. We aimed to evaluate effects of sampling conditions on faecal VOC 
profiles and to assess under which conditions an optimal diagnostic accuracy 
in the discrimination between paediatric inflammatory bowel disease (IBD) and 
controls could be obtained.
Methods
Faecal samples from de novo treatment-naïve paediatric IBD patients and healthy 
controls (HC) were used to assess effects of sampling conditions compared to 
the standard operating procedure (reference standard), defined as 500mg of 
sample mass, diluted with 10mL tap water, using field asymmetric ion mobility 
spectrometry (FAIMS). 
Results
A total of 17 IBD (15CD and 2 UC) and 25 HC were included. IBD and HC could 
be discriminated with high accuracy (accuracy=0.93, AUC=0.99, p<0.0001). 
Smaller faecal sample mass resulted in a decreased diagnostic accuracy (300mg 
accuracy=0.77; AUC=0.69, p=0.02; 100mg accuracy=0.70, AUC=0.74, p=0.003). 
A loss of diagnostic accuracy was seen towards increased numbers of thaw-
freeze cycles (one cycle: accuracy=0.61, AUC=0.80, p=0.0004, two cycles: 
accuracy=0.64, AUC=0.56, p=0.753, three cycles: accuracy=0.57, AUC=0.50, 
p=0.5101) and when samples were kept at room temperature for 180 minutes 
prior to analysis (accuracy=0.60, AUC=0.51, p=0.46). Diagnostic accuracy of 
VOC profiles was not significantly influenced by storage duration differences of 
20 months.
Conclusion
Application of 500mg sample mass analysed after one thaw-freeze cycle, showed 
best discriminative accuracy for differentiation of IBD and HC. VOC profiles 
and diagnostic accuracy were significantly affected by sampling conditions, 





Analysis of volatile organic compounds (VOC) is a relatively new technique within the field 
of metabolomics. VOCs are carbon-based chemicals originating from both physiological 
and pathophysiological processes in the human body. Faecal VOCs are considered to 
reflect microbiota composition, function and interaction with the host [1, 2]. They are 
increasingly considered to have potential as biomarker in the diagnostic work-up and 
monitoring of various gastrointestinal diseases, e.g. inflammatory bowel disease (IBD), 
colorectal cancer and even sepsis [3-11]. Various studies have demonstrated the diagnostic 
potential of VOCs in both paediatric and adult IBD populations, by analyzing VOCs deriving 
from urine, exhaled breath and faecal [6, 12-14]. The majority of studies on faecal VOCs 
have been performed using Gas Chromatography/Mass Spectrometry (GC/MS), allowing 
for identification of individual VOCs on molecular level. This technique is expensive, time-
consuming and requires specialised personnel and is therefore not suitable for utilization in 
a clinical setting [15]. Pattern recognition based techniques, like electronic noses (eNose) 
and field asymmetric ion mobility spectrometry (FAIMS), are examples of instruments that 
are lower in expense and faster, allowing for their application as a non-invasive biomarker in 
clinical practice. However, traditional eNoses contain sensors that are notorious for batch-
to-batch variation, fouling and ageing effects and sensors drift [14, 16]. Novel measurement 
of VOCs using physical techniques, coupled with pattern recognition, like FAIMS, have a 
higher sensitivity and minimal drift. It achieves separation by measuring the differences in 
mobility of ionised molecules in high-electric fields.  
Data on the potential influence of sampling and storage methods on faecal VOC profiles are 
scarce. We aimed to evaluate effects of environmental factors and sampling conditions on 
faecal VOC profiles, using FAIMS. In addition, we aimed to assess under which conditions 
an optimal diagnostic accuracy could be obtained in the differentiation between paediatric 
IBD and controls. This may lead to the development of rationale-based standardization 
protocols on faecal VOC analysis, paving the way towards reliable comparisons between 




This case-control study was performed at the outpatient clinic of the paediatric 
gastroenterology departments in two tertiary referral hospitals, the VU University medical 
centre (VUmc) and the Emma Children’s Hospital, Academic Medical Centre (AMC), both 
located in Amsterdam, The Netherlands. 
Study participants
Inflammatory bowel disease 
IBD subjects were selected from an existing cohort of de novo treatment-naïve paediatric 
patients, consisting of  125 subjects (78CD, 47UC), aged 4 to 17 years, recruited between 
October 2013 and July 2017 at the VU University Medical Centre (VUmc) and Academic 
Medical Centre (AMC). Diagnosis of IBD was based on endoscopic, histologic and 
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radiologic findings, according to the revised Porto-criteria[17]. Localisation and behaviour 
of IBD were classified during endoscopy, based on the Paris Classification[18]. Physician 
Global Assessment (PGA) combined with levels of C-reactive protein (CRP) and faecal 
calprotectin (FCP) were used as an index of the clinical disease activity [19, 20]. All IBD 
patients were asked to collect a faecal sample prior to endoscopy and bowel preparation 
[14]. Inclusion criteria also included sufficient faecal material for VOC analysis (3.4 grams 
per subject). Exclusion criteria were use of antibiotics, probiotics or immunosuppressive 
therapy in the three months prior to inclusion, a concomitant diagnosis of a gastrointestinal 
disease or immunocompromised disease (i.e. HIV, leukemia) and abdominal surgery (except 
for appendectomy). In addition, children with proven infectious colitis (parasites in stools, or 
positive stool culture for Salmonella spp., Shigella spp.,Yersinia spp., Campylobacter spp., 
or toxigenic Clostridium spp.) were excluded. 
Healthy controls
Healthy controls (HC) were children aged 4 to 17 years selected from elementary and 
high schools in North-Holland, the Netherlands between June 2016 and December 2016. 
All participants were asked to collect a faecal sample, and complete a questionnaire on 
abdominal symptoms, bowel habits, including consistency of stool using the Bristol stool 
chart, medication use and medical history[21]. Exclusion criteria for HC were similar to IBD, 
with the addition of diagnosis of IBD and/or a functional gastrointestinal disorder according 
to the Rome IV criteria based on the questionnaires. 
Matching procedure
From the original cohort of 125 IBD patients, 106 were not eligible for this study due to 
insufficient quantities of the faecal samples. A total of 17 IBD patients (15CD, 2UC)  could 
be matched on age at sample collection and gender with 25 participants in the HC group. 
Ethical considerations
This study was approved by the Medical Ethical Review Committee (METc) of the VU 
University Medical Centre (VUmc) under file number 2016.393, and by the local medical 
ethical committee of the Emma Children’s Hospital (AMC). Written informed consent was 
obtained from all parents, and from the children in case of age over 12 years.
Sample collection IBD and controls
All study participants collected fresh faecal samples in a stool container (Stuhlgefäß 
10ml, Frickenhausen, Germany). Patients with IBD collected their faecal sample prior to 
endoscopy and bowel lavage. Participants were instructed to store the faecal samples in 
the freezer at home directly after collection. The samples were transported to the hospital in 
cooled condition, using cooling elements or ice cubes. Directly upon arrival in the hospital 
the samples were stored in the freezer (-24 °C) until analysis.
Sample preparation IBD and controls
The influence of faecal samp le mass, number of thaw-freeze cycles, duration of storage in 
room temperature, were assessed by comparing VOC-profiles derived from subsamples 
taken from the original faecal sample of each HC  and IBD subject. The subsamples were 
weighted on a calibrated scale (Mettler Toledo, AT 261 Delta Range, Ohio, United States), 
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labelled and re-stored in a -24°C freezer until further handling. We compared the variables 
of interest with our standard operating procedure (reference standard), defined as a mixture 
of 500mg of faecal, diluted with 10mL tap water and kept in room temperature for 10 
minutes prior to analysis. These reference standard settings were chosen since they were 
used in several previous studies on faecal VOC profiling in a range of gastroenterology 
diseases and have provided us with positive results [14, 22].
Variables of interest
Effect of faecal sample mass on diagnostic accuracy of faecal VOC profiles was assessed 
by comparing subsamples weighing 100mg and 300mg with the reference standard mass 
of 500mg. 
The influence of the number of thaw-freeze cycles on the diagnostic accuracy was analysed 
by comparing the reference standard to subsamples, which underwent one, two and three 
additional thaw-freeze cycles. For every additional cycle, the sample was kept at room 
temperature for 10 minutes and subsequently kept on dry ice until the sample was frozen. 
In order to assess the effect of duration of storage at room temperature on the diagnostic 
accuracy, VOC from samples kept at room temperature (18 degrees) for 180 minutes were 
compared to the reference standard. Variables of interest are presented in Table 1.
As described above, the effect of every variable on the diagnostic accuracy of faecal VOCs 
were assessed by comparing IBD subjects with HC. In addition, we assessed the influence 
of the variables on the VOC pattern. By combining the HC and IBD subjects, we were able 
to compare the variables to the reference standard. 
Table 1. Variables of interest




Time out of freezer 
(min)
Reference standard 500 0 10 
Mass variable 1 300 0 10 
Mass variable 2 100 0 10 
Thaw-freeze variable 1 500 1 10 
Thaw-freeze variable 2 500 2 10 
Thaw-freeze variable 3 500 3 10 
180 minutes out of freezer 500 0 180 
Storage time 1 500 0 10 
Storage time 2 500 0 10 
FAIMS analysis
For this study a commercially available FAIMS instrument (Lonestar®, Owlstone, Cambridge, 
UK) was used. Prior to the analyses, the FAIMS instrument was checked for contamination 
using air and water blanks. The faecal samples were thawed to room temperature for ten 
minutes prior to VOC analysis, and manually homogenised after diluting the faecal sample 
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with 10mL tap water by using a micropipette of 5000µl. The Lonestar® was setup as used 
in previous studies[14, 22, 23]. To transport the sample headspace into the Lonestar®, 
compressed air (0.1MPa) was used as the carrier gas. This air meets the European 
Pharmacopoeia criteria for medical air and its composition, pressure, temperature and 
water density are checked for continuality regularly. When entering the Lonestar, this carrier 
gas is filtered by a Carbon filter (Restek, Bellefote, VS). The flow rate was set on 2.0L/min, 
the temperature for the sample holder was set at 35°C, for the lid at 70°C and 100°C for the 
filter region. After every sample run, the Lonestar® was refreshed using 5mL of tap water. 
Furthermore, the dispersion field was set between 0% and 100% (in the ratio of the high 
electric field to low electric field) and passed through 51 equal settings.  The compensation 
voltage was set between +6V and -6V in 512 steps for each dispersion field. All samples were 
analysed randomly. Each faecal sample was analysed three times subsequently, resulting in 
three matrices, taking 540s to perform. In order to preclude environmental effects, the 
first matrix was excluded from analyses since this measurement includes the heaspace gas 
generated from both the sample and the environment (e.g. air in tubes). For the statistical 
analysis, only the second matrix was used for optimal diagnostic potential. The third 
measurement was made as a back-up file, but was not used in this study. The raw data output 
was analysed at the School of Engineering, University of Warwick, United Kingdom[15].
Statistical analysis
The demographic data of each group (IBD patients and healthy controls) were compared 
using the Man-Whitney-U test for non-parametric continues data, and the Fisher’s exact 
test for dichotomous data using SPSS Statistics (version 22, IBM, NY, USA). As previously 
reported, the FAIMS produces high dimensional data in terms of the number of features 
and covariates measured per sample. Therefore, a data compression was performed before 
feature identification and classification. Each FAIMS data (sample) consists of 52224 data 
points in a 2D matrix. Data compression was undertaken by applying a 2D discrete wavelet 
transformation. For the variables of interest in which the accuracy to discriminate between 
IBD and HC was assessed, feature selection and classifier training were performed to 90% of 
data (training set) and class predictions were produced from 10% of the data set (test set), in 
a 10-fold cross validation. The Wilcoxon-rank-sum test was used to calculate p-values in the 
training sets to identify which features best for disease prediction. From this, 4 statistically 
important features were used. Four classification algorithms were applied, Sparse Logistic 
Regression, Random Forrest, Gaussian Process and Support Vector Machine. A receiver 
operator characteristic (ROC) curve was created to predict the area under the curve (AUC), 
p-values, sensitivity, specificity, positive predictive value (PPV), negative predictive value 
(NPV) and diagnostic accuracy. For the influence of sampling method on VOC composition, 
in which IBD and HC samples were combined and measurements of the same subjects 
samples were repeated, data were analysed using SPSS statistics 22 (IMB). The raw sensor 
data was recombined with feature selection using the Wilcoxon rank sum tests. Paired t-tests 
were performed to assess the potential of the features to discriminate between sample 
handling methods. Scatterplots for the discrimination between samples were created for 
each variable of interest. Axes depict the recombination of the raw sensor data by means 
of features. Individual VOC profiles are illustrated as marked points. The intersection of the 
lines deriving from the invidual VOC profiles demonstrates the mean VOC profile of this 




Our main target of this study was to assess the optimum sampling method to discriminate 
between IBD and healthy controls based on VOC analyses by means of FAIMS.  We found 
there is a gap of knowledge on the effects of sample storage duration on VOC integrity. 
Therefore, the effect of duration of storage in the freezer was analysed by repeating 
measurements from a previous study, conducted by van Gaal et al. in which faecal VOC 
profiles of 36 de novo IBD patients were compared to 24 HC[14]. Based on the availability 
of faecal samples from this study, 10 IBD (all CD) subjects and 10 HC could be included for 
reassessment of VOC profiles. Storage time differed 20 months between the measurements, 
with a median storage time in the freezer of 43 months for the first and 63 months for 
the second measurements. Baseline characteristics and disease specifics of these study 
subjects are described in Table 3. For both these analyses, the reference standard was used. 
Diagnostic accuracy to detect IBD as well as the difference in VOC profile were assessed 




Seventeen de novo, treatment-naïve paediatric IBD patients (15CD, 2UC) were selected 
from the original cohort and were matched to 25 HC. Patient characteristics are shown in 
table 2. There were no significant differences in age, sex and sample age between IBD and 
HC. The range of the sample age was, however, larger in the IBD group compared to HC.  
Table 2. Baseline characteristics
Inflammatory bowel disease
Healthy controls
(n=25) p-valueCrohn’s disease (n=15)
Ulcerative colitis
(n=2)
Sex, male (n, [%]) 10[66.7] 0[0] 14[56] 0.858
Age, yr (median[IQR]) 13.0[11-15] [10-16]* 12.0[4.0] 0.614
Sample age, mos 
(median [IQR])
11.0[2-16] [11-26]* 11.0[1.0] 0.376
Physician’s global assessment
Quiescent 1 0 NA
Mild 9 2 NA
Moderate 5 0 NA
















Ileal (L1) 1 NA NA
Colonic (L2) 5 NA NA
Ileocolonic (L3) 6 NA NA
Proximal disease (L4) 1 NA NA
1Crohn’s disease behaviour
B1 (NSNP) 14 NA NA
B1p (NSNP+p) 0 NA NA
B2 (S) 1 NA NA
B2p (S + p) 0 NA NA
B3 (P) 0 NA NA
B3p (P + p) 1 NA NA
1Ulcerative colitis localisation
Proctitis (E1) NA 1 NA
Left-sided (E2) NA 1 NA
Extensive (E3) NA 0 NA
All values were obtained at study inclusion. Localisation was obtained by ileocolonoscopy and 
esophagogastroduodenoscopy before treatment initiation, and magnetic resonance enteroclysis. 
Abbreviations: IQR, interquartile range; NA, not applicable; NSNP, non-stricturing non-penetrating; S, 
stricturing; P, penetrating; p, peri-anal disease. 1Based on Paris classification for inflammatory bowel 
disease (24) *min-max values ** one missing value
For the assessment of the influence of sample age on diagnostic accuracy, faecal samples 
of 10 IBD patients (CD only) and 10 HC were selected from the previous study and re-
measured[14]. Patients characteristics for this variable are described in Table 3. 






Sex, male (n, [%]) 5[50] 2[20] 0.350
Age, yr (median [IQR]) 14.1[3.38] 7.8[3.72] 0.007
Sample age first measurement, 
mos (median[IQR])
23.4[21-31] 52.2[51-52.4]* 0.000
















Faecal calprotectin (µg/g) 
(median[IQR])
1067[1218] NA
CRP (mg/l) (median[IQR]) 29[29] NA
1Crohn’s disease localisation
Ileal (L1) 0 NA
Colonic (L2) 3 NA
Ileocolonic (L3) 7 NA
Proximal disease (L4) 5 NA
1Crohn’s disease behaviour
B1 (NSNP) 8 NA
B1p (NSNP+p) 0 NA
B2 (S) 0 NA
B2p (S + p) 0 NA
B3 (P) 1 NA
B3p (P + p) 1 NA
All values were obtained at study inclusion. Localisation was obtained by ileocolonoscopy and 
esophagogastroduodenoscopy before treatment initiation, and magnetic resonance enteroclysis. 
Abbreviations: IQR, interquartile range; NA, not applicable; NSNP, non-stricturing non-penetrating; S, 
stricturing; P, penetrating; p, peri-anal disease. 1Based on Paris classification for inflammatory bowel 
disease (24) *one value missing.
Faecal VOC profiles per variable of interest
The results of the VOC analysis displayed per variable of interest are shown in Table 4. For 
each analysis, the outcome of the Sparse Logistic Regression is noted. A complete overview 
of the data generated by the four different classification models is given in supplemental 
Table 1a-1d.
Standard operating procedure
A typical FAIMS pattern (flame) of both the IBD samples and control samples is depicted 
in Figure 1. By application of the reference standardsettings, IBD and HC could be 
differentiated with high accuracy (Accuracy, AUC (95% CI), Sensitivity, Specificity, PPV, NPV, 
P values; 0.93, 0.99 (0.96 – 1), 0.94, 0.96, 0.94, 0.96, 1.178e-10)(Table 4, Supp table 1a-1d, 
Figure 2). 
Sample mass
IBD could be differentiated from HC using a lower sample mass, but diagnostic accuracy 
decreased compared to reference standard for both 300 mg per sample (Accuracy, AUC 
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(95% CI), Sensitivity, Specificity, PPV, NPV, P values; 0.77, 0.69 (0.52 – 0.86), 0.88, 0.44, 0.52, 
0.85, 0.02101) and 100 mg per samples (Accuracy, AUC (95% CI), Sensitivity, Specificity, 
PPV, NPV, P values; 0.70, 0.74 (0.59 – 0.90), 0.76, 0.72, 0.65, 0.82, 0.00364)(Table 4, Supp 
table 1a-1d, Figure 1). 
Thaw-freeze cycles
After adding one extra thaw-freeze cycle to reference standard, a decrease in diagnostic 
accuracy was observed (Accuracy, AUC (95%CI), sens, spec, PPV, NPV, P values; 0.61, 
0.80(0.65-0.94), 0.76, 0.80, 0.72, 0.83) (Table 4, Supp table 1-4, Figure 1). After addition 
of a second and third thaw-freeze cycle, differences in VOC profiles between IBD and HC 
dissolved (Accuracy, AUC (95%CI), sens, spec, PPV, NPV, P values; 0.64, 0.56 (0.38 – 0.74), 
0.76, 0.48, 0.50, 0.75, 0.7534 and 0.57, 0.50 (0.32 – 0.69), 0.47, 0.72, 0.53, 0.67, 0.5101 
respectively)(Table 3, Supp table 1a-1d). 
Figure 1. Typical FAIMS pattern of patients with inflammatory bowel disease and healthy controls
Depicted with a blue background are the positive ion currents. Depicted with a red background are the 
negative ion currents. 
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Figure 2. Receiver operating characteristics for each variable of interest for the differentiation 
between inflammatory bowel disease and healthy state
All receiver operating characteristic curves are obtained by Sparse Logistic Regression analyses. 
Abbreviations: AUC, area under the curve; IBD: Inflammatory bowel disease; HC: Healthy controls.
Duration of storage at room temperature
After keeping the samples at room temperature for 180 minutes prior to VOC analysis, 
differences in VOC outcome between IBD and HC dissolved (Accuracy, AUC (95%CI), sens, 
spec, PPV, NPV, P values; 0.60, 0.51 (0.32 – 0.70), 0.59, 0.68, 0.56, 0.71, 0.4596)(Table 4, 
Supp table 1a-1d).
Influence of sampling method on overall VOC composition
In order to assess the influence of sampling conditions on the detected VOC patterns, HC and 
IBD subjects were combined to form one single study group. The comparisons between the 
four features are shown in Table 5. Differences in VOC pattern between sampling methods 
are depicted in Figure 3. Both faecal samples weighing 300mg and 100mg demonstrated 
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a significantly different VOC profile compared to the standard reference mass of 500mg 
(Feature 1,2 and 4: p-value <0.001 for and feature 3: p-value=0.027 for 300mg, feature 1-4: 
p-value<0.0001 for 100mg). All of the variables in thaw-freeze cycles differed to a similar 
extent from the reference standard (feature 1-4: p-value <0.0001 for all variables). A similar 
difference as with the previous variables was seen when comparing the VOC profiles of 
the reference standard to the VOC profiles of samples kept at room temperature for 180 
minutes prior to VOC analysis (feature 1-4: p-value<0.0001). 
Post hoc analyses: Duration of storage in freezer
The diagnostic accuracy to discriminate IBD from controls was not influenced by differences 
in duration of storage time prior to VOC analysis (43 versus 63 months) (Accuracy, AUC 
(95%CI), sens, spec, PPV, NPV, P values; 0.75, 0.75 (0.53 – 0.97), 0.70, 0.80, 0.78, 0.73, 
0.0262 versus 0.75, 0.73 (0.49 – 0.97), 0.80, 0.70, 0.73, 0.78, 0.0376) (Table 4, Supp table 1a-
1d, Figure 1). The VOC composition of the two variables showed a significant difference in 
three features (feature 1, 2 and 3 with p-values of <0.0001, <0.0001 and 0.021, respectively)
(Table 5, Figure 3). 
Figure 3. Scatterplot for the differentiation between sampling methods measured by field asymmetric 
ion mobility spectrometry
Scatterplot for the differentiation between sampling methods measured by field asymmetric ion 
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mobility spectrometry, including (a) sample mass; (b) number of freeze-thaw cycles; (c) 180 minutes out 
of freezer; (d) storage duration. Axes depicted are recombinations of the raw sensor data by means 
of feature selection using Wilcoxon rank sum analyses, creating four features per measurement. The 
marked points are the individual VOC signals. The intersection of the lines deriving from the individual 
signals are the mean VOC profile of that specific variable. 
Table 4. Performance characteristics for the differentiation between IBD and Healthy for all of the 












1.178e-10 0.93 0.99   
(0.96 - 1)
0.0014 0.94   
(0.71 - 1)
0.96   
(0.8 - 1)
0.94 0.96
Mass variable 1 
(17IBD, 25HC)
0.02101 0.77 0.69   
(0.52 - 
0.86)
0.47 0.88   
(0.64 - 
0.99)




Mass variable 2 
(17IBD, 25HC)
0.003642 0.70 0.74   
(0.59 - 
0.9)
0.44 0.76  
 (0.5 - 
0.93)






0.0004713 0.61 0.8   
(0.65 - 
0.94)
0.49 0.76   
(0.5 - 0.93)






0.7534 0.64 0.56   
(0.38 - 
0.74)
0.66 0.76  
 (0.5 - 
0.93)






0.5101 0.57 0.5   
(0.32 - 
0.69)
0.063 0.47   
(0.23 - 
0.72)




180 minutes out of 
freezer (17IBD, 25HC)
0.4596 0.60 0.51   
(0.32 - 
0.7)
0.13 0.59   
(0.33 - 
0.82)




Storage duration, first 
measurement  
(10CD vs 10 HC)
0.0262 0.75 0.75   
(0.53 - 
0.97)
0.47 0.7   
(0.35 - 
0.93)





second measurement  
(10CD vs 10 HC)
0.0376 0.75 0.73   
(0.49 - 
0.97)
0.58 0.8  
(0.44 - 
0.97)




For each analysis, the best Sparse Logistic Regression outcome is shown.  Sensitivities, specificities, 
p-values and AUCs are reported for the respective optimum cut-points.. Abbreviations: AUC, area 
under the curve; PPV: positive predictive value; NPV: negative predictive value. *Reference standard is 
defined as 500mg sample, diluted in 10mL water, thawed 10 minutes to room temperature.
Chapter 2. Optimised sampling methods for eNose analysis
32
Table 5. Paired feature analyses per variable of interest with corresponding p-values









500 vs 300 <0.0001 <0.0001 0.027 <0.0001
500 vs 100 <0.0001 <0.0001 <0.0001 <0.0001
Number of freeze-thaw cycles
Measured directly vs one cycle <0.0001 <0.0001 <0.0001 <0.0001
Measured directly vs two cycle <0.0001 <0.0001 <0.0001 <0.0001
Measured directly vs three cycle <0.0001 <0.0001 <0.0001 <0.0001
Kept at room temperature
180 Minutes <0.0001 <0.0001 <0.0001 <0.0001
Storage time
First vs second measurement <0.0001 <0.0001 0.021 0.825
P-value < 0.05 is considered significant.
DISCUSSION
In the present study, VOC profiles and diagnostic accuracy were influenced significantly by 
altering sampling conditions. Application of 500mg faecal sample mass diluted with 10mL, 
thawed for 10 minutes prior to analysis after a single thaw-freeze cycle, showed the best 
discriminative accuracy for differentiation of paediatric IBD and HC.
To our knowledge, this is the first published study to assess under which sampling conditions 
an optimal accuracy can be obtained in the differentiation between paediatric IBD and 
healthy state, by analyzing the faecal volatile metabolome using FAIMS. Studies assessing 
optimization of sampling methods for faecal metabolome analyses have mainly focused 
on gas chromatography – mass spectrometry (GC-MS), nuclear magnetic resonance 
spectroscopy (NMR-spectroscopy) and liquid chromatography – mass spectrometry (LC-
MS), which are targeted and untargeted methods for identification of specific metabolites. 
These studies may hypothetically provide guidance to standardization for the pattern-based 
FAIMS technique. The results of this study will be discussed and compared to the available 
literature in the following sections. Regarding sample mass, similar results to eNose, GC-
MS, NMR-spectroscopy and LC-MS studies on the faecal metabolome, in both humans and 
rats, were found in our study, showing a difference between the use of 500mg from that 
of lower masses [16, 24, 25]. Deda and colleagues have shown that the sample weight to 
volume ratio has a major effect on the number and signal intensity of features detected in 
faecal samples with GC-MS. This also applied for the spectral signal intensity when using 
NMR-spectroscopy, and for the peak area intensity when using LC-MS[24]. The increased 
accuracy to differentiate between IBD and HC when using a larger faecal mass, as observed 
in our study, may be explained by this increase of richness in number and intensity of VOCs. 
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Observed differences in VOC profiles between faecal samples enduring one versus multiple 
thaw-freeze cycles, are in line with previous research on VOC patterns using different eNose 
devices [16, 26].  It could be hypothesised that these effects are caused by changes in 
microbiota composition or function, although in a previous study no differences were found 
in microbiota composition between analyses of fresh samples versus samples frozen at 
minus 80 degrees and subsequently thawed prior to analysis [27]. A recent study suggested 
a release of microbial intracellular contents following thaw-freeze cycles, possibly explaining 
the effects of thaw-freeze cycles on VOC outcome[28]. In our study, it was shown that the 
diagnostic accuracy decreased with the addition of one extra thaw-freeze cycle, and that 
IBD could not be differentiated from HC after addition of multiple thaw-freeze cycles. 
Consequently, future studies on faecal VOC should limit the number of thaw-freeze cycles 
prior to analysis to a maximum of two.
Consistent with the results from a previous study on faecal VOCs using an eNose device, 
we measured significant differences between faecal VOC profiles measured directly after 
thawing (as used in the reference standard) and after 180 minutes stored at room temperature 
with an accuracy of 0.84 [16]. Furthermore, it was demonstrated that the diagnostic accuracy 
decreased when samples were kept at room temperature for 180 minutes (AUC= 0.53). These 
results are in line with a previous study on the impact of storage conditions on crude faecal 
samples measured by NMR-spectroscopy, showed that metabolic variation was influenced 
by storage at room temperature and 4 °C[28]. The metabolic profiles of faecal samples did 
not change after keeping the samples at room temperature for 1 hour. However, samples 
stored for a longer time prior to the analyses gradually shifted. The overall changes that 
were seen included decreased levels of fumarate, succinate, glutamate and increased levels 
of methanol, phenylalanine and alanine and short chain fatty acids like acetate, butyrate, 
propionate and valerate. To a lesser extent, the same shifts were seen in samples kept at 4 
°C, which indicates that the lower temperature slows down the impact on sample integrity, 
resulting in less alterations in the metabolic profile. In another study comparing VOC profiles 
of faecal samples kept at 1°C for 14 hours prior to GCMS analysis, there were no significant 
changes in VOC profiles before and after 14 hours [25]. Since the differences between IBD 
and HC in this study were analysed by means of pattern-recognition, specific metabolic 
alterations cannot be elucidated in this study. However, it could be hypothesised that the 
unstable VOC composition when keeping the samples at room temperature, is caused by 
ongoing fermentation by the faecal microbiota. Since fermentative processes have shown 
to be reduced at lower temperature, this could explain why VOC integrity remained stable 
when samples were kept at 1 and 4 degrees in previous studies[28]. Another explanation 
is the emission of volatiles in the sample, and contamination with background volatiles. 
Fermentation, emission and contamination could be avoided by measuring the sample 
directly after collection. However, clinical implementation of VOC analyses would then 
become a logistic challenge.  
Literature on the influence of storage time of faecal VOCs is scarce. In a study assessing 
VOC profiles of urine using a similar FAIMS method to the current study, a nine-month 
shelf-life for urine samples was suggested after it was shown that chemical information 
was lost over time, regarding both diversity and concentration of gas emission[29]. In 
addition, in a previous study assessing the effect of sample age on serum VOCs measured 
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by GCMS a significant difference in metabolite composition was already seen after storage 
of three weeks in the freezer [30]. In the current study, faecal VOC profiles for IBD, seem less 
influenced by storage time compared to the previous studies on urine and serum, keeping 
a similar (high) diagnostic accuracy after storage of 43 months and 63 months. Interestingly, 
the samples chosen for this comparison, were used in a larger study by van Gaal et al. where 
an area under the curve of 0.76 was found after a mean storage time of 23 months for the 
IBD group (25CD, 21UC) and 39 months for the HC group[14]. The increase in the AUC of 
this sub analysis, although analysed at the same moment, can be explained by the fact that 
the remaining samples only consisted of CD patients and HC. In the previous study, the 
AUC for the differentiation between CD and HC was 0.90. There is, however, an important 
consideration to this post hoc analyses. The diagnostic accuracy was only assessed after a 
median storage duration of 43 and 63 months. Since there are no previous measurements, 
it could be possible that massive changes in VOC composition have influenced diagnostic 
accuracy in the initial months after collection. We cannot exclude this influence based on 
this study.   
The main strength of this study is that we used an IBD group and an HC group to assess not 
only differences in VOC patterns between sampling methods, but also to assess the influence 
on the diagnostic accuracy for disease detection. In addition, we used the same subjects’ 
samples for each of the analysis, accounting for various confounding factors of influence 
on faecal VOCS (e.g. smoking habits, medication use, diet). During each experiment, the 
remaining variables of interest were kept the same, ensuring optimal comparison based 
on the variable of interest. Our study also has several limitations. Most importantly, for the 
influence of storage time on diagnostic accuracy for IBD, we have made use of raw data of a 
previous study and have re-assessed samples with sufficient sample mass. For this analyses 
we were only able to include CD patients, and no UC. In addition, sample age differed 
between groups, which could have influenced diagnostic accuracy by the influence of 
metabolic degradation on VOC profiles at both measurements. Second, we have made use 
of unfiltered and unsterilized tap water for sample dilution, and compressed medical air as 
carrier gas. This protocol was chosen since it has been found a reliable sampling method for 
the differentiation between various diseases and healthy controls based on faecal VOCs[31-
34]. To avoid VOC profile contamination, we have run air and water blanks which were 
checked on contamination peaks, and met the cleanliness criteria.  In addition, we have 
analysed the samples in a random order, and have excluded the first matrix of every sample 
analyses to avoid air contamination. However, we cannot fully guarantee exclusion of VOC 
contamination by differences in tap water composition between measurements. Third, we 
have not explored the difference between the diagnostic accuracy when using fresh versus 
frozen samples. As previously described, this seems of important influence on urine and 
serum VOCs. However, since a diagnostic accuracy of 0.99 was found in this study, we 
believe that freezing our samples has not significantly influenced our study outcomes. Last, 
it is possible that optimized faecal sampling conditions are disease specific, and faecal VOC 
biomarkers to diagnose IBD might have different sensitivity to variations in sampling method 
compared to faecal VOC biomarkers for other gastrointestinal diseases. We did, however, 
find significant differences in VOC profiles between sampling methods, emphasizing the 
importance of the use of one standardised sampling method. Furthermore, it is important 
to point out that we made use of pattern-recognition in this study, which complicates the 
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assessment of the influence of specific metabolites. We have chosen to validate specifically 
the FAIMS method since this device is an easy-to-use tool which could be suitable for 
clinical implementation [35]. 
This study highlights the need for one standardised methodology, in both research setting 
and when using VOCs analysis as a (future) clinical tool. Based on this and previous study 
results, we would like to suggest to use a standardised protocol with preferably faecal 
sample masses of 500mg, no more than one thaw session prior to VOC analysis, and 
analyzation of samples directly after thawing or, if impossible, keeping the samples frozen 
until further analyses. Future studies should assess the difference in diagnostic accuracy 
between fresh samples and frozen samples, and the influence of storage duration using 
multiple measurement moments after sample collection. 
In conclusion, this study showed a high discriminative accuracy to differentiate between 
IBD and HC when using the standard operating procedure. It was shown that the use of 
less than 500mg, multiple thaw-freeze cycles, storage at room temperature and storage in 
freezer all influence the diagnostic accuracy. We therefore suggest to use one standardised 
protocol when performing faecal VOC analysis. In addition, further studies should focus on 
finding IBD specific VOCs to allow for targeted pattern-recognition.
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 Faecal volatile organic compounds (VOCs) are gaseous metabolic products which 
are increasingly considered potential non-invasive biomarkers for the detection of 
various (gastrointestinal) diseases. The influence of lifestyle factors on faecal VOC 
patterns remains unexplored but is of importance prior to implementation of VOC 
analysis as a diagnostic tool. The aim of this study was to investigate the effects of 
age, gender, body mass index, smoking status, dietary preferences, medication 
use and co-morbidity on faecal VOC patterns. 
Methods
For this study, faecal samples of patients undergoing a colonoscopy were collected 
prior to endoscopy. All participants completed a questionnaire on lifestyle factors, 
co-morbidity and medication use. Patients without colonic abnormalities were 
included in this study. Faecal VOC patterns were analysed by means of an 
electronic nose (eNose) device (Cyranose® 320).
Results
From the 1039 participants willing to participate in the initial study, 211 were 
eligible as controls. All unique lifestyle variables investigated in this study affected 
the faecal VOC composition. The strongest influences were caused by low BMI, 
a vegetarian diet and an active smoking status, whereas the least influence was 
found for the variables gender, age > 55 years and previous smokers.
Conclusion
Age, gender, BMI, smoking habits, dietary preferences, co-morbidity and 
medication use all have unique effects on faecal VOC composition. Future studies 
should carefully consider this influence on VOC outcome when defining VOC 




Over the past few decades, the usefulness of non-invasive biomarkers for the detection 
and follow-up of gastrointestinal diseases has been recognised. Non-invasive biomarkers 
may contribute to a refined selection of high-risk individuals in both clinical settings 
and population based screening programs, and for monitoring of disease courses. This 
may lead to earlier disease detection, increased curation rates and may lower the need 
for invasive diagnostic testing and disease treatment. Examples of biomarkers currently 
used in gastroenterology are faecal calprotectin (FCP) for the detection and follow-up of 
inflammatory bowel disease (IBD), and the faecal immunochemical test (FIT) for the detection 
of colorectal cancer (CRC) and adenomas in population based screening. These tests are 
amongst the first non-invasive biomarkers used, however, accuracies of both biomarkers are 
hampered by either a limited sensitivity or specificity [1, 2]. Therefore, the search for more 
accurate non-invasive biomarkers remains warranted. 
The analysis of volatile organic compounds (VOCs) is a relatively new technique in the 
field of biomarker exploration. These carbon-based gaseous chemicals can be measured 
in the headspace of fluids (e.g. urine and faecal) or breath and are considered the end-
products of metabolic processes in the human body. Faecal VOCs are also thought to 
reflect the interaction between intestinal microbiota and host[3]. The VOC composition 
may be analysed with chemical analytical techniques, of which gas chromatography-mass 
spectrometry (GC-MS) is the golden standard. Although these methods allow for stable and 
reliable measurements, they usually require specialised personnel, are time-consuming and 
costly. Another way to analyse the VOC composition is by means of pattern-recognition 
measured with an electronic nose (eNose). Using this technique, volatiles cannot be 
identified to a molecular level. Instead, diagnosis is done on the complete VOC pattern, 
created by all the present volatiles taken together. Advantages of eNose techniques are their 
ability for easy-to-use, fast and relatively inexpensive measurements, which underline their 
potential for use in clinical practice[4]. Several studies have demonstrated the potential of 
faecal VOC patterns to detect gastrointestinal diseases[5-8]. These are mainly case-control 
studies based on the analysis of a broad range of VOCs. The next step in developing cost-
effective VOC pattern-based tests is the construction of sensor arrays which allow for the 
measurement of disease specific VOCs. To reach an optimal diagnostic accuracy, it is of 
importance that the sensors within the array are not influenced by other factors than the 
disease state of interest. Especially those factors notorious for altering metabolism and gut 
microbiota composition are likely to affect the VOC pattern, however, information on the 
extent of their influence is limited[9-11]. Previous studies have reported effects of gender 
and BMI on specific faecal volatiles using GC-MS, but data on their influence on the total 
faecal VOC patterns is lacking[12, 13]. In addition, an influence of dietary habits on VOC 
patterns may be expected, as a previous study has shown effects of a gluten free diet on 
the VOC composition of breath samples, though again, using GC-MS[14]. Regarding the 
use of pattern-recognition, there is some data available revealing an influence of smoking 
on faecal VOC patterns as measured by an eNose (Cyranose 320 ®)[15]. We aimed to 
evaluate the extent of the effects of gender, age, BMI, smoking habits, diet, co-morbidity 
and medication use on faecal VOC patterns as measured by an eNose. 




This proof of concept study was performed between February 2015 and November 2017 at 
the outpatient clinic of the Gastroenterology and Hepatology departments in one tertiary 
referral hospital (Amsterdam UMC, location VUmc) and two general hospitals (OLVG West 
in Amsterdam and Spaarne Gasthuis, location Hoofddorp and Haarlem), all located in The 
Netherlands.
Study participants
All patients aged 18 years and older who were scheduled to undergo a colonoscopy at 
one of the three contributing hospitals were asked to participate in this study. To ensure 
that VOC outcomes would not be influenced by mucosal abnormalities, patients were only 
included if no colonic abnormalities were observed during colonoscopy (with the exception 
of haemorrhoids, diverticula and small fibroma). Histology reports were checked in the case 
of mucosal biopsies and patients were excluded if histologic abnormalities were reported 
by the pathologist (e.g. reactive mucosal alteration, infiltration, dysplasia). Other exclusion 
criteria were other confirmed bowel diseases (e.g. celiac disease, IBD), inadequate bowel 
cleansing, failure to perform a complete colonoscopy (defined as intubation up to the 
caecum), a missing questionnaire and/or the collection of insufficient faecal sample mass 
to perform this study. In addition, participants were excluded when they had not enough 
knowledge of the Dutch language to complete the questionnaire. Study design is depicted 
in Figure 1.
Sample collection
All patients were provided a stool container (Stuhlgefäß 10ml, Frickenhausen, Germany) and 
asked to collect a faecal sample prior to bowel preparation and colonoscopy and to store the 
sample in their own freezer (-20 C) within one hour following bowel movements. In addition, 
participants were asked to complete an online or paper questionnaire which included 
questions on age, gender, BMI, smoking status, dietary intake, abdominal symptoms, bowel 
habits, patient history, family history and medication use. The samples were transported to 
the hospital by the participant on the day of their scheduled colonoscopy using ice packs 
and/or ice cubes. Samples were stored at -24°C directly upon arrival at the hospital
Variables of interest
We aimed to assess the effect of the variables gender, age, BMI, smoking status, dietary 
preferences, co-morbidity and medication use on VOC composition. All of the variables 
were based on the reported outcomes of the questionnaire. All of the variables were 
categorical. To exclude bias of the effects of hormonal treatment on faecal VOC samples 
of transgender patients, the variable gender consisted of three options: male, female and 
other. Age, BMI and smoking status were all divided into four categories: 18-35; 36-50; 
51-65 and >65 years old for the age variable, <18.5; 18.5-25; 25-30 and >30 kg/m2 for 
BMI, and smokers; former smokers (quit <5 years ago); former smokers (quit >5 years ago) 
and non-smokers for the smoking status variable. Diet was categorised as ‘no adjustments 
made’ and ‘adjustments made’, with the addition of a vegetarian subgroup. Furthermore, 
the influence of co-morbidity with non-colonic diseases and the influence of medication use 
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on faecal VOC profiles were assessed. Co-morbidity was divided into a ‘no co-morbidity 
reported’ and ‘one or more comorbidities reported’ group. Subgroups of patients with 
diabetes mellitus (type 1 and 2 combined) and subgroups of patients with hypertension 
were also compared to patients with no reported comorbidities. Medication use was 
described as ‘no medication use’ or ‘use of one or more drugs in the past three months’, 
with subsets of participants using/having used proton pump inhibitors (PPIs) and antibiotics 
(AB) three months prior to analyses because of their specific effect on the gastrointestinal 
tract. These subsets were compared to the participants with no reported medication use.
Figure 1. Study design
Sample preparation
From the original samples, one subsample of 0.5 g per participant was weighted on a 
calibrated scale (Mettler Toledo, AT 261 Delta Range, Ohio, United States), transferred into 
a 3 mL sealed vacutainer (BD vacutainer, Franklin Lakes, NJ, USA), labelled and re-stored 
in a -20°C freezer until further handling. The amount of sample was chosen to provide 
an optimum ratio of VOCs to the sample headspace, as validated in a previous sampling 
method study for VOC pattern-recognition using field asymmetric ion mobility spectrometry 
(FAIMS)[16]. Samples were thawed to room temperature, 30 minutes prior to VOC analysis 
allowing faecal VOCs to fill the headspace of the sample. These reference standard settings 
are in line with several previous studies on faecal VOC profiling in a range of diseases which 
allowed for the discrimination between cases and healthy controls[17].  
Cyranose 320®
Faecal volatile organic compounds were measured by means of a Cyranose 320® eNose 
(Smiths Detections, Pasadena, CA, USA), a handheld chemical gas sensing apparatus, 
designed to identify VOC patterns of chemical mixtures. The Cyranose 320® consists 
of a NoseChip®, an array of 32 polymer nanocomposite sensors, each having a specific 
interaction with distinct VOCs based on a difference in sensor material. The interaction with 
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VOCs causes the sensormatrix to swell and this change in volume subsequently increases 
their electrical resistance signal. The sensors response is measured as a relative resistance 
change specific for each sensor ((maximum resistance – baseline resistance)/baseline 
resistance). The combination of relative resistance alterations form a so called ‘smellprint’, 
specific for unique vapors. The Cyranose® utilizes a software (PCNose) and advanced 
pattern-recognition algorithms which enables the user to create a library of VOC patterns 
for single samples and sets of samples. 
Faecal volatile organic compound analysis
Samples were analysed in random order in 5 subsequent days. The vacutainer was 
connected to the Cyranose320® in an air-tight loop system, piercing two needles (BD Blunt 
fill needle 1.2 x 40 mm, Franklin Lakes, NJ, USA) attached to two tubes (Argyle Covidien 
tube 3mm, Mansfield, MA, USA) into the cap of the vacutainer on the needle side, and into 
the snout and outlet of the Cyranose320® on the tube side. Three-way valves (stopcock 
connecta plus, McFarlane Medical, Melbourne, Australia) were included in the system to 
control airflow direction and a syringe waterfilter (NalgeneTM 25mm Syringe Filter, Thermo 
ScientificTM, Massachusetts, USA) was inserted to prevent contamination of the eNose by 
condensation. A baseline reference signal was obtained for 30 seconds prior to the actual 
VOC analysis. This was done by linking a VOC-filter (A1, North Safety, Middelburg, The 
Netherlands) to the inlet of the eNose. The actual faecal sample analysis was then performed 
for 60 seconds and subsequently the sensors were purged for 60 seconds with VOC-filtered 
air to wash the faecal VOCs off the sensors and create a new baseline reference for the next 
sample analysis. In case the Cyranose 320® was not used for 30 minutes in between faecal 
sample measurements, purging of the sensors was again done for 30 seconds. After this, 
an empty sample was measured to prevent the so called ‘first-sniff effect’. The signal of this 
sample was then used to calculate cross-validation, to ensure comparability of new sample 
measurements to previously analysed samples. All needles, tubes, connectors and three-
way valves were replaced between each sample analysis to prevent contamination of VOCs 
from previous samples[17]. 
Statistical analysis
Baseline characteristics for all study participants were computed using SPSS Statistics 
(version 22, IMB, NY, USA). The eNose data analyses were performed in R version 3.4.4 
and consisted of a total of 76 variables: a total of 42 demographic and lifestyle variables 
andthe outcomes of the 32 sensors. Unscaled and scaled heatmaps of the sensor data were 
created to visualize the effect of the VOCs on sensor outcomes (Suppl Figure 1 and Figure 
2). Spearman correlation was used to assess the correlation between sensor outcomes, 
to visualize variability in sensor response (Suppl Figure 2). Spearman correlation was also 
used to calculate correlation coefficients of lifestyle variables, to discover presence of 
possible confounding factors.  Spearman correlation is a non-parametric method to assess 
the relationship between two variables. Then, factor analysis was used to represent the 32 
sensors by a smaller number of variables. Factor analysis is a widely used method for the 
reduction of multidimensional data. Advantage of this method compared to other data 
reduction methods, as for example principal component analysis (PCA), is that this type of 
analysis accounts of random errors of the data, thus, creating less loss of information and 
therefore a more reliable data reduction. The generated scree plot was used to choose the 
45
3
number of factors to be extracted (Supp Figure 4). Then, per variable of interest, the sum 
of the relative electrical resistance change is calculated per factor (the sum of the mean 
scores per sensor within that factor*the weight of the sensor within that factor). To visualize 
the effects of the variables on the factors, the scores representing these variables were then 
plotted in a chart, per category of interest of each variable, with one factor on the X-axis and 
one factor on the Y-axis.  This was chart was then used to interpret effects of the variables 
on the VOC pattern. 
Ethical considerations
This study was approved by the Medical Ethical Review Committee (METc) of the VU 
University Medical Centre under file number 2014.404, and by the local medical ethical 
committee of the OLVG West and Spaarne Gasthuis. Written informed consent was obtained 
from all study participants. 
RESULTS
 
Characteristics of study population
A total of 1039 participants (578 Amsterdam UMC, 381 Spaarne Gasthuis, 80 OLVG West), 
collected a faecal sample prior to colonoscopy of which 266 participants had no mucosal 
abnormalities during endoscopy (Figure 1). Of these, 55 participants were excluded, 26 
due to missing/incomplete questionnaires, 17 due to insufficient sample mass and 12 due 
to the fact that they were included twice because of subsequent colonoscopies. Baseline 
characteristics are reported in Table 1.
Table 1. Baseline characteristics of all study participants (n=211)
Age (mean, min-max) 60.5 (26-83)
Age groups (n [%])
18-35 9 [3.8]
36-50 (n=37) 31 [14.7]
51-65 (n=104); 93 [44.1]





BMI (mean, min-max)* 26.0 [16.2-61.3]
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Smoking status (n [%]) **
Non-smoker 99 [46.9]
Smoker 31 [14.7]
Quit smoking 81 [38.4]
≤5 years 13 [6.2]
> 5 years 68 [32.2]








Diet groups (n [%])
Regular diet 182 [86.3]
Vegetarian diet 7 [3.3]
Other dietary preferences†† 22 [10.4]
Co-morbidity (n [%])
No co-morbidity reported 126 [59.7]




Medication use (n [%])
No medication use 50 [23.7]
Use of one or more drugs 161 [76.3]
PPI 45 [21.3]
OAB 28 [13.3]
Reason for endoscopic assessment (n [%])
Positive FIT 20 [9.5]
Rectal blood loss 26 [12.3]
Change in bowel habits 33 [15.6]
Surveillance 48 [22.7]
Abdominal pain 32 [15.2]
Diarrhea 12 [5.7]






Family history of CRC 17 [8.1]
Monitoring after diverticulitis 2 [0.9]
Monitoring after abscess 3 [1.4]
Monitoring after CRC surgery or EMR of TVA 6 [2.8]
Other††† 5 [2.4]
*12 missing values; **1 missing value; †43 missing values ; ††other consisted of various diets (e.g. 
glutenfree (5), lactosefree (3), vegan, less chicken, protein rich, low in carbs, FODMAP, less sugar and 
salt); ‡consists of pulmonal diseases (15) including COPD, asthmatic bronchitis and lung fibroses and 
38 other comorbidities, including thyroid disease (8), rheumatoid arthritis (4), heart disease (3), irritable 
bowel syndrome (2), high cholesterol (2); abbreviations BSC: Bristol stool chart (stool consistency scale 
comprising seven options with 1 being the most watery and 7 the least), PPI: proton-pump inhibitor, 
OAB: oral antibiotics, DM: Diabetes Mellitus, HTS: Hypertension; ††† Other consisted of bloating (1), 
soiling (1), low iron levels (1), rectal slime loss (1), follow-up of aphtous lesion. Abbreviations: CRC, 
colorectal cancer; EMR, endoscopic mucosa removal; TVA, tubulovillous adenoma. 
Figure 2. Scaled heatmap of sensor data outcomes split per sample and per sensor. Sensor outcomes 
are depicted on the X-as, samples are depicted on the Y-as. Per sensor, the mean and standard deviation 
are computed across all samples. Then, each measurement is subtracted from the mean, dividing it by 
its standard deviation per sensor to scale all measurements across all sensors.
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Figure 3. Spearman’s correlation coefficients between lifestyle variables. A strong positive correlation 
was set as 0.7-1.0, moderate positive correlation 0.5-0.7, weak positive correlation 0.3-0.5, no 
correlation -0.3-0.3, weak negative correlation -0.3 to -0.5, moderate negative correlation -0.5 to -0.7, 
strong negative correlation -0.7 to 1.0. Abbreviations: OAB, oral antibiotic use; PPI, proton pump 
inhibitor use; HTS, hypertension; DM, diabetes mellitus; BMI, body mass index. A moderate positive 
correlations are seen between PPI use and HTS, PPI use and co-morbidity. Weak correlations are found 
between medication use and HTS, OAB use and HTS, medication use and co-morbidity, age and PPI use. 
Sensor resistance analysis 
Density plots of the sensor outcomes demonstrated a normal distribution for all sensors. 
Heatmaps of the sensor outcomes were obtained using pre-defined breaks (supplementary 
figure 1). Then, the sensor data was scaled across all sensors. Figure 2 depicts the heatmap 
of these scaled sensor outcomes per sample per sensor. It is found that the sensor outcomes 
of a singular faecal sample have a common tendency to either have outcomes above, 
on, or below all mean sensor outcomes. Based on the Spearman coefficient test, strong 
correlations were found between most of the sensor outcomes(supplementary fig 2). 
Lifestyle variable analysis
Variable frequencies are reported in Table 1 and their distribution amongst faecal samples 
is visualised in Supplementary figure 3. Spearman coefficient test was used to assess 
correlations between variables and is visualised in Figure 3. A moderate positive correlation 
was found between PPI use and HTS, and between PPI use and co-morbidity (correlation 
coefficient between 0.5 and 0.7). In addition, a weak correlation was found between the 
following variables: medication use and HTS, OAB use and HTS, medication use and co-
morbidity, age and PPI use (correlation coefficient between 0.3 and 0.5). There was no linear 




Figure 4: Factor analyses for all lifestyle variables of interest combined. Outcomes for factor 1 are 
scaled on the X-axis and outcomes for factor 2 are scaled on the Y-axis. For both factors, the further from 
zero the variable is depicted (either negative or positive), the larger the sum of the relative electrical 
resistance change is for that factor, or in other words, the further from zero the variable is depicted the 
larger the influence on all sensors within that factor taken together. For example, large influence on 
sensors taken together here are BMI<18.5, vegetarian diet and ‘other diet’, gender specified as other 
(n=1), an active smoking status, an age between 18-35 years, the use of antibiotics and the presence of 
co-morbidity. Lowest effect on factors is seen for gender, ex-smokers, age > 55 years.
The influence of lifestyle variables on volatile organic compound patterns
For the factor analysis, the two first factors were chosen based on the Scree Plot 
(Supplementary Figure 4). The first two factors accounted for 0.515 and 0.403 of the 
total variance, meaning they explained 91.7% of the total variance taken together. The 
sensor representations within the two factors are described in Supplementary Table 1 and 
supplementary Figure 5. The factor analyses per variable are combined and depicted 
in Figure 4. Outcomes of the factor analysis per lifestyle variable of interest are listed in 
Supplementary Figure 6. For both factors, the further from zero the variable is depicted 
(either negative or positive), the larger the sum of the relative electrical resistance change is 
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for that factor, or in other words, the larger the effect of that variable on the sensors taken 
altogether.  
For the variable age, the lowest age group (18-35 years) has the lowest scores for both 
factor 1 and 2. The age group 36-50 has a low score on factor 1 and a high score on 
factor 2. The remaining age groups (51-65, >65 years) both have values of approximately 
0 on both the factors. For the variable gender, males and females have small opposite 
values being negative on both factors for males, and positive for females. Gender reported 
as ‘other’ is an outlier in this measurement, however, it needs to be noted that this was 
only one participant. The body mass index group <18.5 is the most outstanding subgroup 
within this variable with very low scores on both factor 1 and 2, whereas the subgroups 
18.5-25, 25-30 and >30 all have values of approximately 0 on factor 2. Non-smokers and 
previous smokers (either longer and shorter than 5 years) all have values of approximately 
0 on both the factors, whereas smokers have high values on both. A regular diet scores 
approximately 0 on both factors, but a vegetarian diet has high values on factor 1, and other 
diets taken together have a high value on factor 2. The variables co-morbidity, hypertension 
and diabetes all show high values on factor 2. The overall use of one or more drugs has a 
score near 0 for both factors, whereas the use of OAB three months prior to inclusion has 
high values on factor 1, and the use of PPI has low scores on factor 2. 
DISCUSSION
In the present study, we have assessed the influence of lifestyle factors of adults without 
colonic abnormalities on the faecal VOC patterns as measured by an electronic nose. All 
of the lifestyle variations investigated in this study were shown to affect the VOC factor 
analyses. This means that these variables should be taken into account when interpreting 
study outcomes and when performing faecal VOC analysis either by matching on these 
variables or by calculating correction factors for the intended device.  
The potential of VOC patterns to differentiate between colonic diseases and healthy state 
has been demonstrated in various studies using VOC profiles originated from faecal, breath 
and urine (e.g. colorectal cancer, inflammatory bowel disease)[7, 8, 18-20]. These studies 
have all shown the presence of disease-specific VOC patterns, which may be used for the 
development of disease-specific sensors. To our knowledge, this is the first published study 
to explore and compare faecal VOC patterns of a wide spectrum of lifestyle variations in 
controls that may be of influence on disease specific VOC patterns. Studies assessing the 
effects of lifestyle on VOC patterns are scarce and have mainly focused on one specific 
variable. These studies may provide guidance to the standardization of a correction factor 
for lifestyle variations. The results of the current study will be discussed and compared to 
the available literature in the following sections. 
Gender affects the (hormonal) metabolism and the gut microbiota, and therefore differences 
could be expected in the faecal VOC composition[21]. Previously, VOC composition 
differences between 521 male and 822 female healthy adults have been investigated in 
breath using gas chromatography-mass spectrometry (GC-MS). In line with our study results, 
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a difference in VOC composition was found, but this was not sufficient to discriminate males 
from females[12]. 
Over the past few decades, BMI has been shown to have a correlation with the abundance 
and variety of bacterial strains of the gut microbiota[21]. The effects of BMI on faecal VOC 
composition have been subject of a study in which samples of 30 obese patients with a 
BMI of >30 and suspected non-alcoholic fatty liver disease (NAFLD) were compared to 
30 healthy controls using the chemical analytical technique GC-MS[13]. They found 12 
different faecal VOCs (e.g. aldehydes, ketones) significantly reduced and 18 faecal VOCs 
(e.g. propanoic, butanoic and pentanoic esters) significantly increased in obese patients 
compared to healthy controls. These differences are expected to appear in the VOC pattern 
as well, however, in the current study similar outcomes were found for participants with 
BMIs ranging between 18.6 and >30. This difference could be explained by a varying 
methodology and patient populations such as the inclusion of solely NAFLD patients, no 
correction for co-morbidity and no information on dietary habits. To our knowledge, there 
are no studies published in which the effects of a low BMI on VOC composition have been 
studied. Therefore it is important to note that in the current study, particularly the values of 
the subgroup BMI<18.5 were different compared to the other BMI groups. 
Smoking has previously been subject of a study in which faecal VOC patterns of 11 smokers, 
21 non-smokers and 24 former smokers were compared using an eNose (Cyranose 320®)
[15]. In line with this study, discrimination of smokers and non-smokers was possible. 
Former smokers could not be distinguished from both non-smokers and smokers based 
on the faecal VOC pattern, however, they noted a wide divergence in abstinence of 
smoking time (6 months – 43 years). In the current study, abstinence of smoking time 
was divided into subgroups of >5 years and <5 years, which both had outcomes on the 
factor analyses similar to non-smokers. Based on our study results, only the effect of 
active smoking should be taken into consideration when performing faecal VOC analysis. 
Studies on dietary influences on VOC patterns are scarce, yet, in one previous study in 
which breath samples from 20 HC were compared to the same 20 HC while on a gluten-
free diet were measured by GC-MS, differences in VOC compositions were observed[14]. In 
another study, differences were found in the faecal VOC patterns of 15 breast fed premature 
infants compared to 15 formula fed premature infants using an eNose[22]. In addition, 
long term dietary habits have been shown to affect the microbial composition and colonic 
fermentation, especially in plant based diets and in restricted calorie intake which may 
also be reflected in the faecal VOC composition[23, 24]. The influence of age on the gut 
microbiota has been subject of various studies and it has become clear that amongst adults 
the microbiota diversity varies widely and may be influenced by multiple factors as puberty, 
the ovarian cycle, pregnancy and menopause . In the current study, especially the age 
groups 18-35 and 36-50 years old demonstrated different outcomes in the factor analyses, 
which are the age groups most involved in these events. 
Whether non-gastrointestinal co-morbidity influences the faecal microbiota via changes in 
the metabolism or vice versa has not yet been unraveled, however, associations between 
the gut microbiota and various metabolic diseases have been observed (e.g. hypertension, 
diabetes mellitus, atherosclerosis, liver cirrhosis)[25-27]. In the current study it was 
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demonstrated that the presence of co-morbidity, as well as the presence of HTS and DM 
had let to different outcomes compared to participants who reported no comorbidities.
It is well known that the use of antibiotics influences the abundance of the microbiota 
in taxonomic richness and causes a change in community[28] [29]. In patients using PPIs, 
an overrepresentation of oral bacteria has been found[30, 31]. These microbial alterations 
may be represented in the faecal VOC composition. In the current study, small opposite 
outcomes were found for the use of no drugs compared to the ‘use of one or more drug’ 
and ‘use of PPI’, whereas OAB use outcomes differed substantially. This corresponds with 
the literature on the faecal gut microbiota and this suggests that these drugs should be 
taken into account when studying potential VOC biomarkers. 
In this study we have investigated the change in electrical resistance per sample per sensor 
by means of an eNose, which led to the insight that the sensor outcomes of a single faecal 
sample assessment had a common tendency to either have outcomes above, on, or below 
all mean sensor outcomes. This was also demonstrated by strong correlations between the 
sensor outcomes. In general, it would be preferred to use VOC sensors that are sensitive to 
disease specific VOCs and less to lifestyle variances. The current study outcomes, however, 
suggest that the VOCs within the sample had a similar effect on most of the sensors. This 
may be due to a similar sensitivity of the sensors to VOCs in general, or samples in general 
may differ in the level of VOCs they hold. Should the first be the case, correction factors 
per lifestyle variable may be calculated for the change in electrical resistance per samples. 
Should the latter be the case, a general stable sample VOC outcome would be necessary 
to calculate these correction factors for the samples specifically. 
The main strength of this study is that we used a large prospective cohort of an endoscopy 
controlled group, to decrease the chance of colonic abnormalities influencing faecal VOC 
patterns. In addition, we combined all the lifestyle variables into one factor analysis which 
allowed for a reliable comparison of the influence the variables had on faecal VOC patterns. 
Another strength of this study was the standardised protocol of faecal sample collection, 
storage and VOC analysis. Our study also has several limitations. Most importantly, 
although this cohort was relatively large, some subgroups were small which hampered the 
possibilities to perform reliable statistics. Especially the subgroups age 18-35 years (n=9), 
BMI <18.5 (n=6) and vegetarian diet (n=7) were small, but notably, they accounted for the 
subgroups of largest influence on VOC patterns. Nevertheless, since the clinical variables 
were not used to yield the factors, these results are independent, and albeit the fact that 
these subgroups are small, they have yielded enough variability on the sensors and are 
responsible to these large variance components. 
In addition, it is important to note that we did not include a subgroup of participants with 
colon diseases. It may be possible that the influence of the lifestyle variables is of different 
significance on patients with colon diseases since we have not investigated the amount 
of change in electrical resistance these diseases establish. For example, should colon 
cancer cause a change in electrical resistance ten times as large as BMI<18.5, the influence 
of BMI<18.5 would become negligible. Last, it is important to note that the analyses 
performed with the eNose are all based on pattern-recognition and thus, the specific VOCs 
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accounting for the change in electrical resistance cannot be identified by this technique. 
We have chosen to explore the influence of lifestyle variables on faecal VOC patterns using 
the Cyranose 320®, since pattern-recognition based techniques usually are  easy-to-use 
devices which allow for fast and inexpensive measurements, and the Cyranose 320® has 
previously been shown to hold potential for the differentiation between various diseases 
and healthy state[5, 7, 8, 17]. This underlines its potential for implementation in clinical 
practice.
In conclusion, this prospective study highlights the influence of the variables age, gender, 
BMI, smoking habits, dietary preferences, co-morbidity and medication use on faecal VOC 
patterns, and therefore underlines the need for the correction for these lifestyle variables 
when performing faecal VOC analysis studies. It should be noted that, albeit faeces 
was used as a medium in this study, VOCs may be found in all bodily excrements and 
therefore the influences of lifestyle factors found in the current study may also apply for 
other mediums used (i.e. urine, plasma and/or breath). Future studies investigating disease 
specific VOC-profiles should therefore investigate whether the range of change in electrical 
resistance of these variables influences the disease associated VOC pattern, or, should 
preventively account for these influences in their study design either by matching on these 
lifestyle variables or by calculating correction factors for the intended device. In addition, it 
is important to investigate the VOC patterns of multiple colonic diseases in one study. This 
way, reference values can be calculated per disease and sensitivity and specificity for these 
disease specific VOC patterns can be investigated accordingly. 
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Supplementary figure 1. Heatmap of sensor data distribution. In this heatmap the absolute sensor 
outcomes are depicted per sensor per sample. Colors for sample outcomes are based on pre-defined 
breaks set as 0, 0.005, 0.01, 0.02, 0.04, 0.1. Sensors are depicted on the X-axis and samples are 
depicted on the Y-axis.  
 
Supplementary Figure 2. Spearman correlation of sensor variables. Sensors are depicted on both 
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the X-axis and Y-axis. A strong positive correlation was set as 0.7-1.0 (deeply red), moderate positive 
correlation 0.5-0.7 (red), weak positive correlation 0.3-0.5 (light red), no correlation -0.3-0.3 (white), 
weak negative correlation -0.3 to -0.5 (light blue), moderate negative correlation -0.5 to -0.7 (blue), 
strong negative correlation -0.7 to 1.0 (deeply blue).
Supplementary Figure 3: Distribution of lifestyle variables amongst faecal samples
 
Supplementary Figure 3. Scaled heatmap of variable distribution per sample per lifestyle variable of 
interest. Variables are depicted on the X-as, samples are depicted on the Y-as. Per variable, the mean 
and standard deviation are computed across all samples. Then, each measurement is subtracted from 
the mean, dividing it by its standard deviation per sensor to scale all measurements across all sensors.
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Supplementary Figure 4. Scree plot of parallel analyses. The first two factors account for 0.52 and 0.40 
of the total sensor outcome variance, which means that together they explain 0.92 of the total variance. 




Supplementary Figure 5. Visualization of sensor representation in each two of the factors. The first 
two factors account for 0.515 and 0.403 of the total sensor outcome variance, which means that 
together they explain 0.92 of the total variance. Therefore the first two factors are chosen for the 
factor analyses.
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Supplementary Figure 6: Scaled factor analyses per lifestyle variable of interest. Outcomes for factor 1 
are scaled on the X-axis and outcomes for factor 2 are scaled on the Y-axis. For both factors, the further 
from zero the variable is depicted, the larger the sum (either negative or positive) of the relative electrical 
resistance change for that factor. A: age per group 18-35; 36-50; 51-65; >65, B: Gender, C: Body Mass 
Index per group <18.5; 18.6-25; 25.1-30; >30, D: Smoking status per group non-smokers, quit >5years 
ago, quit <5years ago, smokers, E: diet in groups no dietary adjustments made; vegetarian diet; other 
diet, F: one or more comorbidities reported, G: Diabetes reported, H: Hypertension reported, I: Use of 
one or more drugs, J: Use of proton pump inhibitors, K: Use of oral antibiotics.
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Supplementary Table 1: Loadings of sensors in each of the two factors
Sensors ML1 ML2  
S1 0.803 0.476
S2  0.785 0.497
S3  0.811 0.513
S4  0.784 0.521
S5 0.563 0.816
S6  0.281 0.626
S7  0.793 0.600
S8  0.747 0.653

























Sensor loadings 16.475 12.882
Proportion Var 0.515  0.403
Cumulative Var 0.515  0.917
Loadings of sensors in each of the two factors. The loading per factor is shown for each sensor. The 
first two factors account for 0.515 and 0.403 of the total sensor outcome variance, which means that 
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The diagnostic work-up of paediatric irritable bowel syndrome (IBS) and functional 
abdominal pain – not otherwise specified (FAP-NOS), commonly includes invasive 
tests for discrimination from inflammatory bowel disease (IBD). Since this carries 
a high burden on patients, an ongoing need exists for development of non-
invasive diagnostic biomarkers for IBS and FAP-NOS. Several studies have shown 
microbiota alterations in IBS/FAP, which are considered to be reflected by faecal 
volatile organic compounds (VOC). The aim of this study was to evaluate whether 
paediatric IBS/FAP-NOS could be discriminated from IBD and healthy controls by 
faecal VOC analysis.
Methods
IBS/FAP-NOS was diagnosed according to the ROME IV criteria, and de novo 
IBD patients and healthy controls (HC) aged 4 to 17 years were matched on age- 
and sex. Faecal VOCs were analysed by means of field asymmetric ion mobility 
spectrometry (FAIMS).
Results
Faecal VOCs of 15 IBS/FAP-NOS, 30 IBD (15 ulcerative colitis, 15 Crohn’s disease) 
patients and 30 HC were analysed and compared. Differentiation between IBS/
FAP-NOS and IBD was feasible with high accuracy (AUC (95%CI), P-values; 0.94 
(0.88-1),  <0.00001). IBS/FAP-NOS profiles could not be differentiated from HC 
(0.59 (0.41-0.77), 0.167), whereas IBD profiles could with high accuracy (0.96 (0.93 
– 1), <0.00001).
Conclusion
Paediatric IBS/FAP-NOS could be differentiated from IBD by faecal VOC analysis 
with high accuracy, but not from healthy controls. The latter finding limits the 
potential of faecal VOCs to serve as diagnostic biomarker for IBS/FAP-NOS. 
However, VOC could possibly serve as additional non-invasive biomarker to 




Irritable bowel syndrome (IBS) and functional abdominal pain – not otherwise specified 
(FAP-NOS) are functional gastrointestinal disorders in children, with a worldwide prevalence 
of about 13%, often lasting for over five years after the diagnosis has been established 
[1]. Since biochemical diagnostic biomarkers are yet not available, the diagnosis relies on 
the symptom-based ROME IV criteria [2]. To fulfil one of the different ROME IV criteria, 
the symptoms must not be explained by another medical condition after appropriate 
evaluation. Differentiation between IBS and somatic disorders like inflammatory bowel 
disease (IBD) can be difficult. To exclude somatic diseases, the diagnostic work-up may 
include colonoscopy, which carries a high burden on patients and leads to high costs and 
risk of complications [3, 4]. Currently, faecal calprotectin (FCP) is the most commonly used 
non-invasive diagnostic biomarker to discriminate between IBS/FAP-NOS and IBD, which 
is characterised by a high sensitivity for mucosal inflammation (0.98, 95%CI 0.95-0.99), but 
limited specificity (0.68, 95% CI 0.50-0.86) [5]. Therefore, the search for an accurate, non-
invasive biomarker to differentiate between functional gastrointestinal disorders and IBD 
remains warranted.
Alterations of the intestinal microbiota have been described in IBS/FAP-NOS patients[6]. 
However, described results are contradictory and a specific microbial signature has not yet 
been defined. Furthermore, microbiota analysis is not easily applicable as non-invasive 
biomarker in clinical practice, since the analysis is complex, time-consuming and expensive[7]. 
Assessment of volatile organic compound (VOC) composition, which is considered to reflect 
microbiota composition and function, is a novel field in metabolomics(8). VOC analysis has 
shown potential to serve as a diagnostic biomarker for a broad range of gastrointestinal 
diseases, in particular those linked to microbial dysbiosis, e.g. Clostridium difficile infection, 
IBD, colorectal cancer and necrotizing enterocolitis [8-11]. Field asymmetric ion mobility 
spectrometry (FAIMS) is an easy-to-use, pattern based technique to assess VOC profiles, 
characterised by high reproducibility and relatively low costs, and therefore holds the 
potential as a point of care tool[12]. 
We hypothesised that paediatric IBS/FAP-NOS and IBD could be differentiated based on 
differences in faecal VOC profiles. The aim of this study was to investigate whether faecal 
VOC patterns, analysed by FAIMS, could serve as biomarker to differentiate IBS/FAP from 
IBD and from healthy controls, in a paediatric population.
METHODS
Study design
This case-control study was performed at the outpatient clinics of the paediatric 
(gastroenterology) departments of two tertiary centres VU university medical centre,  Emma 
Children’s Hospital, Academic Medical Centre (AMC), and one general hospital, OLVG Oost 
(all centres located in Amsterdam, the Netherlands).The study was performed between 
December 2013 and December 2016. 




Children aged 4 to 17 years visiting the outpatient clinic in one of the three hospitals 
between August 2016 and December 2016, and fulfilling the ROME IV criteria for IBS 
or FAP-NOS were eligible to participate[2]. During clinical appointment, patients were 
asked to participate in this study. Patients of whom informed consent was obtained, were 
provided a stool container and a questionnaire on abdominal symptoms, defecation 
pattern, including consistency of stool using the Bristol stool chart, medication use and 
medical history. Exclusion criteria were the use of anti-/probiotics or immunosuppressive 
therapy three months prior to inclusion, immunocompromised disease (i.e. leukemia, 
human immunodeficiency virus), diagnosis of a gastrointestinal disease, proven infectious 
colitis in the month before presentation (determined by positive stool culture for Salmonella 
spp., Shigella spp., Yersinia spp. Campylobacter spp., Clostridium spp. toxins, or parasites 
in stools) and a history of gastrointestinal surgery (except appendectomy). From all IBS and 
FAP-NOS patients included in this study, faecal calprotectin levels were assessed to exclude 
IBD. 
Inflammatory bowel disease
Participants aged 4 to 17 years were extracted from an existing cohort consisting of de novo 
treatment-naïve paediatric IBD patients (59 CD, 40 UC), included at the VU University medical 
centre and the Emma Children’s Hospital (AMC) between December 2013 and October 2015 
for a study on diagnostic faecal biomarkers. All participants were instructed to collect a faecal 
sample prior to bowel cleansing,  ileocolonoscopy and esophagogastroduodenoscopy. 
The diagnosis of IBD was made according to the revised diagnostic Porto-criteria for 
paediatric IBD, including endoscopic, histologic and radiologic findings by means of MR 
enteroclysis [13]. Localisation and behaviour of disease were classified according to the 
Paris Classification[14]. Clinical activity was determined at study inclusion based on the 
Physician Global Assessment (PGA-score), levels of faecal calprotectin (FCP >250ug/g was 
considered active disease) and C-reactive protein (CRP). Exclusion criteria were similar to 
the IBS/FAP-NOS group, except for exclusion when diagnosed with IBD.
Healthy controls
Children aged 4 to 17 years attending elementary and high schools in the province North-
Holland, The Netherlands, were instructed to collect a faecal sample. Similar to the IBS/FAP-
NOS group, all participants completed a questionnaire containing similar items. Exclusion 
criteria were functional gastrointestinal disorders according to the ROME IV criteria, diagnosis 
with a gastrointestinal or immunocompromised disease, history of gastrointestinal surgery 
(except appendectomy), or the use of pro- or antibiotics three months prior to inclusion. 
Matching procedure
A total of 15 IBS/FAP-NOS patients (9 IBS, 6 FAP-NOS) were strictly matched to 15UC, 15CD 
and 30HC, based on age and gender. For this, the following procedure was performed. 
First, from the 99 IBD patients (59 CD, 40 UC) of the existing cohort, all of the eligible 
subjects were strictly matched to IBS/FAP-NOS patients. Then, IBD patients were randomly 
included from the matched groups in a 1:1:1 ratio (IBS/FAP-NOS to UC to CD). After this, 30 




Patients were instructed to collect a fresh faecal sample in a stool container (Stuhlgefäß 
10ml, Frickenhausen, Germany) and instructed to store the sample in the refrigerator at 
home directly following bowel movement. The samples were transported to the hospital 
by one of the researchers, using cool elements and a cool bag. Here, samples were directly 
stored at -20 ºC until further handling.
Sample analysis
Faecal volatile organic compounds analysis was performed using FAIMS (Lonestar,Owlstone, 
Ltd.), according to the protocol as described in an earlier study by Bomers et.al. [9]. In short, 
faecal samples were thawed to room temperature ten minutes prior to VOC analysis. A 
mixture of 0.5g faecal sample and 3.5mL tap water was manually shaken to homogenize the 
sample. Compressed air (0.1MPa) was used as carrier gas to transfer the sample headspace 
into the FAIMS device. The Lonestar was set up in a pressurised configuration with a flow 
rate of 2L/min. The temperatures were set at 35°C for the sample holder, 70°C for the lid 
and 100°C for the filter region. After the procedure the air in the Lonestar was refreshed 
by analyzing the headspace of 10mL tap water[15]. The dispersion field passed through 51 
equal settings between 0% and 100% (in the ratio of the high electric field to low electric 
field). The compensation voltage was set between +6V and -6V in 512 steps for each 
dispersion field[9]. Each faecal sample was analysed three times sequentially, producing 
three matrices in 540s. For the statistical analysis, only the third matrix was used for optimal 
diagnostic potential[12]. 
Statistical analysis
The demographic data of each group (IBS/FAP-NOS, UC, CD and HC) was compared using 
the Kruskal-Wallis-H test with addition of the Wilcoxon-rank-sum test for continuous data. 
The Fisher’s exact tests was performed for dichotomous data using IBM SPSS version 22. 
Each FAIMS data consists of the 52224 data point in a 2D matrix. A pre-processing method 
was first performed to each data by applying 2D discrete wavelet transform. This step aims 
to decompose the data and extract subtle chemical signals hidden within a much larger 
signal. A 10 fold cross validation was then applied, where feature selection and classifier 
training was performed to 90% of data (training set) and class predictions produced from 
10% of data (test set). A Wilcoxon rank sum test as feature selection was used to calculate 
p-values in training set to identify which features best for disease prediction. From this, 
44 statistically important features were used. Four classification algorithms were applied, 
Sparse Logistic Regression, Random Forest, Gaussian Process, and Support Vector Machine. 
A receiver operator characteristic curve was created to predict area under curve (AUC), 
sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and 
p-values.
Ethical considerations
This study was approved by the Medical Ethical Review Committee (METc) of the VU 
University Medical Centre under file number 2015.393, and by the local medical ethical 
committees of the other two participating centres. Written informed consent was obtained 
from all parents, and from the child in case of age over twelve years.




Baseline characteristics and disease specifics of the study subjects are displayed in Table 1. 
There were no significant differences in age, sex and BMI between the IBS/FAP-NOS, IBD 
and HC subgroups. Levels of FCP were below 250ug/g in the IBS/FAP-NOS group, with the 
exception of one patient (476 ug/g) in which it normalised after repeating the measurement, 
while the IBD group had a median FCP level of 1237 ug/g (IQR [580 – 1885]). At study 
inclusion, the majority of IBS/FAP-NOS patients had experienced abdominal symptoms for 
over a year, with frequencies varying from once a week to daily. All of the children in the 
HC group were asymptomatic. Faecal frequency was higher in the IBS/FAP-NOS group 
compared to the HC group, although this was not significant. In addition, no differences in 
faecal consistency based on the Bristol Stool Chart and way of delivery were found between 
IBS/FAP-NOS and HC.  









Sex, male (n [%]) 9 [60] 8 [53] 8 [53] 15 [50]
Age (median [IQR]), years



















BMI (median [IQR]) NA NA 16.7 [5] 17.0 [3]
Bristol stool chart (n [%])
    Type 2
    Type 3
    Type 4










Stool frequency (n [%])
    2 times a week or less
    3-6 times a week
    Once a day
    2-3 times a day













    Caesarean section (n [%])






Frequency of symptoms (IBS/
FAP) (n [%])
    None
    Once a week
    2 to 4 times a week










Duration of symptoms ((n [%])
    Over a year
    2 to 12 months























Quiescent 1 0 NA NA
Mild 0 3 NA NA
Moderate 5 5 NA NA
Severe 9 7 NA NA
Faecal calprotectin (µg/g) 
(median[IQR])
1214 [627-1860] 1260 [401-1950] 22 [4.8 – 133] NA
CRP (mg/l) (median[IQR]) 21 [7-68] 4 [<2.5 – 7] NA NA
Crohn’s disease localisation1
Ileal (L1) 0 NA NA NA
Colonic (L2) 6 NA NA NA
Ileocolonic (L3) 9 NA NA NA
Proximal disease (L4) 5 NA NA NA
Crohn’s disease behaviour1
B1 (NSNP) 11 NA NA NA
B1p (NSNP+p) 2 NA NA NA
B2 (S) 0 NA NA NA
B2p (S + p) 0 NA NA NA
B3 (P) 0 NA NA NA
B3p (P + p) 2 NA NA NA
Ulcerative Colitis1
Proctitis (E1) NA 3 NA NA
Left-sided (E2) NA 2 NA NA
Extensive (E3) NA 10 NA NA
All values were obtained at study inclusion. Localisation of IBD was obtained by ileocolonoscopy 
and esophagogastroduodenoscopy before treatment initiation, and MR enteroclysis. Abbreviations: 
IQR, interquartile range; NA, not applicable; NSNP, non-stricturing non-penetrating; S, stricturing; P, 
penetrating; p, peri-anal disease. 1Based on Paris classification for inflammatory bowel disease(14). * 
Missing data from one subject. ** Missing data from two subjects. ¥ Significant differences between all 
subgroups p<0.001, analysed using Wilcoxon-rank-sum tests.
IBS/FAP-NOS versus IBD
The results of the VOC analysis by FAIMS technique are shown in Table 2. For each analysis, 
the best performing of the four different applied classification models is shown.  A complete 
overview of the data generated by the four classification models is given in supplemental 
Table 1-4. Faecal VOCs of IBS/FAP-NOS patients differed from IBD patients (AUC ± 95%CI, 
sensitivity, specificity, PPV, NPV, P-values; 0.94 (0.88-1), 1, 0.87, 0.79, 1, 0.00000002613). 
Corresponding Receiver Operating Characteristic (ROC)-curves are visualised in Figure 
1. An overview of the complete outcome of the four performed classifiers is displayed 
in supplementary tables 1-2. In addition, there were significant differences between VOC 
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profiles of IBS/FAP-NOS patients and both UC and CD subgroups (table 2, Supp table 1-4). 
A complete overview of the data generated by the four classification models is given in 
supplemental Table 1-4.
IBS/FAP-NOS versus HC
Children diagnosed with IBS/FAP could not be discriminated from HC (AUC ± 95%CI, 
sensitivity, specificity, PPV, NPV, P-values; (0.59 (0.41-0.77), 0.6, 0.63, 0.45, 0.76, 0.1667) 
(Table 2, Supp table 1-4, Figure 1).
IBD versus HC
Patients with IBD could be distinguished from HC (AUC ± 95%CI, sensitivity, specificity, PPV, 
NVP, P-values; 0.96 (0.9-1), 0.93, 0.97, 0.97, 0.94, 0.0000000003962) (Table 2, Supp table 
1-4, Figure 1). Both IBD subtypes UC and CD could each be differentiated from HC (Table 2, 
Supp table 1-4). Differentiation between CD and UC was not possible based on faecal VOC 
profiles (AUC ± 95%CI, sensitivity, specificity, PPV, NPV, P-values; (0.67 (0.47-0.88), 0.6, 0.8, 
0.75, 0.67, 0.05799) (Table 2, Supp table 1-4).
IBS versus FAP
Patient with IBS could not be discriminated from patients with FAP-NOS (AUC ± 95%CI, 
sensitivity, specificity, PPV, NPV, P-values; (0.76 (0.44-1), 1, 0.6, 0.83, 1, 0.9504) (Table 2, 
Supp table 1-4).
Table 2. Performance characteristics for the discrimination of irritable bowel syndrome, functional 
abdominal pain-not otherwise specified, inflammatory bowel disease and healthy controls by faecal 
VOC analysis.
AUC (95% CI) Sensitivity Specificity PPV NPV P
IBS/FAP-NOS vs IBD 0.94 (0.88 - 1) 1 0.87 0.79 1 0.00000002613
IBS/FAP-NOS vs CD 0.87 (0.73 – 0.1) 0.93 0.82 0.82 0.92 0.0001617
IBS/FAP-NOS vs UC 0.96 (0.91 – 1) 1 0.8 0.83 1 0.000007501
IBS/FAP-NOS vs HC 0.59 (0.41 - 0.77) 0.6 0.63 0.45 0.76 0.1667
IBS vs FAP-NOS 0.76 (0.44 – 1) 1 0.6 0.83 1 0.9504
IBD vs HC 0.96 (0.93 – 1) 0.93 0.97 0.97 0.94 0.0000000003982
UC vs HC 0.98 (0.94 – 1) 0.93 0.97 0.93 0.97 0.0000000005654
CD vs HC 0.95 (0.88 – 1) 0.93 0.93 0.88 0.97 0.0000001636
CD vs UC 0.67 (0.47 – 0.88) 0.6 0.8 0.75 0.67 0.05799
Sensitivities, specificities, p-values and AUCs are reported for the respective optimum cut-points.. 
Abbreviations: AUC, area under the curve; PPV: positive predictive value; NPV: negative predictive 
value; IBS: Irritable bowel syndrome; FAP-NOS: functional abdominal pain-not otherwise specified; 
IBD: Inflammatory bowel disease; UC: ulcerative colitis; CD: Crohn’s disease; HC: Healthy controls.
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Duration of sample storage
Duration of storage of the collected faecal samples did not differ between IBS/FAP-NOS 
and HC.  IBD samples were stored for a significantly longer period compared to both other 
subgroups (medium in months; CD 31.7; UC 45.1; IBS/FAP 0.6; HC 1.4, P<0.001).  
Figure 1. Receiver operating characteristics for irritable bowel syndrome/functional abdominal pain-
not otherwise specified versus inflammatory bowel disease, ulcerative colitis and Crohn’s disease and 
IBD versus healthy controls.
AUCs are reported for the Sparse logistic regression analyses. Abbreviations: AUC, area under the 
curve; IBS: Irritable bowel syndrome; FAP-NOS: functional abdominal pain-not otherwise specified; 
IBD: Inflammatory bowel disease; UC: ulcerative colitis; CD: Crohn’s disease; HC: Healthy controls.
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DISCUSSION
In this multicentre case-control study, we observed that faecal VOC profiles could differentiate 
between paediatric IBS/FAP-NOS patients and children with new onset, treatment naïve 
IBD with high accuracy, but not from HC. Furthermore, we have validated previous study 
results indicating that IBD and HC could be discriminated by VOC composition with high 
accuracy.
Studies on the potential of faecal VOC profiling to discriminate paediatric IBS/FAP-NOS 
from IBD have not yet been performed. Ahmed et. al. compared faecal VOC profiles of 
30 adult diarrhea-predominant IBS (IBS-D) patients, with 62 active CD, 48 active UC and 
109 healthy subjects using gas chromatography-mass spectrometry (GC-MS)(16). In that 
study, IBS-D could be discriminated from IBD based on 44 significantly different levels of 
metabolites. Specifically, increased levels of 35 metabolites, mostly consisting of esters from 
short chain fatty acids and (derivates of) cyclohexanecarboxylic acid, were seen in the IBS-D 
group, whereas only 6 metabolites (aldehydes and ketones) were increased in CD, and three 
(1-propanol,2-methyl, undecane, methoxy-phenyl oxine) in UC. All of these metabolites were 
used to construct a discriminatory model with high diagnostic accuracy (AUC IBS-D vs CD 
0.97; IBS-D vs UC 0.96; p=0.001). This diagnostic accuracy is comparable to that observed 
in our study. In addition, in the study by Ahmed and colleagues, significantly increased 
levels of 48 faecal metabolites were identified in adult IBS-D patients compared to HC (28 
increased in IBS-D of which 22 were esters, 20 increased in HC with no specific pattern 
and all weak associations) and were used for a discriminatory model as well (AUC 0.92; 
p<0.05). In the present study, however, VOC profiles of IBS/FAP-NOS were not significantly 
different compared to VOC profiles of HC. This difference could possibly be explained 
by our relatively small sample size. Another explanation could be our heterogeneous IBS/
FAP-NOS group in which subjects experienced a variety of symptoms (diarrhea, abdominal 
pain, bloating, constipation), whereas Ahmed. et. al. solely included patients with diarrhea-
predominant IBS type. However, we observed no significant differences in VOC profiles 
between the two subgroups IBS and FAP-NOS. In addition, the diagnostic accuracy could 
differ due to the fact that GC-MS and FAIMS analyse metabolite signals based on different 
techniques[17]. However, since the diagnostic accuracy to differentiate between IBS/FAP-
NOS and IBD is highly similar between these studies, we believe this had minimal influence 
on our study outcomes. 
In a study performed by Walton et. al., differences in faecal VOC composition between 
adult IBS (n=26), active CD (n=22), active UC (n=20) and HC (n=19) were assessed by means 
of GC-MS. Increased levels of metabolites (especially propanoic and butanoic acids and 
products from amino acid fermentation) were found in all disease groups, but were only 
significantly elevated in CD patients[18]. Unfortunately, no AUC values were provided, 
which complicates comparison with our study. The authors did report considerable overlap 
of volatile compound levels between the different subgroups, and a wide dynamic range in 
all groups including the controls.
Volatile organic compounds are considered to reflect (changes in) microbiota composition 
and function(8). In a recent study, gut microbiota composition of patients with IBS (n=30) 
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and IBD (60 UC, 50 CD) were compared to HC (n=50) using DNA sequencing[19]. Here, 
progressive increase in abundance of species belonging to the phyla Proteobacteria and 
Firmicutes were detected from HC to IBS to IBD, whereas Bacteriodetes representation 
was gradually reduced along this spectrum. The fact that differences in the microbiota 
composition between IBS and HC were shown in this study, whereas we did not find these 
differences based on VOC pattern, contradicts the above-mentioned hypothesis. However, 
not all microbial changes might reflect in corresponding alterations of VOC composition. 
Furthermore, VOC composition is not only influenced by the gut microbiota but also by 
systemic metabolic processes and exogenous VOCs from diet and medication [20]. Despite 
these facts, our results are in line with the finding that microbial differences between IBD 
and HC are more pronounced than between IBS and HC. 
Until now, paediatric studies on faecal VOCs as non-invasive biomarker for IBD have 
focused on the discrimination between IBD patients and healthy subjects, showing high 
accuracy to discriminate between the two groups[10, 21]. This high diagnostic value was 
found again in the current study. In the previous studies, however, children with abdominal 
symptoms were not included, limiting to reliable explore the specificity of VOC analysis to 
discriminate IBD from an intention to diagnose population. Since differentiation between 
IBS/FAP-NOS and active IBD is often challenging in daily practice, a strength of this 
study was that a paediatric IBS/FAP-NOS group was included. In addition, potential bias 
by colonic lavage, colonoscopy and medication on VOC composition was circumvented 
in IBD patients, since we only included de novo treatment-naïve IBD patients. Another 
strength is the participation of three medical centres, two tertiary hospitals and one general 
hospital. Furthermore, the performance characteristics of VOC analysis were assessed using 
supervised learning models, which are suitable for high-dimensional, complex datasets as 
they allow for reduction of dimensionality. These classifiers have previously been shown 
effective in studies involving human microbiota[22]. We have provided a complete overview 
of results of all applied learning models applied, as it is not known yet which model is most 
useful for faecal VOC analysis. 
There were also several limitations. First, the researchers were not blinded for both 
VOC and data analysis Second, the IBS/FAP-NOS group represents an heterogeneous 
population, although no significant differences in VOC profiles were observed between 
these two subgroups. We therefore believe that the heterogeneity of this group has not 
significantly influenced study outcomes. Another limitation was that we have not taken 
potential influence of medication and diet on faecal VOC outcome into account, which 
could possibly have influenced outcome[23, 24].  In addition, it is known that faecal 
calprotectine has a lower accuracy in CD patients with isolated proximal or ileal CD. It 
may be possible that these patients can be distinguished based on VOC patterns, since 
microbiota changes may differ compared to HC and colonic CD and UC, and VOCs are 
considered to reflect microbiota composition and function. Based on this study, it is hard 
to draw conclusions about the application of VOC pattern-based diagnostics for specific 
groupgroups since we did not include CD patients with isolated proximal or ileal disease. 
Lastly, the potential influence of sample storage time on metabolic degradation of VOCs 
has not yet been studied. It could be hypothesised that storage duration influences VOC 
outcome by metabolic degradation, even in frozen state.  Since storage time of the IBD 
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samples differed from that of the HC/IBS/FAP-NOS samples, this may possibly have 
affected outcome. However, the diagnostic accuracy to differentiate between IBD and HC is 
similar to our earlier studies, in which samples with comparable storage duration were used 
[10]. We therefore believe that metabolite degradation has had no substantial influence 
on presented results. Furthermore, it is important to point out that we used a pattern-
recognition method in this study, rather than identification of individual volatiles. We have 
chosen to use specifically the FAIMS method since this device is an easy-to-use tool which 
could be suitable for clinical implementation. Analysis by tools which can detect VOCs on 
individual level are expensive and time-consuming, and can therefore not be sued in daily 
practice [12]. 
Our findings implicate that faecal VOC analysis may have potential to serve as non-
invasive biomarker to discriminate IBS/FAP-NOS from IBD, with a higher specificity (87%) 
compared to the currently used FCP (specificity 68%), but not IBS/FAP-NOS from healthy 
state. Combination of biomarkers like FCP and faecal VOCs could possibly lower the rate 
of unnecessary colonoscopies in the diagnostic process of IBS/FAP-NOS patients. This was, 
however, a proof of principle study to explore the diagnostic value of faecal VOCs in IBS/
FAP-NOS patients. Whether this technique sufficiently contributes to this diagnostic process 
needs to be elucidated in a larger ‘intention-to-diagnose’ cohort, in which patients with 
suspected IBD should be divided in a case and control group based on FCP, combined with 
upper- and lower endoscopy findings and radiography (like MR enteroclysis). In addition, 
discrimination between IBS/FAP-NOS-like symptoms and active disease in the course of 
IBD patients who present with nonspecific abdominal pain may be challenging in clinical 
practice, by limited specificity of FCP. Whether VOC analysis could serve as an additional 
biomarker in this specific population needs to be evaluated in future studies including IBD 
and non-IBD patients with high FCP levels. 
In conclusion, we have shown that patients with IBS/FAP-NOS could be distinguished from 
IBD with a high diagnostic accuracy, but not from HC, by faecal VOC analysis using FAIMS 
technology. This signifies its potential role as additional non-invasive biomarker in the 





1. Gieteling MJ, Bierma-Zeinstra SM, Passchier J, et al. Prognosis of chronic or recurrent abdominal 
pain in children. J Pediatr Gastroenterol Nutr. 2008;47:316-326
2. Hyams JS, Di Lorenzo C, Saps M, et al. Functional Disorders: Children and Adolescents. 
Gastroenterology. 2016.02.015[ePub ahead of print]
3. Hoekman DR, Rutten JM, Vlieger AM, et al. Annual Costs of Care for Paediatric Irritable Bowel 
Syndrome, Functional Abdominal Pain, and Functional Abdominal Pain Syndrome. J Pediatr. 
2015;167:1103-1108 e1102
4. Levy I, Gralnek IM. Complications of diagnostic colonoscopy, upper endoscopy, and enteroscopy. 
Best Pract Res Clin Gastroenterol. 2016;30:705-718
5. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with 
suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 2010;341:c3369
6. Zhuang X, Xiong L, Li L, et al. Alterations of gut microbiota in patients with irritable bowel 
syndrome: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2017;32(1):28-38
7. Weinstock GM. Genomic approaches to studying the human microbiota. Nature. 2012;489:250-
256
8. Boots AW, Smolinska A, van Berkel JJ, et al. Identification of microorganisms based on headspace 
analysis of volatile organic compounds by gas chromatography-mass spectrometry. J Breath Res. 
2014;8:027106
9. Bomers MK, Menke FP, Savage RS, et al. Rapid, accurate, and on-site detection of C. difficile in 
stool samples. Am J Gastroenterol. 2015;110:588-594
10. van Gaal N, Lakenman R, Covington J, et al. Faecal volatile organic compounds analysis using 
field asymmetric ion mobility spectrometry: non-invasive diagnostics in paediatric inflammatory 
bowel disease. J Breath Res. 2017;12(1):016006
11. de Meij TG, van der Schee MP, Berkhout DJ, et al. Early Detection of Necrotizing Enterocolitis by 
Faecal Volatile Organic Compounds Analysis. J Pediatr. 2015;167:562-567 e561
12. Covington JA, van der Schee MP, Edge AS, et al. The application of FAIMS gas analysis in medical 
diagnostics. The Analyst. 2015;140:6775-6781
13. Levine A, Koletzko S, Turner D, et al. ESPGHAN revised porto criteria for the diagnosis 
of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 
2014;58:795-806
14. Levine A, Griffiths A, Markowitz J, et al. Paediatric modification of the Montreal classification for 
inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17:1314-1321
15. Arasaradnam RP, Westenbrink E, McFarlane MJ, et al. Differentiating coeliac disease from 
irritable bowel syndrome by urinary volatile organic compound analysis--a pilot study. PLoS One. 
2014;9:e107312
16. Ahmed I, Greenwood R, Costello Bde L, et al. An investigation of faecal volatile organic 
metabolites in irritable bowel syndrome. PLoS One. 2013;8:e58204
17. Arasaradnam RP, Covington JA, Harmston C, et al. Review article: next generation diagnostic 
modalities in gastroenterology--gas phase volatile compound biomarker detection. Aliment 
Pharmacol Ther. 2014;39:780-789
18. Walton C, Fowler DP, Turner C, et al. Analysis of volatile organic compounds of bacterial origin in 
chronic gastrointestinal diseases. Inflamm Bowel Dis. 2013;19:2069-2078
19. Lopetuso LR, Petito V, Graziani C, et al. Gut Microbiota in Health, Diverticular Disease, Irritable 
Bowel Syndrome, and Inflammatory Bowel Diseases: Time for Microbial Marker of Gastrointestinal 
Chapter 5. Faecal scent profiles in children with IBD-like symptoms
96
Disorders? Dig Dis. 2018;36(1):56-65
20. Forbes SL, Rust L, Trebilcock K, et al. Effect of age and storage conditions on the volatile organic 
compound profile of blood. Forensic Sci Med Pathol. 2014;10:570-582
21. de Meij TG, de Boer NK, Benninga MA, et al. Faecal gas analysis by electronic nose as novel, non-
invasive method for assessment of active and quiescent paediatric inflammatory bowel disease: 
Proof of principle study. J Crohns Colitis. 2014.09.004[Epub ahead of print]
22. Knights D, Costello EK, Knight R. Supervised classification of human microbiota. FEMS Microbiol 
Rev. 2011;35:343-359
23. Voreades N, Kozil A, Weir TL. Diet and the development of the human intestinal microbiome. 
Front Microbiol. 2014;5:494
24. Lin A, Bik EM, Costello EK, et al. Distinct distal gut microbiome diversity and composition in 




Supplemental Table 1. Performance characteristics with corresponding area under the curve, 
sensitivity, specificity, positive and negative predictive value of faecal volatile organic compound 
analysis for the discrimination of irritable bowel syndrome, functional abdominal pain-not otherwise 
specified, inflammatory bowel disease and healthy controls using the supervised classification method 
Sparse Logistic Regression







IBS/FAP-NOS vs IBD <0.0001 0.92 (0.84 – 1) 0.93 (0.68 – 1) 0.8 (0.61 – 0.92) 0.7 0.96
IBS/FAP-NOS vs CD 0.002 0.8 (0.63 - 0.98) 0.8 (0.52 - 0.96) 0.8 (0.52 - 0.96) 0.8 0.8
IBS/FAP-NOS vs UC <0.0001 0.94 (0.84 - 1) 1 (0.78 - 1) 0.87 (0.6 - 0.98) 0.88 1
IBS/FAP-NOS vs HC 0.219 0.57 (0.4 - 0.75) 0.8 (0.52 - 0.96) 0.4 (0.23 - 0.59) 0.4 0.8
IBS vs FAP-NOS 0.950 0.76 (0.44 - 1) 1 (0.69 - 1) 0.6 (0.15 - 0.95) 0.83 1
IBD vs HC <0.0001 0.96 (0.92 - 1) 0.93 (0.78 - 0.99) 0.93 (0.78 - 0.99) 0.93 0.93
UC vs HC <0.0001 0.98 (0.94 – 1) 0.93 (0.68 - 1) 0.97 (0.83 - 1) 0.93 0.97
CD vs HC <0.0001 0.95 (0.9 - 1) 1 (0.78 - 1) 0.73 (0.54 - 0.88) 0.65 1
CD vs UC 0.058 0.67 (0.47 – 0.88) 0.6 (0.32 – 0.84) 0.8 (0.52 – 0.96) 0.75 0.67
Supplemental Table 2. Performance characteristics with corresponding area under the curve, 
sensitivity, specificity, positive and negative predictive value of faecal volatile organic compound 
analysis for the discrimination of irritable bowel syndrome, functional abdominal pain-not otherwise 
specified, inflammatory bowel disease and healthy controls using the supervised classification method 
Random Forrest
IBS/FAP-NOS vs IBD <0.0001 0.93 (0.85 - 1) 0.93 (0.68 - 1) 0.83 (0.65 - 0.94) 0.74 0.96
IBS/FAP-NOS vs CD 0.0004 0.86 (0.72 - 0.99) 1 (0.78 - 1) 0.6 (0.32 - 0.84) 0.71 1
IBS/FAP-NOS vs UC <0.0001 0.96 (0.91 - 1) 1 (0.78 - 1) 0.8 (0.52 - 0.96) 0.83 1
IBS/FAP-NOS vs HC 0.282 0.55 (0.37 - 0.74) 0.8 (0.52 - 0.96) 0.4 (0.23 - 0.59) 0.4 0.8
IBS vs FAP-NOS 0.703 0.42 (0.039 - 0.8) 0.7 (0.35 - 0.93) 0.6 (0.15 - 0.95) 0.78 0.5
IBD vs HC <0.0001 0.96 (0.9 - 1) 0.93 (0.78 - 0.99) 0.97 (0.83 - 1) 0.97 0.94
UC vs HC <0.0001 0.96 (0.91 - 1) 0.93 (0.68 - 1) 0.97 (0.83 - 1) 0.93 0.97
CD vs HC <0.0001 0.92 (0.82 - 1) 0.93 (0.68 - 1) 0.87 (0.69 - 0.96) 0.78 0.96
CD vs UC 0.398 0.52 (0.3 – 0.73) 1 (0.79 – 1) 0.13 (0.017 – 0.4) 0.54 1
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Supplemental Table 3. Performance characteristics with corresponding area under the curve, 
sensitivity, specificity, positive and negative predictive value of faecal volatile organic compound 
analysis for the discrimination of irritable bowel syndrome, functional abdominal pain-not otherwise 
specified, inflammatory bowel disease and healthy controls using the supervised classification method 
Gaussian Process









<0.0001 0.94 (0.88 - 1) 1 (0.78 - 1) 0.87 (0.69 - 0.96) 0.79 1
IBS/FAP-NOS 
vs CD
0.0002 0.87 (0.73 - 1) 0.93 (0.68 - 1) 0.8 (0.52 - 0.96) 0.82 0.92
IBS/FAP-NOS 
vs UC
<0.0001 0.94 (0.85 - 1) 1 (0.78 - 1) 0.87 (0.6 - 0.98) 0.88 1
IBS/FAP-NOS 
vs HC
0.167 0.59 (0.41 - 0.77) 0.6 (0.32 - 0.84) 0.63 (0.44 - 0.8) 0.45 0.76
IBS vs FAP-NOS 0.570 0.48 (0.14 - 0.82) 0.5 (0.19 - 0.81) 0.8 (0.28 - 0.99) 0.83 0.44
IBD vs HC <0.0001 0.95 (0.88 - 1) 0.93 (0.78 - 0.99)) 0.93 (0.78 - 0.99) 0.93 0.93
UC vs HC <0.0001 0.98 (0.94 - 1) 0.93 (0.68 - 1) 0.93 (0.78 - 0.99) 0.88 0.97
CD vs HC <0.0001 0.93 (0.86 - 1) 0.87 (0.6 - 0.98) 0.9 (0.73 - 0.98) 0.81 0.93
CD vs UC 0.659 0.46 (0.24 – 0.67) 1 (0.78 – 1) 0.067 (0.0017 – 0.32) 0.52 1
Supplemental Table 4. Performance characteristics with corresponding area under the curve, 
sensitivity, specificity, positive and negative predictive value of faecal volatile organic compound 
analysis for the discrimination of irritable bowel syndrome, functional abdominal pain-not otherwise 

















0.2878 0.45 (0.26 - 0.63) 0.53 (0.27 - 0.79) 0.57 (0.37 - 0.75) 0.38 0.71
IBS vs 
FAP-NOS
0.9354 0.74 (0.42 - 1) 0.9 (0.55 - 1) 0.6 (0.15 - 0.95) 0.82 0.75
IBD vs HC 0.0000000001787 0.92 (0.84 - 1) 0.93 (0.78 - 0.99) 0.9 (0.73 - 0.98) 0.9 0.93
UC vs HC 0.00000009573 0.93 (0.85 - 1) 0.93 (0.68 - 1) 0.93 (0.78 - 0.99) 0.88 0.97
CD vs HC 0.00000001636 0.95 (0.88 - 1) 0.93 (0.68 - 1) 0.93 (0.78 - 0.99) 0.88 0.97
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ABSTRACT
Endoscopic evaluation is mandatory in establishing the diagnosis of paediatric 
inflammatory bowel disease (IBD), but unfortunately carries a high burden on 
patients. Volatile organic compounds (VOC) have been proposed as alternative, 
noninvasive diagnostic biomarkers for IBD. The current study aimed to assess and 
compare the potential of faecal and urinary VOC as diagnostic biomarkers for 
paediatric IBD in an intention-to-diagnose cohort. In this cohort study, patients 
aged 4–17 years, referred to the outpatient clinic of a tertiary referral centre under 
suspicion of IBD, were eligible to participate. The diagnosis was established by 
endoscopic and histopathologic assessment, participants who did not meet the 
criteria of IBD were allocated to the control group. Participants were instructed to 
concurrently collect a faecal and urinary sample prior to bowel lavage. Samples 
were analysed by means of gas chromatography–ion mobility spectrometry. 
In total, five ulcerative colitis patients, five Crohn’s disease patients, and ten 
age and gender matched controls were included. A significant difference was 
demonstrated for both faecal (p-value, area under the curve; 0.038, 0.73) and 
urinary (0.028, 0.78) VOC profiles between IBD and controls. Analysis of both 





Inflammatory bowel disease (IBD), classically divided into the two phenotypes—Crohn’s 
disease (CD) and ulcerative colitis (UC)—presents in childhood in approximately 25% of 
de novo cases and its incidence has increased over the past decades to ten per 100,000 
children [1,2]. Establishing IBD diagnosis in this population can be challenging, since 
presenting clinical symptoms are commonly heterogeneous and nonspecific. To date, 
the gold standard for the diagnosis of IBD remains endoscopic evaluation and histologic 
examination of mucosal biopsies, however, this is an invasive procedure which carries a 
high burden on patients [3]. Faecal calprotectin (FCP) has been demonstrated as a useful 
noninvasive biomarker in the selection of patients eligible for further endoscopic evaluation, 
however, its specificity (68%) is limited, resulting in false-positive results and, subsequently, 
the performance of unnecessary colonoscopies [4]. Therefore, the search for noninvasive 
diagnostic IBD tests remains warranted [5].
Volatile organic compounds (VOC) have emerged as a promising alternative. These 
gaseous molecules are products of physiologic and pathophysiologic metabolism and are 
emitted from various bodily excrements. Alterations in cellular metabolic processes (e.g., in 
diseased state, microbiome metabolism, and microbiota-host interaction) are reflected by 
changes in the emitted VOC composition [6]. For VOC analyses, gas-chromatography-mass 
spectrometry (GC–MS) is considered the gold standard, because of its ability to identify 
specific VOC based on their physiochemical properties [7]. A relatively new method has 
been introduced for VOC analyses, being gas chromatography–ion mobility spectrometry 
(GC–IMS), in which traditional GC is combined with an orthogonal separation of molecules 
based on ion mobility [8]. By combining these two methods, the sensitivity for VOC analyses 
can be increased. 
Faecal VOC are most extensively studied in microbiome-associated gastro-intestinal 
diseases, since faecal VOC are largely produced during bacterial fermentation in the gut 
and reflect microbial composition, function, and microbiota–host interaction [9]. Faecal VOC 
analyses have demonstrated to allow for differentiation of a variety of diseases, including 
colorectal carcinoma, celiac disease, and IBD [5,10,11]. Similarly, testing of urinary VOC 
has potential to identify various diseases, such as cancer, diabetes and adult IBD [12–15]. 
IBD-related VOC can be detected in both exhaled breath and urine, however, exhaled 
breath analysis has shown to be challenging because of sample instability and the need 
for comprehensive analytical methods [7,16–19]. Collection of faecal has been described 
to evoke feelings of embarrassment and concerns about hygiene by patients [20]. In most 
countries, however, collection of urine samples is considered as more user friendly and, 
therefore, less of a burden for patients [21]. Furthermore, urine can be more easily provided 
on demand in situations where fast analysis is required to accelerate the diagnostic process. 
Therefore, it is aimed in the current study to assess and compare the diagnostic accuracy of 
faecal and urinary VOC in de novo paediatric IBD by means of GC–IMS. 




The current case-control pilot study was part of an ongoing cohort study, in which patients 
(aged 4–17 years) are included at the paediatric gastroenterology department outpatient 
clinic of a tertiary referral centre (Amsterdam University Medical Centre; locations: VU 
medical centre (VUmc) and Amsterdam medical centre (AMC)) [22–25]. For the current 
study, patients suspected of IBD in the period May 2017 to February 2019 were eligible to 
participate. Exclusion criteria were a proven bacterial or viral gastroenteritis during the month 
prior to inclusion, use of immunosuppressive therapy, antibiotic or probiotic treatment in 
the last three months prior to inclusion, diagnosis with an immunocompromising disease, 
and insufficient ability to understand the Dutch language. Furthermore, participants who 
were not able to deliver both samples (i.e., faecal and urine) were excluded.
Participants, and in case of participants aged under 12 years, parents, were asked for 
informed consent after their first visit to the outpatient ward. The Medical Ethical Review 
Committee of the VUmc approved the study protocol (file number 2015.393, amendment 
number A2017.188).
All patients underwent diagnostic endoscopic evaluation because of suspected IBD based 
on clinical symptoms and/or biochemical abnormalities (e.g., elevated FCP). Participants 
were allocated to either the IBD or control group, based on the combination of endoscopy, 
histology, biochemical, and radiological findings, according to the currently applied 
international diagnostic criteria [1]. Disease localisation and behaviour in IBD cases were 
assessed based on the Paris classification [26]. IBD cases were matched to controls based 
on age and gender. 
Sample and Data Collection
Participants were asked to concurrently collect a faecal and urine sample in containers 
(Stuhlgefäβ 10 mL, Frickenhausen, Germany), prior to bowel lavage. Participants were 
asked to store the samples in their freezer at home within one hour after collection and 
bring the samples to the hospital in cooled condition on their next regular appointment at 
the outpatient clinic. Samples were then directly stored at −20 °C until further handling. In 
addition to the sample collection, participants were asked to complete an online accessible 
and secured questionnaire (Castor EDC®) on dietary preferences, clinical symptoms, 
Bristol stool scale, bowel habits, extra-intestinal symptoms, residency, medical history, and 
medication use. Additional clinical information was collected from medical files, including 
IBD disease activity based on the physician global assessment (PGA) and laboratory values 
(CRP and FCP) [27,28]. 
Sample Preparation
Sample preparation was performed according to our standard operating procedure, 
previously described by Rouvroye et al. [29]. In short, a calibrated scale (Mettler Toledo, 
AT 261 Delta Range, Columbus, OH, USA) was used to weigh approximately 500 mg of 
faecal and frozen urine sample. Subsequently, the sample was transferred to a glass vial (20 
mL, Frickenhausen, Germany), which was restored in a −20 °C freezer [22]. The faecal and 
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urine samples were sent to the BioMedical Sensors Lab, School of Engineering, University 
of Warwick (Coventry, UK) on dry ice (−80 °C) for VOC analyses. 
Sample Analyses
Samples were analysed following the methods by Rouvroye et al. [29]. Samples were 
randomly analysed by means of GC-IMS (FlavourSpec®, G.A.S., Dortmund, Germany). This 
device consists of a GC column front-end, coupled with a drift tube IMS. The complex 
chemical mixture deriving from the sample headspace were pre-separated by the GC, 
before detection by IMS. Within the IMS, VOC ions were created by soft chemical-ionization 
(low-radiation tritium (H3) source). These ions were fed into a drift tube, which were 
propelled along it by an electric field. Against the flow of ions a buffer gas was added (in 
our case pure nitrogen). In general, larger molecules were struck more times than smaller 
molecules, losing momentum and, thus, taking longer to travel along the tube. As a result 
each substance’s drift time is dependent on the interaction of the ion with the electric field 
and the buffer gas. A Faraday plate was used to measure the resulting ion current, as a 
function of time [30]. The GC–IMS was connected to an automatic sampling system with a 
chiller allowing processing of a batch of 32 samples kept in cooled condition (4 °C) until the 
start of the analyses to minimize sample degradation (PAL RSi, CTC Analytics AG, Zwingen, 
Switzerland). In the eight minutes before analysis, the samples’ temperature was raised to 
80 °C. Then, a syringe transported the headspace from the vial into the injector port of the 
instrument and into the GC column. Nitrogen 99.9% (3.5 bar), served as a carrier gas at 
40 °C for GC separation, and as drift gas for IMS at 45 °C. GC flow rate was set at 20 mL/
minute (34.175 kPa) for six minutes, while a 150 mL/min flow rate (0.364 kPa) was used for 
IMS. 
Statistical Analyses
The Statistical Package for the Social Sciences (SPSS, IBM version 22.0) was used to perform 
the statistical analyses on demographics. Patient demographics and clinical characteristics 
were compared using a Fisher’s exact test for dichotomous and ordinal data, and an 
independent t-test for parametric continuous data. In case of non-parametric continuous 
data, a Mann–Whitney U test was performed. A p-value < 0.05 was considered as a statistical 
significant difference. 
Prior to the statistical analyses of VOC profiles, the GC–IMS data was pre-processed to 
only crop areas containing relevant chemical data, which is located centrally within the 
data. Group noise was filtered after setting a threshold limit and, finally, a correction was 
performed for instrumental disturbances by baseline correction. This reduced the data 
points per sample from around 11 million to a more manageable 100,000. Classification 
was performed applying a 10-fold cross-validated approach, in which the data was split 
into a 90% training set and a 10% test set. The 100 most discriminatory features were 
identified by Wilcoxon rank-sum test (undertaken within the fold) and then used to train five 
different classifiers: random forest, Gaussian process, sparse logistic regression, support 
vector machine, and neural network algorithms. Subsequently, these models were applied 
to the test set. This process was repeated until every sample was classified as a test sample 
and from the resultant classification probabilities, statistical results were calculated. This 
method is part of our standard pipeline used in similar studies [18,29,31]. Statistical analyses 
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were performed using R packages, including randomForest for random forest, glmnet for 
sparse logistic regression, kernlab for support vector machines, neuralnet for neural network 
analysis, and kernlab for Gaussian processes.
RESULTS
Baseline Characteristics
In total, ten IBD (five UC and five CD) and ten matched controls were included from the 
intention to diagnose cohort (Figure 1). The baseline characteristics are listed in Table 1. 
Faecal calprotectin was significantly higher (median 1208 µg/g, p-value 0.009) in the IBD 
group compared to the control group (median 50 µg/g). No differences were found for the 
remaining variables, as listed in Table 1.
Figure 1. Study design. Inclusion flowchart Abbreviations: n, number; IBD, inflammatory bowel 
disease; CD, Crohn’s disease; UC, ulcerative colitis.
In Table 2, the diagnoses established after diagnostic endoscopy in the control group are 
listed. Three children were diagnosed with irritable bowel syndrome or functional abdominal 
pain, three had an alternative diagnosis, and in four children no alternative diagnosis was 
established. Three children in the IBD group used prescribed medication, opposed to six 
children in the control group (Table 3).
VOC Analysis
The discrimination of IBD from controls based on faecal VOC profiles, was statistically 
significant when training the algorithm using the neural network analysis (area under the 
curve (AUC) (95% confidence interval (CI)), p value, sensitivity, specificity; 0.73 (0.47–0.99), 
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0.038, 0.70, 0.90), Figure 2A. For urinary VOC profiles, a similar accuracy was reached for 
the discrimination between IBD and controls using the sparse logistic regression classifier 
(0.78 (0.57–1), 0.028, 0.80, 0.70), Figure 2B. The results of the remaining statistical analyses 
are listed in Supplemental Tables 1 and 2. An example of GC–IMS output of faecal and 
urine, collected by the same participant, is displayed in Figure 3. 
Table 1. Baseline characteristics.
IBD (n = 10) Controls (n = 10) p-value
Sex male (n, %) 4 (40) 4 (40) 1.00
Age years (median, IQR) 15.0 (10.4–17.1) 14.2 (9.6–16.6) 0.71
BMI kg/m2 (mean, SD) 18.9 (4.35) 21.3 (3.66) 0.20
Bristol stool scale (median, IQR) 6.0 (4.0–6.5) 6.0 (3.0–6.0) 0.97
FCP µg/g (median, IQR) 1208.0 (1023.5–3086.5) 50.0 (14.5–900) 0.01
CRP mg/L (median, IQR) <2.5 (<2.5–39.5) <2.5 (<2.5–4.35) 0.15
Sample weight faecal mg (median, IQR) 500.5 (485.3–512.5) 502.5 (486.3–508.8) 0.88
Sample weight urine mg (median, IQR) 644.5 (532.8–726.0) 628.5 (592.0–663.3) 0.79










Proximal disease (L4) 1
Crohn’s Disease behaviour
B1 (NSNP) 4





Ulcerative Colitis (n = 5) localisation
Proctitis (E1) 0
Left sided (E2) 2
Extensive (E3) 3
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Values were obtained at inclusion. CD and UC localisation and behaviour were determined using the 
Paris classification, based on findings during ileocolonoscopy and esophagogastroduodenoscopy and 
magnetic resonance enteroclysis before start of treatment [26]. Abbreviations: CRP, C-reactive protein; 
FCP, faecal calprotectin; IQR, interquartile range; SD, standard deviation; NSNP, non stricturing non-
penetrating; S, stricturing; P, penetrating; p, perianal disease.
Table 2. Diagnoses controls.
Diagnosis Number 
Irritable bowel syndrome 2
Functional abdominal pain 1
Helicobacter pylori infection 1
Juvenile polyp 1
Multiple angiodysplasia 1
IBD excluded without alternative diagnosis 4
All diagnoses in the controls were established after diagnostic endoscopy. In four children, no diagnosis 
was established. Abbreviations: IBD, inflammatory bowel disease.
Table 3. Medication usage.
IBD n Controls n
Number of participants receiving medication 3 6
Type of prescribed medication
Ferrous fumarate 1 Macrogol 2
Ethinylestradiol/Desogestrel 1 Ibuprofen/Naproxen 2







All values were obtained at inclusion. In the control group, more medication usage was reported. 
Several participants were prescribed more than one type of medication. Abbreviations: n, number; 
IBD, inflammatory bowel disease; *, inhaler. 
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Figure 2. Faecal and urinary VOC profiles for the differentiation between inflammatory bowel disease 
and controls. (A)Receiver operating characteristic (ROC) curves display the ROC curve for the faecal 
VOC profile, and (B) displays the ROC curve for urinary VOC profile for the discrimination of IBD from 
controls. Abbreviations: AUC, area under the curve.
Figure 3. Example output of GC-IMS analysis. Here, the GC-IMS of faecal (A) and urinary (B) VOC 
profiles of one IBD patient are displayed. On the y-axis, the retention time indicates the separation 
time of the analyte by means of gas chromatography. The color represents the VOC concentration 
using color spectrum from blue to red, indicating low concentration to high concentration, respectively.
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DISCUSSION
In the current study, the diagnostic accuracies of faecal and urinary VOC profiles to detect 
IBD were assessed and compared, using an endoscopy-controlled intention to diagnose 
cohort. Diagnostic accuracies were similar for both faecal and urine VOC profiles. 
The potential of faecal VOC analysis in paediatric IBD has been previously studied. Van 
Gaal et al. used field asymmetric ion mobility spectrometry (FAIMS) to analyse faecal VOC 
composition, which allowed for discrimination between 36 paediatric IBD patients and 24 
healthy controls (HC) (AUC 0.76, sensitivity 0.79, specificity 0.79, p-value < 0.001) [23]. 
In another study on paediatric IBD, a robust difference in faecal VOC profiles between 
26 UC patients and 28 HC (AUC, sensitivity, specificity, p-value; 1.00, 1.00, 1.00, <0.001) 
and between 29 CD and 28 controls (0.85, 0.86, 0.67, <0.001) were observed [25]. In the 
current study, similar diagnostic accuracies were identified for the discriminationof IBD from 
controls. However, due to smaller sample size, no sub-analyses could be performed to 
assess the diagnostic accuracy of faecal VOC analyses in the discrimination of both entities 
from controls. 
To the best of our knowledge, the current study is the first in which the potential of urinary 
VOC profiles in paediatric IBD is assessed. In adult IBD, urinary VOC analysis allowed for 
discrimination between IBD and HC by means of an eNose device (Fox 4000; AlphaMOS, 
Toulouse, France) and FAIMS [15]. The FAIMS analysis demonstrated similar diagnostic 
accuracies (AUC 0.75, p-value < 0.001), while VOC profiles analysed by the eNose device 
(AUC 0.88, p-value < 0.001) exceeded the accuracy as observed in the current study. 
The variation in diagnostic accuracies can be explained by several aspects. In the current 
study, a paediatric intention to diagnose cohort was established, whereas in the study 
by Arasaradnam et al., adult patients with an established IBD diagnosis which received 
treatment were included. Additionally, IBD cases were compared to healthy controls, rather 
than with symptomatic patients, in which it is expected that there is a larger difference 
between healthy controls and cases, than is seen between symptomatic non IBD patients 
compared to IBD cases. Furthermore, different analytical techniques were applied, 
Arasaradnam et al. used an eNose device and FAIMS, whereas in the current study a novel 
technique, GC–IMS, was applied. Lastly, in the current study, a more diverse control group 
was included, which could possibly have led to a lower diagnostic accuracy. 
Since the algorithms applied in the current study have different internal learning structures 
and certain algorithms tend to perform better in different data collections, multiple 
algorithms were assessed in order to identify the best performing algorithm per bodily 
excrement [32]. Additionally, it is hypothesised that different VOCs can be detected in urine 
and faecal. Analyses of faecal VOCs is believed to reflect the gut microbiota composition 
and local inflammatory processes. On the contrary, urinary VOCs associated with IBD are 
more likely to be a combination of compounds that diffused from the intestine into the 
bloodstream and VOCs that are associated with general inflammation, which therefore 
can be detected in urine [15,33]. However, to confirm this hypothesis, in-depth studies are 
needed to identify specific VOCs in both urine and faecal. 
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The main strength of this study is the inclusion of cases and controls from an endoscopy-
controlled intention-to-diagnose cohort. Especially when aiming to find a novel non-
invasive biomarker to prevent the performance of (unnecessary) endoscopic assessment 
of paediatric patients, it is important to include a realistic selection of patients with gastro-
intestinal symptoms representing clinical practice, since this is the population that would 
potentially gain the most from an alternative diagnostic biomarker. In addition we included 
de novo IBD patients, circumventing bias by VOC altering effects of bowel lavage and 
immunosuppressive medication [34]. All controls were successfully matched to a case based 
on age and gender. Additionally, there were no differences in BMI between groups, which 
is a known factor affecting the VOC profile outcome [35]. By comparison of two different 
bodily excrements, concurrently collected by participants, we were able to identify the 
most suitable bodily excrement to analyse. Urine offers practical advantages compared to 
faecal while maintaining a similar diagnostic accuracy and should, therefore, be considered 
as a clinically implementable bodily excrement for VOC analysis. To assess the diagnostic 
accuracy of faecal and urinary VOCs, we chose to perform the analysis by means of GC–IMS. 
These analyses are quick (approximately ten minutes per sample), sample pre-treatment 
is not required and the system setup is relatively easy [8,18,36]. Furthermore, machine 
learning algorithms can be trained to quickly recognize a disease specific profile without the 
need of the identification of individual VOC, making the GC–IMS output suitable for future 
clinical application. Lastly, there was no statistical difference between sample storage time 
between groups, which is demonstrated to affect VOC profile outcome [21,22].
This pilot study is limited by a relatively small sample size; consequently, no sub-analyses 
could be performed, assessing the diagnostic accuracy of faecal and urinary VOCs in the 
discrimination of both phenotypes from controls. Additionally, cases and controls could 
not be matched based on the possible confounding effect of medication use because 
of the variety of types of medication that were reported. One control patient was using 
esomeprazole, a proton pump inhibitor, that has been shown to influence the faecal VOC 
pattern [35,37]. Although the other reported medicines have not been described to affect 
the VOC profile, this difference might have influenced the VOC outcome.
Both faecal and urinary VOC analyses allowed for the discrimination of de novo IBD from 
controls by means of GC–IMS, with similar diagnostic accuracies, making them potential 
adjuvant biomarkers in the diagnostic work up of IBD. 
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Table S1. Statistical analyses of Faecal VOC profiles for the discrimination of IBD from controls








0.53 [0.25-0.81] 0.4 [0.12-0.74] 0.8 [0.44-0.97] 0.67 0.57 0.602 0.140
Random 
forest
0.53 [0.24-0.82] 0.3 [0.067-0.65] 1.0 [0.69-1.00] 1.00 0.59 0.425 0.936
Gaussian 
Process




0.60 [0.34-0.86] 0.8 [0.44-0.97] 0.5 [0.19-0.81] 0.62 0.71 0.218 0.618
Neural 
Network
0.73 [0.47-0.99] 0.7 [0.35-0.93] 0.9 [0.55-1.00] 0.88 0.75 0.038 0.499
Here, all the statistical analyses performed on the faecal VOC profiles are listed. For these analyses, 
100 features were used in the 10 fold cross validation. The neural network analysis is identified as the 
best performing algorithm for the discrimination of IBD from controls based on faecal VOC profiles. 
Abbreviations: AUC, area under the curve; CI, confidence interval; PPV, positive predictive value; NPV, 
negative predictive value; IBD, inflammatory bowel disease; VOC, volatile organic compounds.
Table S2. Statistical analyses of urinary VOC profiles for the discrimination of IBD from controls








0.78 [0.57-1.00] 0.8 [0.44-0.97] 0.7 [0.35-0.93] 0.73 0.78 0.028 ‬ 0.502
Random 
forest
0.69 [0.44-0.94] 1.0 [0.69–1] 0.5 [0.19-0.81] 0.67 1.00 0.070 0.876
Gaussian 
Process




0.47 [0.19-0.75] 0.4 [0.12-0.74] 0.8 [0.44-0.97] 0.67 0.57 0.604 0.608
Neural 
Network
0.41 [0.14-0.68] 0.6 [0.26-0.88] 0.5 [0.19-0.81] 0.55 0.56 0.764  0.293
Here, all the statistical analyses performed on the urinary VOC profiles are listed. For these analyses, 100 
features were used in the 10 fold cross validation. The Sparse logistic regression analysis is identified as 
the best performing algorithm for the discrimination of IBD from controls based on faecal VOC profiles. 
Abbreviations: AUC, area under the curve; CI, confidence interval; PPV, positive predictive value; NPV, 
negative predictive value; IBD, inflammatory bowel disease; VOC, volatile organic compounds.
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Inflammatory bowel disease (IBD) is diagnosed and monitored using endoscopic 
assessment, which is invasive and costly. In this study, potential of faecal volatile 
organic compounds (VOC) analysis for IBD detection and identification of disease 
activity was evaluated.
Methods
IBD patients visiting outpatient clinics of participating tertiary hospitals were 
included. Active disease was defined as FCP ≥250 mg/g, remission as FCP <100 
mg/g with Harvey Bradshaw Index <4 for Crohn’s disease (CD) or Simple Clinical 
Colitis Activity Index <3 for ulcerative colitis (UC). Healthy controls (HC) were 
patients without mucosal abnormalities during colonoscopy. Faecal samples were 
measured using gas chromatography-ion mobility spectrometry. 
Results
A total of 280 IBD patients collected 107 CDa, 84 CDr, 80 UCa and 63 UCr samples. 
Additionally, 227 HC provided one faecal sample. UC and CD were discriminated 
from HC which was highly accurate (AUC (95%CI): UCa vs HC 0.96(0.94-0.99); 
UCr vs HC 0.95(0.93-0.98); CDa vs HC 0.96(0.94-0.99); CDr vs HC 0.95(0.93-
0.98)). There were small differences between UC and CD (0.55(0.50-0.6)) and no 
differences between active disease and remission (UCa vs UCr 0.63(0.44-0.82); 
CDa vs CDr 0.52(0.39-0.65)). 
Conclusion
Our study outcomes imply that faecal VOC analysis holds potential for IBD 




Crohn’s disease (CD) and ulcerative colitis (UC) are chronic gastrointestinal diseases 
characterised by periods of relapse and remission, and are together referred to as 
inflammatory bowel disease (IBD). A worldwide increase in incidence as well as prevalence 
of IBD has been observed. In Europe, prevalence of 505 UC patients per 100.000 persons 
(Norway) and 322 CD patients per 100.000 persons (Germany) have been reported[1]. 
The gold standard to diagnose and monitor mucosal inflammation in IBD patients is 
ileocolonoscopy, substantiated by histological assessment of biopsy specimens and/or 
radiology. This diagnostic workup is invasive, expensive, and carries a risk of complications. 
Therefore the identification of  a specific, non-invasive IBD biomarker or biomarkers remains 
warranted.
Volatile organic compounds (VOCs) are gaseous carbon-bound chemicals and are thought 
to represent both metabolic processes in the human body and the interaction between gut 
microbiota and host[2]. These molecular end-products can be found in all bodily excretions 
dependent on their volatility and sample temperature. The great potential of faecal VOC 
profiles as non-invasive biomarkers have been described for various gastrointestinal 
diseases[3-5]. The detection of paediatric IBD using faecal VOC patterns has also been 
subject of various studies, with promising results[6-8]. The literature on its potential in 
adults, who are generally characterised by more comorbidity and medication use, is limited. 
The aim of the current study is to validate the potential of faecal VOC patterns to detect IBD 
and to assess their potential to identify disease exacerbation in adults.
METHODS
Study design
This study was performed at the outpatient clinics of the Gastroenterology and Hepatology 
department in two tertiary referral hospitals (Amsterdam UMC, location VUmc, Amsterdam 
and Maastricht University Medical Centre (MUMC+) in Maastricht), and two district hospitals 
(OLVG West in Amsterdam and Spaarne Gasthuis (SG), location Hoofddorp and Haarlem) 
all located in The Netherlands. 
Ethical statement
The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki 
(6th revision, 2008) as reflected in a priori approval by the Medical Ethical Review Committee 
(METc) of the Amsterdam UMC, location VUmc under file number 2016.135, by the METc of 
the MUMC+ under file number NL24572.018.08, and by the local medical ethical committee 
of the OLVG West and Spaarne Gasthuis. Written informed consent was obtained from all 
study participants. Once sample collection was completed, all samples were shipped to the 
School of Engineering, University of Warwick (Coventry, UK) for VOC analysis.
Study participants
Inflammatory bowel disease patients
All patients aged 18 years or older with an established diagnosis of IBD based on clinical, 
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endoscopic, histological and/or radiological criteria and with a scheduled consult at the 
outpatient clinic of one of the two tertiary referral hospitals were asked to participate in this 
study[9]. Patients were asked to collect a faecal sample and to complete a questionnaire, 
which included information on age, gender, BMI, smoking status, abdominal symptoms, 
medication use, comorbidity and clinical disease activity based on the Harvey Bradshaw 
Index (HBI) for CD patients and the Simple Clinical Colitis Activity Index (SCCAI) for UC 
patients [10, 11]. Active disease was defined as FCP level of ≥250 mg/g. Remission was 
defined as FCP <100 mg/g combined with HBI <4 points or SCCAI <3 points. All IBD 
patients were included in the primary statistical analysis assessing the diagnostic potential 
of faecal VOCs to differentiate between IBD and HC. Only IBD patients with clearly defined 
disease activity based on FCP and HBI/SCCAI levels were included in the secondary 
analyses aiming to assess differences in faecal VOC pattern between active disease and 
remission. Demographic and clinical data (including Montreal classification and history of 
bowel surgery) were obtained from electronic patient files[12]. 
Healthy controls
All patients aged 18 years and older with a scheduled colonoscopy at the Amsterdam UMC, 
OLVG West and Spaarne Gasthuis were asked to participate in this study regardless of their 
endoscopy indication. They were asked to complete a questionnaire on demographics, 
smoking status, abdominal symptoms, bowel movements, dietary intake, comorbidity and 
medication use. Patients without endoscopic abnormalities observed during endoscopy 
were included in this study as healthy controls (except asymptomatic external haemorrhoids, 
asymptomatic diverticula and/or small anal fibromas). In case of mucosal biopsies to exclude 
microscopic alterations, subjects were only included as HC if no histologic abnormalities 
were detected. Exclusion criteria were a history of bowel disease (e.g. celiac disease, IBD, 
CRC), failure to perform complete colonoscopy because of various reasons (e.g. inadequate 
bowel cleansing, pain) and/or collection of insufficient faecal sample mass to perform VOC 
analysis.
Sample collection
Inflammatory bowel disease Amsterdam University Medical Centres
Between February 2015 and November 2017, IBD patients were asked to collect two faecal 
samples (Stuhlgefäß 10ml, Frickenhausen, Germany) from the same bowel movement prior 
to the consult: one for FCP levels and one for VOC analysis. The FCP sample was sent to 
the hospital by mail. The sample for VOC analysis was the participant’s own freezer within 
one hour following collection and transported to the hospital in cooled condition using ice 
packs and/or ice cubes on the day of their consultation. The samples were stored at -24°C 
directly upon arrival at the hospital.
Inflammatory bowel disease Maastricht University Medical Centre 
Between October 2009 and December 2010 patients were asked to collect stool from one 
bowel movement on the day of their consult and bring it fresh to the hospital. This stool 
sample was stored in the fridge (4 °C) directly upon arrival at the hospital. From this bowel 
movement, two samples were prepared on the day of delivery. One for FCP measurements 
(using ELISA in Amsterdam UMC and FEIA in MUMC+) and one for research purposes. The 




Between February 2015 and November 2017, patients from the Amsterdam UMC, OLVG 
West and SG collected a faecal sample in a container (Stuhlgefäß 10ml, Frickenhausen, 
Germany)  prior to bowel cleansing and endoscopic assessment. They were asked to store 
their sample in their own freezer within one hour after collection. These samples were 
transported to the hospital in cooled condition using ice packs and/or ice cubes on the day 
of their endoscopy. The samples were stored at -24°C directly upon arrival at the hospital.
Sample preparation
For the faecal VOC analysis, subsamples of 500mg per participant (with a maximum 
deviation 5%) were weighted on a calibrated scale (Mettler Toledo, AT 261 Delta Range, 
Ohio, United States). This was done whilst keeping the samples on dry-ice to avoid thawing 
of the samples during preparation. Samples were then labelled and re-stored in glass vials 
(20ml headspace vial, Thames Restek, Saunderton, UK), in a -24°C freezer until further 
handling. As confirmed by our research team in a previous sampling method study on faecal 
VOC analysis, the 500mg weight was carefully chosen to provide an optimum amount of 
VOCs in the headspace of the sample [13]. The subsamples were shipped to the University 
of Warwick on dry ice for faecal VOC analysis.
Faecal volatile organic compound analysis
Faecal samples were analysed using gas chromatography ion mobility spectrometry 
(GC-IMS, FlavourSpec®, G.A.S., Dortmund, Germany) conform our previously published 
studies[14, 15]. In short, the instrument consists of a gas chromatography column (GC), 
coupled to an ion mobility spectrometry (IMS) drift tube. First, the GC column provides 
separation of the mixture of chemicals found in the headspace of the faecal sample. This 
separation is based on the levels of attraction between the molecules in the faecal volatile 
mixture (mobile gas phase) and molecules in the stationary phase. These chemicals are 
then driven to the IMS column. Within the IMS, a low-radiation tritium (H3) source causes 
to chemicals to create reactant ions with the gas atmosphere in the column. These ionised 
VOCs then travel at atmospheric pressure against the flow of an inert drift gas, in this 
case, nitrogen. In general, larger molecules collide more times than smaller molecules, 
losing momentum and thus, taking longer to travel along the tube. The drift time of each is 
substance therefore determined by the ion’s mass and geometrical structure. The resulting 
ion current is measured by an electrometer as a function of time[16]. Figure 1 gives an 
example output from the instrument. Here the y-axes is the retention time and the x-axes is 
the IMS drift time. As can be seen, the majority of the image is blue, which is the signal when 
there is no chemicals present. The white and red ‘blobs’ are chemicals being detected. The 
red line through the whole image is the output when there no chemicals present and is the 
response to the carrier gas.
Statistical analysis
Prior to the statistical analyses, a number of pre-processing steps are used to reduce the 
dimensionality of the data to speed up the analysis steps. As can be seen from Figure 1, the 
majority of the data (non-background) is located at the central section of the plot, thus there 
is high data dimensionality, but low information content. Therefore, the data is cropped 
to only the ‘areas of interest’. This area is decided upon by visual inspection of all of the 
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samples, to ensure that all of the chemical information is included. A threshold was applied 
to remove background noise and finally corrected for instrumental disturbances by baseline 
correction. This reduces data points per sample from approximately 11 million to a more 
manageable 100,000.  The data was split into three sets, 70% for training and validation 
and 30% as test set. A Wilcoxon rank-sum test was used to find the 20, 50 and 100 most 
discriminatory features and Sparse Logistic Regression, Random Forest, Gaussian Process, 
Support Vector Machine and Neural Net classification were used to provide statistical results 
from the 30% test set, based on the training and validation sets.
RESULTS
Baseline characteristics
A total of 280 IBD patients (164 CD patients, 112 UC patients, 4 IBD-undetermined) were 
included. Sample collection is depicted in Figure 2. In total, 495 faecal IBD samples (292 
CD, 197 UC, 6 IBD-U) were collected during the follow-up period of this study. Of these, 
107 were active CD (CDa), 84 were CD in remission (CDr), 80 were active UC (UCa) and 63 
were UC in remission (UCr) according to the previously mentioned criteria. The number of 
samples collected per individual varied as 159 patients provided one sample, 65 patients 
were sampled twice, 34 patients collected three samples, 10 patients collected four 
samples, 10 patients collected five samples, and two participants provided six and eight 
samples. Samples of IBD patients were compared to 227 HCs who all collected a single 
sample. Baseline demographics of all study participants are given in Table 1. There was no 
statistically significant difference in gender and smoking status between IBD patients and 
HC. The mean age of the IBD group was 46.1 (±29.8) compared to 60.6 (±11.8) for HC. The 
mean FCP levels for active disease and remission were 664.6 mg/g and 29.9 mg/g for CD 
and 1108.5 mg/g and 39.5 mg/g for UC, respectively (Table 2).
 
Figure 1. Example output of gas chromatography – ion mobility spectrometer. The y-axes is the 
retention time and the x-axes is the IMS drift time. White and red blobs are chemicals being detected. 
The red line through the whole image is the output when there no chemicals present and is the 




Figure 2. Sample collection scheme. In total, 495 faecal IBD samples (292 CD, 197 UC, 6 IBD-U) 
were collected during the follow-up period of this study. Of these, 107 were active CD, 84 were CD 
in remission, 80 were active UC and 63 were UC in remission according to the previously mentioned 
criteria. Abbreviations: MUMC+,   Maastricht University Medical Centre; Amsterdam UMC, Amsterdam 
University Medical Centres; IBD-U, Inflammatory bowel disease undetermined; CD, Crohn’s Disease; 
UC, ulcerative colitis.









Gender, f (n, [%]) 107 [65.2] 54 [48.2] 1 [25] 129 [56.8]
Age, y mean ± s.d. 45.3 [19-82] 51.1 [18-80] 49 [36 – 64] 60.6 ±11.8
Smoking 
Current (n, [%]) 37 [22.6] 6 [5.4] 1 [25] 37 [16.3]
Past (n, [%]) 56 [34.1] 59 [52.7] 3 [75] 92 [40.5]
Never (n, [%]) 67 [40.9] 43 [38.4] 0 [0] 98 [43.2]
Medication use at inclusion
Aminosalicylates (n, [%]) 22 [13.4] 54 [50.0] 1 [25] NA
Corticosteroids (n, [%]) 26 [15.9] 14 [12.5] 0 [0] NA
Immunosuppresives 
Thiopurines (n, [%]) 58 [35.4] 28 [25.0] 2 [5] NA
Methotrexate (n, [%]) 12 [7.3] 3 [2.7] 0 [0] NA
Biologicals
Anti-TNF (n, [%]) 61 [37.2] 26 [23.2] 1 [25] NA
Selective (n, [%]) 5 [3.0] 0 [0] 0 [0] NA
Table continues










Antibiotics 3 months prior 
to inclusion (n, [%])
7 [4.3] 6 [5.4] 0 [0] 32 [14.1]
Surgery prior to inclusion (n, [%]) 72 [43.9] 15 [14.3] 0 [0] NA
Ileocecal resection (n, [%]) 57 [37.8] 2 [1.2]* NA NA
(Partial) Colectomy (n, [%]) 31 [18.9] 15 [9.1] NA NA
Small bowel resection (n, [%]) 5 [3.0] 0 [0] NA NA
Montreal Classification at inclusion
Age at diagnosis, y
A1 ≤ 16 (n, [%]) 20 [13.4] 4 [3.6] 1 [25] NA
A2 = 17 – 40 (n, [%]) 93 [56.7] 61 [54.5] 1 [25] NA
A3 ≥ 41 (n, [%]) 51 [31.1] 47 [42.0] 2 [50] NA
Localisation Crohn’s disease



































E1 Proctitis (n, [%]) NA 9 [8.0] NA NA
E2 Left-sided (n, [%]) NA 53 [47.3] NA NA
E3 Pancolitis (n, [%]) NA 49 [43.8] NA NA
Abbreviations: CD, Crohn’s Disease; UC, ulcerative colitis; IBD-U, inflammatory bowel disease 
undetermined; HC , healthy control; f, female; y, year; n, number of participants; NA, not applicable. 
*Ileocecal resection in UC group was solely performed in combination with (partial) colectomy 
**Montreal classification of one participant missing.
Faecal volatile organic compound analysis
The results of the VOC analysis by means of GC-IMS are shown in Table 3. For every 
comparison, the results from the Sparse Logistic Regression classification based on the 100 
most discriminative features are presented. A complete overview of data generated using 
all five classifiers based on the 20, 50 and 100 most discriminative features are given in 
Supplemental Table 1-3. In addition, in Supplemental Table 4, the results of our post-hoc 
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analysis comparing only samples collected in the same period of time are shown. 
Inflammatory bowel disease versus healthy controls
IBD patients were discriminated from HC with a high diagnostic accuracy (AUC ± 95%CI, 
sensitivity, specificity, PPV, NPV, P-values; 0.96 (0.92 – 0.99), 0.97, 0.92, 0.98, 0.87, <0.0001)
(Table 3, Supplementary table 1-4). Likewise, high diagnostic accuracy was found for 
detection of CD during active state and remission (0.96 (0.94 – 0.99), 1, 0.92, 0.74, 1, 
<0.0001 for active CD; 0.95 (0.93 – 0.98), 1, 0.90, 0.67, 1, <0.0001 for CD in remission) 
(Table 3, Supplementary tables 1-4). This was similar for the detection of UC both during 
active state and remission (0.96 (0.94 – 0.99), 1, 0.92, 0.74, 1, <0.0001 for UCa; 0.95 (0.93 – 
0.98), 1, 0.88, 0.52, 1, <0.0001 for UCr) (Table 3, Supplementary tables 1-4). Corresponding 
Receiver Operating Characteristic (ROC) curves are visualised in Figure 3a-d. 
Table 2. Inflammatory bowel disease activity scores
CDa (n=107) CDr (n=84) UCa (n=80) UCr (n=63)
FCP (mean ± s.d.) 664.6 ± 448.9 29.9 ± 24.4 1108.5 ± 952 39.5 ± 27.3
SCCAI (mean ± s.d.) NA NA 2.9 ± 0.38 0.8 ± 0.20
HBI (mean ± s.d.) 4.1 ± 0.42 1.1 ±  0.16 NA NA
Medication use at time of sample collection
Aminosalicylates (n, [%]) 11 [10.3] 19 [22.6] 35 [43.8] 26 [41.3]
Corticosteroids (n, [%]) 22 [20.6] 8 [8.3] 15 [18.8] 4 [6.3]
Thiopurines (n, [%]) 34 [31.8] 32 [39.1] 21 [26.3] 33 [52.4]
Methotrexate (n, [%]) 7 [6.5] 3 [3.6] 2 [2.5] 0 [0]
Anti-TNF (n, [%]) 46 [43.0] 52 [61.9] 38 [47.5] 26 [41.3]
Selective biologicals (n, [%])† 2 [1.9] 0 [0] 1 [1.3] 0 [0]
Antibiotics (n, [%]) 1 [0.9] 1 [1.2] 4 [5.0] 1 [1.6]
IBD Activity scores. Abbreviations: CDa, active Crohn’s disease; CDr, Crohn’s disease in remission; 
UCa, active ulcerative colitis; UCr, ulcerative colitis in remission; FCP, faecal calprotectin; SCCAI, simple 
clinical colitis activity index; HBI, Harvey Bradshaw Index. Active disease was defined as an FCP level of 
≥250 mg/g, remission was defined as an FCP level of <100 combined with a HBI <4 points or SCCAI 
<3 points. †All users of Vedolizumab.
Crohn’s disease versus ulcerative colitis
Faecal VOC patterns of CD and UC differed significantly, though the diagnostic accuracy 
was very low (0.55 (0.50-0.60), 0.17, 0.96, 0.90, 0.36, 0.03) (Table 3, Figure 3h, Supplemental 
Tables 1-4). Furthermore, there was no difference between UC and CD when comparing 
active disease and remission subgroups separately (Table 3).
Active disease versus remission
There was a slight significant difference in faecal VOC patterns between active IBD (UC and 
CD combined) and remission (0.59 (0.51-0.67), 0.21, 0.96, 0.90, 0.39, 0.019) (Figure 3i). 
However, when comparing active and remission state of CD and UC subgroups separately, 
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this significance was not found (CD active vs CD in remission 0.52 (0.39-0.65), 0.72, 0.43, 0.71, 
0.45, 0.645; UC active vs UC in remission 0.63(0.44-0.82), 0.67, 0.57, 0.79, 0.42, 0.08) (Table 3).
Table 3. Differences in faecal volatile organic compound patterns
AUC (95% CI) Sensitivity Specificity PPV NPV p-value
Inflammatory bowel disease versus healthy controls
IBD versus HC 0.96 (0.92 - 0.99) 0.97 0.92 0.98 0.87 <0.0001 
CD versus HC 0.97 (0.95 - 1) 0.94 0.96 0.97 0.91 <0.0001 
CDa versus HC 0.96 (0.94 - 0.99) 1 0.92 0.74 1 <0.0001 
CDr versus HC 0.95 (0.93 - 0.98) 1 0.90 0.67 1 <0.0001 
UC versus HC 0.95 (0.91 - 0.99) 1 0.91 0.88 1 <0.0001 
UCa versus HC 0.96 (0.94 - 0.99) 1 0.92 0.74 1 <0.0001 
UCr versus HC 0.95 (0.93 - 0.98) 1 0.88 0.52 1 <0.0001 
Active disease versus remission
IBDa versus IBDr 0.59 (0.51 - 0.67) 0.21 0.96 0.90 0.39 0.019 
CDa versus CDr 0.52 (0.39 - 0.65) 0.72 0.43 0.71 0.45 0.645
UCa versus UCr 0.63 (0.44 - 0.82) 0.67 0.57 0.79 0.42 0.082 
Crohn’s disease versus ulcerative colitis
CD versus UC 0.55 (0.50 - 0.60) 0.17 0.96 0.90 0.36 0.031
CDr versus UCr 0.52 (0.39 - 0.65) 0.95 0.18 0.67 0.67 0.607
CDa versus UCa 0.56 (0.37 - 0.75) 0.74 0.43 0.76 0.40 0.744 
All the results of the VOC analysis are obtained using Sparse Logistic Regression classification based 
on the 100 most discriminative features. Sensitivities, specificities, p-values and AUC are reported for 
the respective optimum cut-off points. Abbreviations: IBD, inflammatory bowel disease; CD, Crohn’s 
disease; UC, ulcerative colitis; a, active disease state; r, remission; HC, healthy controls; AUC, area 
under the curve; PPV, positive predictive value; NPV, negative predictive value. 
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Figure 3. Receiver operator characteristic curves for all comparisons. Receiver operator characteristic 
curves for the differentiation between study groups based on Sparse Logistic Regression classification 
using the 100 most discriminative features. A. Inflammatory bowel disease versus healthy controls; B. 
Crohn’s disease versus healthy controls; C Active Crohn’s disease versus heathy controls; D. Crohn’s 
disease in remissions versus healthy controls; E. Ulcerative colitis versus healthy controls; F. Active 
ulcerative colitis versus healthy controls; G. Ulcerative colitis in remission versus healthy controls; H. 
Crohn’s diseases versus ulcerative colitis; I. Active inflammatory bowel diseases versus in remission.
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DISCUSSION
The GC-IMS faecal VOC profiles distinguish adults with IBD, and subgroups of UC and 
CD patients from HC with high diagnostic accuracies, both during active disease state 
and remission. VOC profiles of IBD patients in active disease state and remission differed 
statistically, but these small differences were not clinically relevant.
Sensitivity of faecal VOCs to discriminate between IBD and HC in this study are similar 
to that of the currently used non-invasive biomarker FCP (0.98, 95%CI 0.95-0.99) [17]. 
However, the specificity of faecal VOC patterns both during active disease and remission 
is higher compared to the reported values of FCP (0.81-0.91) in adults. This underlines its 
value for differential diagnosis in clinical practice. 
To the best of our knowledge, the potential of faecal VOC profiles to discriminate IBD from 
HC was previously assessed in only one study in an adult population, including faecal samples 
of 117 CD, 100 UC and 109 HC analysed by gas chromatography – mass spectrometry (GC-
MS)[18]. Although AUC values were not provided, active CD and HC could be separated 
excellently based on three unique metabolites. In contrast to our findings, study results of 
Ahmed et. al did not allow discrimination between UC patients compared to HC. Other 
studies have assessed the diagnostic potential of faecal VOCs for IBD using pattern-based 
techniques in paediatric cohorts, such as electronic nose (eNose) instruments (CD 29, UC 
26, HC 28) and field asymmetric ion mobility spectrometry (FAIMS) (23 CD, 13 UC, 24 
HC)([6, 7]. In the study using eNose technology, similar accuracies to the current study 
were demonstrated for the detection of IBD. In addition, using an eNose there was a clear 
separation of UC and CD phenotypes. Using FAIMS, CD patients were separated from 
HC with high accuracy and moderate separation was found for the discrimination of UC 
compared to both HC and CD samples (AUC of 0.74 and 0.67, respectively). 
In the current study, active IBD was discriminated from remission with a very weak accuracy 
and there was no difference between the active and inactive subgroups of CD as well as 
UC. The existing literature on the differentiation between active and inactive IBD based on 
VOC profiles in adults is both scarce and contradictory. In only one study the assessment of 
IBD activity based on faecal VOC profiles has been described. Inactive CD was separated 
significantly from active CD based on faecal VOC profiles, whereas VOC profiles of active and 
inactive UC were similar[18]. This accuracy was similar to a study on VOC profiles comparing 
135 breath samples of CD in remission with 140 breath samples active CD using GC-MS, 
where an AUC of 0.98 was measured [19]. Though, this accuracy was based on different 
metabolite alterations. In addition, a high diagnostic accuracy to differentiate between 62 
active and 70 inactive UC breath VOC profiles was found by the same research group (AUC 
0.94)[20]. Urinary VOC profiles have also been found to discriminate between active IBD (24 
CD, 24 UC) and remission (4 CD, 4 UC) using the pattern-recognition technique FAIMS, with 
moderate accuracies (AUC CD 0.66, UC 0.74)[21]. 
Alterations in the faecal VOC patterns may be explained by alterations in metabolic processes, 
like the secretion of inflammatory end products in the colon or alterations in dietary intake, 
by microbial dysbiosis or a combination of these. In a recent study on canine olfaction, in 
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vitro breast cancer and colon cancer cells were grown and it was observed that dogs were 
able to differentiate between the metabolic waste retrieved from these cancer cells and 
from benign cells, but not between the cell waste of breast and colon cancer, implying 
that both cancers share a common smell print[22]. The same might apply for inflammatory 
diseases like Crohn’s disease and ulcerative colitis of which it may be hypothesised that the 
VOC patterns of CD and UC patients are based on a shared (metabolic) reaction, explaining 
the similarities in VOC patterns observed in the current study. 
The discrimination between IBD and HC as well as inability to discriminate between active 
and quiescent disease in the current study may partly be explained by one of the main 
sources of faecal VOCs: the gut microbiota. The faecal microbiota of a healthy individual 
consists of over 400 different species which play an important role in the defence against 
invading organisms. There is a large inter-individual diversity in the faecal microbiota 
composition of healthy individuals [23]. Nonetheless, the microbiome of an individual 
is remarkably stable, suggesting the presence of a core microbial community, which is 
dependent of host factors [24, 25]. In multiple studies, this microbial stability has been 
found greater in healthy individuals compared to IBD patients of which the microbial 
composition is defined by more deviations over time and a decrease in diversity, specifically 
in abundance of Firmicutes in CD patients and a decrease in butyrate-producing bacteria in 
UC patients (Faecalibacterium Prausnitzii, Roseburia Hominis) [26-31]. This may well explain 
the high diagnostic accuracy to discriminate between IBD patients and HC based on faecal 
VOC profiles in the current study. Remarkably, this variability of microbial composition in 
IBD patients does not correlate with disease activity. Fluctuations in microbiota composition 
have been observed both during exacerbation and clinical remission, which has hampered 
the identification of microbial changes related to the presence of flare-ups [26, 27, 32]. 
The dissimilarities to other studies considering differentiation between active and remission 
disease state may also be due to the use of different techniques to analyse VOC profiles. In 
the current study, we made use of pattern-recognition, since this is a fast and relatively cheap 
manner to analyse faecal VOCs and is therefore highly adequate for clinical implementation. 
A downside of this technique is the inability to identify specific metabolites. Differences 
between IBD and HC based on faecal VOCs have previously been demonstrated due to an 
altered composition of esters, short chain fatty acids (SCFAs) and cyclo-hexanecarboxylic 
acid, of which the first group is believed to be associated with bacterial dysbiosis[33]. The 
differences between active disease state and remission in faecal as well as breath VOC 
profiles originate from a different group of metabolites, mainly aldehydes and ketones [19, 
20, 34]. These metabolites play a role in inflammatory processes as they are the metabolic 
products of tissue damage and oxidative stress, and may therefore be the result of a more 
general host-response to inflammation rather than an IBD specific metabolic alteration. It is 
possible that the GC-IMS column we used has been sensitive to the range of metabolites 
differentiating IBD from HC, but not to the metabolites produced in inflammatory processes. 
Strength of this study was the large sample size, which allowed for the creation of a training 
and internal validation set for the development of algorithms using the different machine 
learning classifiers and an external validation set to test the best available algorithm. In 
addition, this was a prospective multicentre cohort which made use of endoscopy controlled 
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healthy individuals. The large scale of the cohort has contributed to the generalizability 
and the endoscopy controlled HC group excluded bias by other colonic abnormalities. A 
limitation of this study was the use of clinical activity indices and FCP for defining disease 
activity in the current study, instead of using the gold standard: endoscopic assessment. 
Because of its invasiveness, it was not ethically feasible to ask of participants to undergo 
this investigation without immediate clinical indication. Furthermore, sample age might 
have been of influence on study outcomes, especially on the IBD samples collected in 
the period of 2009-2010[13]. However, the results from our post-hoc analysis where we 
solely compared samples collected in the region of North-Holland within one period of 
time did not give different outcomes, and we therefore believe that this has not influenced 
our results significantly (Supplemental Table 4).  In addition, the use of probiotics may be 
of influence on our study outcomes as we did not include a specific question on this and 
thus we are not able to correct for this in our study results. Last, although we have designed 
this study using pattern-recognition because of its suitability for clinical implementation, 
the inability to detect specific metabolites complicated the comparison to other literature.
Future research assessing faecal VOC patterns for IBD detection should include subgroups 
of patients with non-IBD induced mucosal inflammation for a reliable assessment of its 
specificity. Additionally, to assess the potential of faecal VOCs for IBD monitoring, 
the potential differences in VOC patterns between active IBD and remission should be 
further studied in an endoscopy-controlled cohort with standardised follow-up moments, 
ensuring the sole inclusion of patients with active disease and remission based on mucosal 
appearance and histology findings. These disease (activity) specific profiles would allow for 
fast and accurate IBD detection and follow-up. Third, it would be interesting to compare 
the faecal metabolite composition and microbiota in IBD simultaneously in a multi-omics 
approach, exploring the origin of the faecal VOC pattern alterations.
In conclusion, our results suggest that faecal VOC pattern analysis is a promising technique 
for non-invasive diagnosis of IBD. Because of its high specificity, this new technique may 
be beneficial to patients and health care costs by lowering the number of (unnecessary) 
invasive endoscopies currently needed to diagnose IBD in patients with a high FCP value. 
Since faecal VOC patterns did not allow for differentiation between disease activity state, 
its potential for monitoring intra-individual course of IBD may be hampered and should be 
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Supplemental Table 1. Overview of the data generated using all five classifiers based on the 20 most 
discriminative features using all IBD patients
AUC (95% CI) Sensitivity Specificity PPV NPV p-value
IBD versus HC
Sparse Logistic Regression 0.94 (0.90 – 0.98) 0.99 0.88 0.97 0.96 <0.0001
Random Forest 0.95 (0.92 - 0.99) 0.97 0.92 0.98 0.89 <0.0001
Gaussian Process 0.96 (0.92 – 0.99) 0.99 0.97 0.92 0.98 <0.0001
Support Vector Machine 0.96 (0.93 -0.99) 0.97 0.92 0.98 0.89 <0.0001
Neural Net 0.96 (0.93 – 0.99) 0.97 0.92 0.98 0.89 <0.0001
CD versus HC
Sparse Logistic Regression 0.95 (0.91-0.98) 0.97 0.91 0.94 0.96 <0.0001 
Random Forest 0.95 (0.92 – 0.99) 0.98 0.89 0.93 0.97 <0.0001 
Gaussian Process 0.95 (0.92 – 0.99) 0.97 0.92 0.95 0.96 <0.0001 
Support Vector Machine 0.95 (0.92 – 0.99) 0.97 0.91 0.94 0.96 <0.0001 
Neural Net 0.95 (0.90 – 0.99) 0.97 0.91 0.94 0.96 <0.0001 
CDa versus HC
Sparse Logistic Regression 0.95 (0.93 - 0.97) 1 0.90 0.71 1 <0.0001 
Random Forest 0.97 (0.95 - 0.99) 1 0.95 0.82 1 <0.0001 
Gaussian Process 0.97 (0.96 - 0.99) 1 0.95 0.82 1 <0.0001 
Support Vector Machine 0.97 (0.96 - 0.99) 1 0.95 0.82 1 <0.0001 
Neural Net 0.94 (0.91 - 0.97) 1 0.92 0.74 1 <0.0001 
CDr versus HC
Sparse Logistic Regression 0.95 (0.92 – 0.97) 1 0.90 0.67 1 <0.0001 
Random Forest 0.97 (0.95 – 0.99) 1 0.92 0.71 1 <0.0001 
Gaussian Process 0.97 (0.95 - 0.99) 1 0.94 0.76 1 <0.0001 
Support Vector Machine 0.97 (0.95 - 0.99) 1 0.92 0.72 1 <0.0001 
Neural Net 0.97 (0.95  - 0.99) 1 0.94 0.76 1 <0.0001 
UC versus HC
Sparse Logistic Regression 0.95 (0.92 – 0.99) 1 0.91 0.88 1 <0.0001 
Random Forest 0.96 (0.94 – 0.99) 1 0.93 0.91 1 <0.0001 
Gaussian Process 0.96 (0.93 – 0.99) 1 0.92 0.90 1 <0.0001 
Support Vector Machine 0.96 (0.94 – 0.99) 1 0.93 0.91 1 <0.0001 
Neural Net 0.96 (0.94 – 0.99) 1 0.93 0.91 1 <0.0001 
Table continues
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AUC (95% CI) Sensitivity Specificity PPV NPV p-value
UCa versus HC
Sparse Logistic Regression 0.95 (0.93 - 0.98) 0.97 0.90 0.67 0.99 <0.0001
Random Forest 0.97 (0.95 - 0.99) 1 0.91 0.69 1 <0.0001
Gaussian Process 0.97 (0.95 - 0.99) 1 0.90 0.67 1 <0.0001
Support Vector Machine 0.96 (0.93 – 0.93) 0.99 0.97 0.68 0.99 <0.0001
Neural Net 0.97 (0.95 - 0.99) 1 0.90 0.67 1 <0.0001
UCr versus HC
Sparse Logistic Regression 0.94 (0.91 - 0.96) 1 0.87 0.51 1 <0.0001
Random Forest 0.96 (0.94 - 0.98) 1 0.90 0.56 1 <0.0001
Gaussian Process 0.96 (0.94 - 0.98) 0.96 0.93 0.66 0.99 <0.0001
Support Vector Machine 0.96 (0.94 - 0.98) 0.96 0.93 0.66 0.99 <0.0001
Neural Net 0.96 (0.94 - 0.98) 0.96 0.93 0.66 0.99 <0.0001
IBDa versus IBDr
Sparse Logistic Regression 0.57 (0.50 - 0.64) 0.27 0.8 0.8 0.39 0.034
Random Forest 0.57 (0.50 - 0.64) 0.27 0.8 0.8 0.39 0.035
Gaussian Process 0.57 (0.51 - 0.64) 0.27 0.8 0.8 0.39 0.025
Support Vector Machine 0.56 (0.49 - 0.63) 0.26 0.9 0.8 0.39 0.054
Neural Net 0.55 (0.48 - 0.62) 0.23 0.92 0.84 0.39 0.095
CDa versus CDr
Sparse Logistic Regression 0.50 (0.93 - 0.60) 0.19 0.9 0.79 0.37 0.515
Random Forest 0.51 (0.41 - 0.62) 0.28 0.83 0.76 0.38 0.425
Gaussian Process 0.51 (0.40 - 0.61) 0.11 1 1 0.37 0.442
Support Vector Machine 0.51 (0.41 - 0.62) 0.28 0.83 0.76 0.38 0.425
Neural Net 0.51 (0.41 - 0.62) 0.26 0.87 0.79 0.38 0.406
UCa versus UCr
Sparse Logistic Regression 0.58 (0.41 - 0.75) 0.58 0.64 0.79 0.39 0.194
Random Forest 0.64 (0.46 - 0.82) 0.73 0.57 0.8 0.47 0.062
Gaussian Process 0.61 (0.42 - 0.79) 0.64 0.64 0.81 0.43 0.126
Support Vector Machine 0.63 (0.44 - 0.82) 0.67 0.64 0.81 0.45 0.076
Neural Net 0.61 (0.44 - 0.78) 0.61 0.643 0.8 0.41 0.117
CD versus UC
Sparse Logistic Regression 0.55 (0.51 - 0.60) 0.17 0.96 0.9 0.34 0.030
Random Forest 0.54 (0.49 - 0.60) 0.14 0.98 0.9375 0.36 0.069
Gaussian Process 0.54 (0.49 - 0.60) 0.09 1 1 0.35 0.077
Support Vector Machine 0.54 (0.49 - 0.60) 0.11 0.98 0.92 0.35 0.073




AUC (95% CI) Sensitivity Specificity PPV NPV p-value
CDa versus UCa
Sparse Logistic Regression 0.50 (0.37 - 0.63) 0.67 0.45 0.68 0.44 0.496
Random Forest 0.52 (0.39 - 0.65) 0.79 0.36 0.68 0.5 0.610
Gaussian Process 0.48 (0.35 - 0.61) 0.952 0.12 0.65 0.57 0.605
Support Vector Machine 0.51 (0.38 - 0.64) 0.67 0.45 0.68 0.44 0.463
Neural Net 0.48 (0.35 - 0.61) 0.60 0.51 0.68 0.43 0.605
CDr versus UCr
Sparse Logistic Regression 0.50 (0.50 - 0.50) 1 0 0.71 N/A 1
Random Forest 0.58 (0.40 - 0.76) 0.29 0.93 0.91 0.35 0.811
Gaussian Process 0.53 (0.35 - 0.70) 0.5 0.71 0.81 0.37 0.624
Support Vector Machine 0.57 (0.39 - 0.75) 0.44 0.79 0.83 0.37 0.780
Neural Net 0.64 (0.46 - 0.82) 0.71 0.57 0.8 0.44 0.936
Overview of the data generated using all five classifiers based on the 20 most discriminative features. 
Abbreviations: IBD inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis; a, active 
disease state; r, remission; HC, healthy controls; AUC, area under the curve; PPV, positive predictive 
value; NPV, negative predictive value.
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Supplemental Table 2. Overview of the data generated using all four classifiers based on the 50 most 
discriminative features using all IBD patients
AUC (95% CI) Sensitivity Specificity PPV NPV p-value
IBD versus HC
Sparse Logistic Regression 0.95 (0.92 – 0.99) 0.99 0.91 0.98 0.96 <0.0001
Random Forest 0.97 (0.94 – 1) 0.97 0.93 0.98 0.88 <0.0001
Gaussian Process 0.97 (0.94 – 1) 0.97 0.92 0.98 0.88 <0.0001
Support Vector Machine 0.97 (0.95 – 1) 0.95 0.95 0.99 0.82 <0.0001
Neural Net 0.96 (0.92 – 0.99) 0.96 0.93 0.98 0.85 <0.0001
CD versus HC
Sparse Logistic Regression 0.96 (0.93 – 0.99) 0.96 0.93 0.95 0.95 <0.0001
Random Forest 0.97 (0.95 – 1) 0.97 0.93 0.95 0.96 <0.0001
Gaussian Process 0.97 (0.94 – 1)  0.97 0.93 0.95 0.96 <0.0001
Support Vector Machine 0.97 (0.95 – 1) 0.98 0.92 0.95 0.97 <0.0001
Neural Net 0.96 (0.92 – 1) 0.97 0.93 0.95 0.96 <0.0001
CDa versus HC
Sparse Logistic Regression 0.96 (0.94 - 0.98) 1 0.92 0.76 1 <0.0001 
Random Forest 0.97 (0.96 - 0.99) 1 0.95 0.82 1 <0.0001 
Gaussian Process 0.97 (0.96 - 0.99) 1 0.95 0.82 1 <0.0001 
Support Vector Machine 0.97 (0.95 - 0.99) 1 0.94 0.80 1 <0.0001 
Neural Net 0.97 (0.95 - 0.99) 1 0.94 0.80 1 <0.0001 
CDr versus HC
Sparse Logistic Regression 0.96 (0.94 - 0.98) 1 0.91 0.68 1 <0.0001 
Random Forest 0.97 (0.94 – 0.99) 1 0.92 0.71 1 <0.0001 
Gaussian Process 0.97 (0.94 - 0.99) 1 0.92 0.72 1 <0.0001 
Support Vector Machine 0.97 (0.94 - 0.99) 1 0.93 0.74 1 <0.0001 
Neural Net 0.97 (0.95 - 0.99) 1 0.93 0.74 1 <0.0001 
UC versus HC
Sparse Logistic Regression 0.95 (0.92 - 0.99) 1 0.91 0.88 1 <0.0001 
Random Forest 0.97 (0.94 – 1) 1 0.93 0.91 1 <0.0001 
Gaussian Process 0.97 (0.94 – 1) 1 0.92 0.90 1 <0.0001 
Support Vector Machine 0.97 (0.94 – 1) 1 0.91 0.88 1 <0.0001 
Neural Net 0.97 (0.94 – 1) 0.98 0.93 0.91 0.99  <0.0001 
UCa versus HC
Sparse Logistic Regression 0.97 (0.95 - 0.99) 1 0.90 0.66 1 <0.0001 
Random Forest 0.97 (0.95 - 0.99) 1 0.92 0.70 1 <0.0001 




AUC (95% CI) Sensitivity Specificity PPV NPV p-value
Support Vector Machine 0.97 (0.95 - 0.99) 1 0.90 0.67 1 <0.0001 
Neural Net 0.97 (0.95 - 0.99) 1 0.91 0.69 1 <0.0001 
UCr versus HC
Sparse Logistic Regression 0.95 (0.92 - 0.97) 1 0.88 0.52 1 <0.0001 
Random Forest 0.97 (0.95 - 0.99) 0.96 0.95 0.70 0.99 <0.0001 
Gaussian Process 0.97 (0.95 - 0.99) 0.96 0.95 0.70 0.99 <0.0001 
Support Vector Machine 0.97 (0.95 - 0.99) 0.96 0.95 0.70 0.99 <0.0001 
Neural Net 0.97 (0.95 - 0.99) 0.96 0.95 0.70 0.99 <0.0001 
IBDa versus IBDr
Sparse Logistic Regression 0.56 (0.50 - 0.63) 0.26 0.88 0.79 0.39 0.042
Random Forest 0.57 (0.50 - 0.65) 0.3 0.85 0.79 0.39 0.028
Gaussian Process 0.56 (0.49 - 0.63) 0.24 0.90 0.81 0.39 0.080
Support Vector Machine 0.57 (0.50 - 0.64) 0.26 0.90 0.82 0.39 0.040
Neural Net 0.53 (0.46 - 0.60) 0.23 0.88 0.78 0.38 0.215
CDa versus CDr
Sparse Logistic Regression 0.53 (0.41 - 0.65) 0.18 0.93 0.83 0.37 0.292
Random Forest 0.58 (0.44 - 0.70) 0.52 0.63 0.73 0.41 0.116
Gaussian Process 0.56 (0.43 - 0.69) 0.51 0.67 0.74 0.42 0.171
Support Vector Machine 0.56 (0.44 - 0.69) 0.58 0.57 0.72 0.41 0.152
Neural Net 0.62 (0.50 - 0.74) 0.49 0.7 0.76 0.42 0.032
UCa versus UCr
Sparse Logistic Regression 0.57 (0.39 – 0.75) 0.33 0.86 0.85 0.35 0.230
Random Forest 0.63 (0.45 – 0.81) 0.82 0.43 0.77 0.50 0.090
Gaussian Process 0.57 (0.36 – 0.78) 0.85 0.43 0.78 0.55 0.231
Support Vector Machine 0.56 (0.36 – 0.76) 0.85 0.43 0.78 0.55 0.261
Neural Net 0.54 (0.34 – 0.74) 0.82 0.43 0.77 0.50 0.350
CD versus UC
Sparse Logistic Regression 0.55 (0.51 - 0.60) 0.17 0.96 0.9 0.36 0.030
Random Forest 0.54 (0.49 - 0.60) 0.16 0.96 0.89 0.36 0.072
Gaussian Process 0.54 (0.49 - 0.60) 0.17 0.92 0.83 0.35 0.078
Support Vector Machine 0.54 (0.49 - 0.59) 0.17 0.92 0.83 0.35 0.093
Neural Net 0.54 (0.49 - 0.59) 0.16 0.92 0.81 0.35 0.088
Table continues
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AUC (95% CI) Sensitivity Specificity PPV NPV p-value
CDa versus UCa
Sparse Logistic Regression 0.50 (0.37 - 0.63) 0.65 0.48 0.69 0.44 0.500
Random Forest 0.53 (0.40 - 0.67) 0.79 0.36 0.68 0.50 0.305
Gaussian Process 0.49 (0.36 - 0.63) 0.95 0.15 0.66 0.63 0.540
Support Vector Machine 0.51 (0.38 - 0.64) 0.42 0.70 0.71 0.41 0.427
Neural Net 0.52 (0.39 - 0.65) 0.60 0.58 0.71 0.45 0.374
CDr versus UCr
Sparse Logistic Regression 0.43 (0.25 - 0.61) 0.5 0.57 0.74 0.32 0.773
Random Forest 0.45 (0.27 - 0.64) 0.09 1 1 0.31 0.691
Gaussian Process 0.55 (0.38 - 0.72) 0.5 0.79 0.85 0.39 0.715
Support Vector Machine 0.55 (0.36 - 0.73) 0.53 0.64 0.78 0.36 0.691
Neural Net 0.50 (0.31 - 0.69) 0.82 0.36 0.76 0.45 0.500
Overview of the data generated using all five classifiers based on the 50 most discriminative features. 
Abbreviations: IBD inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis; a, active 
disease state; r, remission; HC, healthy controls; AUC, area under the curve; PPV, positive predictive 
value; NPV, negative predictive value.
Supplemental Table 3. Overview of the data generated using all four classifiers based on the 100 most 
discriminative features using all IBD patients
AUC (95% CI) Sensitivity Specificity PPV NPV p-value
IBD versus HC
Sparse Logistic Regression 0.96 (0.92 - 0.99) 0.97 0.92 0.98 0.87 <0.0001 
Random Forest 0.97 (0.95 - 1) 0.97 0.95 0.99 0.88 <0.0001 
Gaussian Process 0.97 (0.95 - 0.99) 0.98 0.93 0.98 0.93 <0.0001 
Support Vector Machine 0.98 (0.95 - 0.99) 0.94 0.95 0.99 0.80 <0.0001 
Neural Net 0.97 (0.93 - 0.99) 0.99 0.92 0.98 0.97 <0.0001 
CD versus HC
Sparse Logistic Regression 0.97 (0.95 - 1) 0.94 0.96 0.97 0.91 <0.0001 
Random Forest 0.98 (0.95 - 1) 0.96 0.93 0.95 0.95 <0.0001 
Gaussian Process 0.98 (0.95 - 1) 0.96 0.93 0.95 0.95 <0.0001 
Support Vector Machine 0.97 (0.93 - 1) 0.97 0.92 0.95 0.96 <0.0001 
Neural Net 0.96 (0.93 - 1) 0.98 0.92 0.95 0.97 <0.0001 
CDa versus HC
Sparse Logistic Regression 0.96 (0.94 - 0.99) 1 0.92 0.74 1 <0.0001 
Random Forest 0.98 (0.96 - 1) 1 0.95 0.84 1 <0.0001 
Gaussian Process 0.98 (0.96 - 1) 1 0.95 0.84 1 <0.0001 
Support Vector Machine 0.98 (0.96 - 1) 1 0.95 0.84 1 <0.0001 




AUC (95% CI) Sensitivity Specificity PPV NPV p-value
CDr versus HC
Sparse Logistic Regression 0.95 (0.93 - 0.98) 1 0.90 0.67 1 <0.0001 
Random Forest 0.97 (0.95 - 0.99) 1 0.93 0.74 1 <0.0001 
Gaussian Process 0.97 (0.95 - 0.99) 1 0.93 0.74 1 <0.0001 
Support Vector Machine 0.97 (0.95 - 0.99) 1 0.94 0.76 1 <0.0001 
Neural Net 0.97 (0.95 - 0.99) 1 0.94 0.76 1 <0.0001 
UC versus HC
Sparse Logistic Regression 0.95 (0.91 - 0.99) 1 0.91 0.88 1 <0.0001 
Random Forest 0.97 (0.93 - 1) 1 0.91 0.88 1 <0.0001 
Gaussian Process 0.97 (0.93 - 1) 0.96 0.95 0.93 0.97 <0.0001 
Support Vector Machine 0.97 (0.94 - 1) 1 0.91 0.88 1 <0.0001 
Neural Net 0.97 (0.94 - 1) 0.98 0.92 0.90 0.99 <0.0001 
UCa versus HC
Sparse Logistic Regression 0.96 (0.94 - 0.99) 1 0.92 0.74 1 <0.0001 
Random Forest 0.98 (0.96 - 1) 1 0.95 0.84 1 <0.0001 
Gaussian Process 0.98 (0.96 - 1) 1 0.95 0.84 1 <0.0001 
Support Vector Machine 0.98 (0.96 - 1) 1 0.95 0.84 1 <0.0001 
Neural Net 0.97 (0.95 - 0.99) 1 0.94 0.80 1 <0.0001 
UCr versus HC
Sparse Logistic Regression 0.95 (0.93 - 0.98) 1 0.88 0.52 1 <0.0001 
Random Forest 0.97 (0.95 - 0.99) 0.96 0.95 0.72 0.99 <0.0001 
Gaussian Process 0.97 (0.95 - 0.99) 0.96 0.95 0.72 0.99 <0.0001 
Support Vector Machine 0.97 (0.95 - 0.99) 0.96 0.95 0.72 0.99 <0.0001 
Neural Net 0.97 (0.95 - 0.99) 0.96 0.95 0.70 0.99 <0.0001 
IBDa versus IBDr
Sparse Logistic Regression 0.59 (0.51 - 0.67) 0.21 0.96 0.90 0.39 0.019 
Random Forest 0.59 (0.51 - 0.68) 0.31 0.88 0.82 0.40 0.017 
Gaussian Process 0.58 (0.49 - 0.66) 0.43 0.75 0.76 0.41 0.039 
Support Vector Machine 0.58 (0.49 - 0.67) 0.43 0.75 0.76 0.41 0.038
Neural Net 0.57 (0.49 - 0.65) 0.29 0.90 0.84 0.40 0.066
CDa versus CDr
Sparse Logistic Regression 0.52 (0.39 - 0.65) 0.72 0.43 0.71 0.45 0.645
Random Forest 0.49 (0.36 - 0.62) 0.33 0.77 0.731 0.38 0.562
Gaussian Process 0.54 (0.41 - 0.67) 0.30 0.83 0.771 0.38 0.291
Support Vector Machine 0.53 (0.39 - 0.66) 0.88 0.27 0.691 0.53 0.674
Neural Net 0.52 (0.39 - 0.64) 0.60 0.57 0.721 0.43 0.606
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AUC (95% CI) Sensitivity Specificity PPV NPV p-value
UCa versus UCr
Sparse Logistic Regression 0.63 (0.44 - 0.82) 0.67 0.57 0.79 0.42 0.082 
Random Forest 0.62 (0.44 - 0.81) 0.85 0.43 0.78 0.55 0.094 
Gaussian Process 0.55 (0.34 - 0.77) 0.88 0.43 0.78 0.60 0.288 
Support Vector Machine 0.50 (0.29 - 0.71) 0.85 0.36 0.76S 0.50 0.514 
Neural Net 0.58 (0.40 - 0.76) 0.82 0.43 0.77 0.50 0.191
CD versus UC
Sparse Logistic Regression 0.55 (0.50 - 0.60) 0.17 0.96 0.90 0.36 0.031
Random Forest 0.54 (0.49 - 0.60) 0.12 0.98 0.93 0.35 0.074
Gaussian Process 0.54 (0.49 - 0.60) 0.17 0.92 0.83 0.35 0.078
Support Vector Machine 0.54 (0.49 - 0.60) 0.17 0.92 0.83 0.35 0.089
Neural Net 0.54 (0.49 - 0.59) 0.16 0.92 0.81 0.35 0.090
CDa versus UCa
Sparse Logistic Regression 0.52 (0.39 - 0.65) 0.95 0.18 0.67 0.67 0.607
Random Forest 0.55 (0.41 - 0.68) 0.54 0.67 0.74 0.46 0.228
Gaussian Process 0.53 (0.40 - 0.66) 0.89 0.27 0.68 0.60 0.311
Support Vector Machine 0.53 (0.41 - 0.66) 0.67 0.48 0.69 0.46 0.308
Neural Net 0.56 (0.43 - 0.69) 0.72 0.48 0.71 0.50 0.832
CDr versus UCr
Sparse Logistic Regression 0.56 (0.37 - 0.75) 0.74 0.43 0.76 0.40 0.744 
Random Forest 0.53 (0.33 - 0.72) 0.53 0.64 0.78 0.36 0.393 
Gaussian Process 0.54 (0.36 - 0.71) 0.41 0.86 0.88 0.38 0.653 
Support Vector Machine 0.58 (0.41 - 0.76) 0.26 1 1 0.36 0.199 
Neural Net 0.59 (0.41 - 0.76) 0.59 0.71 0.83 0.42 0.844 
verview of the data generated using all five classifiers based on the 100 most discriminative features. 
Abbreviations: IBD inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis; a, active 
disease state; r, remission; HC, healthy controls; AUC, area under the curve; PPV, positive predictive 
value; NPV, negative predictive value.
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Supplemental Table 4. Overview of the data generated using all four classifiers based on the 100 most 
discriminative features using only the Amsterdam UMC samples
AUC (95% CI) Sensitivity Specificity PPV NPV p-value
IBD versus HC
Sparse Logistic Regression 0.95 (0.91 – 0.98) 0.98 0.92 0.92 0.98 <0.001
Random Forest 0.97 (0.95 – 0.99) 1 0.92 0.92 1 <0.001
Gaussian Process 0.96 (0.92 – 0.99) 0.98 0.94 0.93 0.98 <0.001
Support Vector Machine 0.96 (0.93 – 0.99) 1 0.91 0.91 1 <0.001
Neural Net 0.94 (0.90 – 0.98) 0.98 0.92 0.92 0.98 <0.001
CD versus HC
Sparse Logistic Regression 0.96 (0.93 – 0.99) 1 0.92 0.85 1 <0.001
Random Forest 0.97 (0.94 – 0.99) 1 0.92 0.85 1 <0.001
Gaussian Process 0.95 (0.92 – 0.99) 1 0.92 0.85 1 <0.001
Support Vector Machine 0.95 (0.91 – 0.99) 1 0.92 0.85 1 <0.001
Neural Net 0.93 (0.88 – 0.97) 0.93 0.94 0.87 0.97 <0.001
UC versus HC
Sparse Logistic Regression 0.96 (0.92 – 0.99) 1 0.90 0.81 1 <0.001
Random Forest 0.96 (0.93 – 0.99) 1 0.91 0.83 1 <0.001
Gaussian Process 0.96 (0.93 – 0.99) 0.96 0.93 0.85 0.98 <0.001
Support Vector Machine 0.96 (0.93 – 0.99) 1 0.91 0.83 1 <0.001
Neural Net 0.90 (0.85 – 0.96) 0.93 0.94 0.86 0.97 <0.001
CD versus UC
Sparse Logistic Regression 0.63 (0.53 – 0.74) 0.64 0.62 0.63 0.63 0.008
Random Forest 0.58 (0.47 – 0.69) 0.63 0.55 0.58 0.59 0.075
Gaussian Process 0.57 (0.46 – 0.68) 0.59 0.65 0.63 0.61 0.106
Support Vector Machine 0.49 (0.38 – 0.60) 0.43 0.64 0.54 0.52 0.436
Neural Net 0.53 (0.42 – 0.63) 0.54 0.62 0.59 0.57 0.320
Overview of the data generated using all five classifiers based on the 100 most discriminative features 
using only the Amsterdam UMC samples. Abbreviations: IBD inflammatory bowel disease; CD, Crohn’s 
disease; UC, ulcerative colitis; a, active disease state; r, remission; HC, healthy controls; AUC, area 
under the curve; PPV, positive predictive value; NPV, negative predictive value.
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In patients with inflammatory bowel disease (IBD), early prediction of changes in 
disease state provides for timely treatment which improves disease outcome. Aim 
of this pilot study is to explore the potential of fecal volatile organic compound 
(VOC) profiles to predict IBD course.
Methods
In this prospective multi-center cohort, IBD patients were asked to collect two 
fecal samples and a questionnaire at set intervals. Biochemically, active disease 
was FCP≥250 mg/g, remission FCP<100 mg/g. Clinically, active disease was a 
Harvey Bradshaw Index (HBI) ≥5 for Crohn’s disease or Simple Clinical Colitis 
Activity Index (SCCAI) ≥3 for ulcerative colitis. Clinical remission was HBI<4 or 
SCCAI≤2. Fecal VOC profiles were measured using Gas Chromatography – Ion 
Mobility Spectrometry (GC-IMS). The fecal samples collected at first time-point 
were included for fecal VOC analysis to predict disease state at the second time-
point.
Results
Total of 182 subsequently collected samples met the disease state criteria. Fecal 
VOC profiles of samples displaying low FCP levels at first measurements differed 
when preceding exacerbation versus remaining in remission (AUC 0.75; p<0.01). 
For high FCP levels at the first time-point displayed different VOC profiles when 
preceding remission compared to when remaining active (B3 vs B4 AUC 0.86; 
P<0.01). Based upon disease activity scores, there were no significant differences 
in any of the comparisons.
Conclusion
The alterations in fecal VOC profile preceding changes in FCP level may be useful 
to detect disease course alterations at an early stage, which would subsequently 
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Endoscopy remains mandatory in the diagnostic work-up of inflammatory bowel 
disease (IBD), but is a costly and invasive procedure. Identification of novel, non-
invasive, diagnostic biomarkers remains a priority. The aim of this study was to 
explore the potential of faecal amino acid composition as diagnostic biomarker 
for paediatric IBD.
Methods
In this case-control study, treatment–naïve, de novo paediatric IBD patients from 
two tertiary centres were included. Endoscopic severity of ulcerative colitis (UC) 
and Crohn’s disease (CD) was based on global physician assessment scores, 
substantiated by levels of faecal calprotectin and C-reactive protein at study 
inclusion. Patients were instructed to collect a faecal sample prior to bowel 
cleansing. Healthy controls were recruited from primary schools in the same 
region. Dedicated amino acid analysis was performed on all samples. 
Results
Significant differences between 30 IBD patients (15 UC, 15 CD) and 15 age 
and sex matched healthy controls (HC) were found in six amino acids (histidine, 
tryptophan, phenylalanine, leucine, tyrosine and valine; all AUC > 0.75 and p < 
0.005), displaying higher levels in IBD. When distributing the patients according 
to type of IBD, a similar spectrum of amino acids differed between UC and HC 
(histidine, tryptophan, phenylalanine, leucine, valine and serine), whereas three 
amino acids were different between CD and HC (histidine, tryptophan and 
phenylalanine). 
Conclusion
Significantly increased levels of six different faecal amino acids were found in 
IBD patients compared to controls. Whether these differences reflect decreased 




Inflammatory bowel disease (IBD) comprises the two main phenotypes ulcerative colitis 
(UC) and Crohn’s disease (CD). These chronic relapsing conditions of the gastrointestinal 
tract usually develop during young adulthood[1-5]. Diagnosis and follow-up of IBD are 
essentially assessed by endoscopic investigation which is a costly, invasive procedure with 
a risk of complications[6]. Especially in children the burden is high, since they need to be 
hospitalised for colonic lavage with administration of laxatives by nasogastric tube and 
ileocolonoscopy has to be performed under general anesthesia. Therefore, the search for 
novel non-invasive diagnostic biomarkers in the diagnostic work-up remains warranted.
Various biomarkers have been evaluated as tool in the diagnostic work-up for IBD, 
with faecal calprotectin (FCP) showing the highest sensitivity for detection of mucosal 
inflammation (0.98, 95%CI 0.95-0.99)[7]. However, FCP is characterised by a relative low 
specificity (0.68, 95% CI 0.50-0.86), limiting its use to differentiate between IBD and other 
gastro-intestinal diseases, such as polyps and infectious gastroenteritis[8-10]. Other widely 
studied biomarkers include metabolic products, which may potentially have a higher 
specificity for IBD detection, since they reflect (patho)physiological processes involved in 
IBD pathogenesis[11].  For example, volatile organic compounds (VOCs), which are carbon 
based chemicals and considered to reflect microbiota composition, seem to have potential 
as non-invasive diagnostic biomarkers for diagnosing and monitoring IBD. Promising results 
have been described in analysis of VOCs deriving from different bodily excretions including 
exhaled breath, faecal and urine[12-21].
By VOCs analysis, however, exclusively gaseous metabolites are captured. The spectrum of 
non-volatile organic compounds in IBD remains yet largely unexplored. In a previous study 
on faecal and serum metabolomic patterns comparing de novo paediatric IBD patients 
and controls, there seemed to be a promising role for especially the faecal metabolome in 
diagnosing (different subtypes of) IBD[22]. In our earlier (unpublished) study on the faecal 
metabolome using ultra performance liquid chromatography (UPLC) combined with high 
resolution mass spectrometry (HR/MS), particularly levels of amino acids differed between 
IBD patients and controls. Therefore, the aim of this study was to explore these differences 
in the composition of faecal amino acids between paediatric de novo IBD patients and 
healthy controls further by means of a dedicated amino acid analysis.
METHODS
Study design
This case-control study was performed at the outpatient clinic of the paediatric 
gastroenterology departments of two tertiary hospitals, VU University medical centre (VUmc) 
and the Emma Children’s Hospital, (Academic Medical Centre), both located in Amsterdam, 
The Netherlands. All subjects had to be familiar with Dutch language, since questionnaires 
were provided in Dutch.
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Study participants
Inflammatory bowel disease patients 
Participants were extracted from a cohort consisting of de novo treatment-naïve paediatric 
IBD patients (94 CD, 56 UC) aged 4 to 17 years, included between December 1st  2011 
and March 10st 2016. Patients were diagnosed with IBD based on endoscopic, histologic 
and radiologic findings using the revised Porto-criteria for paediatric IBD[23]. Localisation 
and behaviour of disease were classified according to the Paris Classification[24]. Included 
patients were instructed to collect a faecal sample for microbiota analysis, prior to bowel 
cleansing[25]. Patients with IBD were randomly selected and matched with controls based 
on age and gender. Exclusion criteria were the use of anti- or probiotics in the three 
months prior to inclusion, prior immunosuppressive therapy or a concomitant diagnosis 
of immunocompromised disease (i.e. HIV, leukemia), underlying gastro-intestinal disease 
(i.e. celiac disease, Hirschsprung’s disease) and history of gastro-intestinal surgery (except 
appendectomy). In addition, patients with proven infectious colitis during the month 
before presentation were excluded. Infectious colitis was determined by parasites in stools 
or positive stool culture for Salmonella spp., Shigella spp., Yersinia spp., Campylobacter 
spp. or Clostridium spp. toxins. Disease activity was measured at study inclusion using the 
global physician assessment (GPA) score, substantiated by faecal calprotectin (FCP), and 
C-reactive protein (CRP). 
Healthy controls
As control group, healthy children aged 4-17 years were recruited between June 2016 
and December 2016 from elementary and high schools located in the Dutch provinces 
North-Holland, South-Holland, and Flevoland. Notably, all included IBD children lived in 
the same topographic regions. Exclusion criteria were similar to the study group, extended 
with gastrointestinal symptoms fulfilling the Rome IV criteria of functional gastrointestinal 
disorders[26, 27]. All children and their parents were asked to complete a questionnaire 
on subject characteristics, medical history, living environment, use of antibiotics in the last 
three months, defecation pattern based on Bristol stool chart scores and gastro-intestinal 
symptoms[28].
Sample collection
Participants were asked to collect a faecal sample in a stool container (Stuhlgefäß 10ml, 
Greiner Bio-One, Frickenhausen, Germany) and instructed to store the sample within 
one hour following bowel movement at the freezer at home at -20°C. The samples 
were transported to the hospital in a cooled condition and stored in a -20°C refrigerator 
immediately after arrival.
Targeted amino acid analysis
To investigate differences in the amino acid composition, faecal samples of IBD patients 
and healthy controls were analysed by means of a targeted High Performance Liquid 
Chromatography (HPLC) technique, specifically amino acid analysis (AAA). For this analysis, 
approximately 300mg faecal and 1000 µL distilled water were mixed by vortex for one 
minute to homogenize the samples. Subsequently, these samples were recoded and 
investigated by an independent laboratory researcher (ES), blinded for the diagnosis. The 
samples were frozen at minus 30 degrees and subsequently freeze-dried for 24 hours (Christ 
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Alpha 2-4) to prevent potential bias by differences in faecal water content. The residual, 
approximately 30-50mg depending on the faecal consistency, was mixed with a quantity 
of distilled water maintaining a faecal-water ratio of 100mg:5mL. This mixture was again 
vigorously homogenised using vortex. For the amino acid profile (aminogram) analysis, 400 
µL of the mixture was pipetted into a filter and centrifuged for 20 minutes at 14.000g (Hettig 
Zentrifugen Mikro 2R). The supernatant was subsequently mixed with an internal standard 
solution with a one-to-one ratio. Finally, this mixture was centrifuged for 10 minutes and 
filtered (Whatman) into compatible containers for the final amino acid analyses (Biochrome 
30). Amino acids were separated by ion-exchange chromatography and detected by UV-
absorbance after post-column derivatization with ninhydrin. 
Statistical analysis
Statistical analyses were performed using SPSS Statistics (version 22, IBM, NY, USA). The 
demographic data of each group (UC, CD patients and healthy controls) were compared 
using the non-parametric Kruskal-Wallis-H tests for continuous data and the Fisher’s exact 
test for dichotomous data. On account of the small sample size, the Mann-Whitney U test 
/ Wilcoxon rank-sum test was used to calculate p-values to identify potential differences in 
aminograms between the IBD phenotypes and the healthy control group. To compensate for 
multiple testing, a p-value of <0.005 was considered significant. In addition, to circumvent 
possible over- or underestimation of the discriminative accuracy, amino acids were excluded 
from the analysis if levels were unquantifiable or undetectable in at least one of the study 
subjects. Amino acid levels of 5 µmol/l or lower were considered unquantifiable, levels of 
0 µmol/l were considered undetectable. A receiver operator characteristic (ROC-)curve was 
created to predict sensitivity and specificity values. Correlations between levels of amino 
acids and CRP, FCP and GPA were analysed using the Spearman rank-order correlation 
coefficient. A formal sample size calculation could not be performed due to a lack of 
previous data on this topic.
Ethical considerations
This study was approved by the Medical Ethical Review Committee (METc) of the VU 
University Medical Centre under file number 2015.393. Written informed consent was 
obtained from all study participants and their parents.
RESULTS
Baseline characteristics
From the initial 96 CD and 56 UC subjects, a total of 99 IBD patients (59 CD, 40 UC) were not 
eligible for this study due to insufficient quantities of collected faecal. From the remainder of 
the cohort, IBD patients were randomly selected and matched with controls based on age and 
gender. Thirty de novo, treatment-naïve IBD patients were included (15 UC, 15 CD) in this study. 
The control group consisted of 15 healthy children. Baseline characteristics and disease specifics 
of the study subjects are described in table 1. No statistical significant differences between 
UC and CD patients were found for the variables FPC, leukocytes and GPA. Higher levels of 
CRP were observed in the CD group compared to the UC group (p=0.013). In addition, IBD 
samples were stored for a significantly longer period compared to samples of healthy controls. 
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Inflammatory bowel disease versus controls
A total of 42 amino acids were detected during AAA of which 23 amino acids were not 
suitable for statistical analysis due to unquantifiable or undetectable levels in at least one 
of the study subjects. The results of the amino acid analysis comparing paediatric IBD 
patients and healthy controls are displayed in table 2, and visualised in upplemental figure 
1 in Box Whisker plots. In six of the 19 amino acids, statistically significant differences 
between IBD patients and healthy controls were observed. In particular, increased levels of 
tryptophan, histidine, phenylalanine, leucine, tyrosine and valine were strongly predictive 
for the discrimination of IBD patients versus healthy controls. For all these amino acids, 
predictive values for the diagnosis of IBD are shown in table 3. Their associated ROC-curves 
are displayed in supplemental figure 2A. No correlations were found between amino acid 
levels and disease activity parameters (GPA, CRP and FCP). An overview of all the measured 
amino acid levels per subject is given in supplemental table 1-3.
IBD subtypes versus controls
Ulcerative colitis versus healthy controls
The same spectrum of amino acids differed significantly between UC and HC, compared 
to the set of amino acids differentiating IBD (UC and CD together) from controls, except 
for tyrosine and serine (Table 2, Supplementary figure 1). In UC, increased levels of serine 
differed significantly from controls (p=.001), whereas tyrosine did not (p=.006). Overall, the 
accuracy of the aminogram to differentiate between UC and HC improved compared to 
the discrimination between IBD and HC. Table 3 depicts the AUC for this UC sub analysis. 
Corresponding ROC-curves are displayed in supplemental figure 2B. In addition, no 
correlations were found between amino acid levels and disease activity parameters in this 
sub analysis.
 
Crohn’s disease versus healthy controls
By focusing on CD subjects versus HC, levels of the amino acids histidine, phenylalanine 
and tryptophan increased significantly in the CD subgroup (Table 2, supplementary figure 1). 
The predictive value of the Crohn’s disease sub analysis is shown in Table 3. Corresponding 
ROC-curves are visualised in supplemental figure 2C. There was no correlation between 
amino acid levels and disease activity parameters.
 
Ulcerative colitis versus Crohn’s disease
There were no significant differences in amino acids profiles between UC and CD (Table 2).
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Sample age, yr (median [IQR]) 15.5 [7.8 – 16.6] 12.0 [7.9 – 15.7] 14.0 [10.5 – 14.6]
Sex, male [%] 60 53 40
Storage time, yr
(median [IQR])
0.6 [0.5 – 0.6] 4.2 [3.4 – 4.9] 3.4 [2.7 – 4.6]
Global Physician Assessment
Quiescent NA 0 0
Mild NA 3 1
Moderate NA 5 5
Severe NA 7 9
Faecal calprotectin (µg/g) (median[IQR]) NA 1260 [393-1950] 1111 [627-1366]
CRP (mg/l) (median[IQR]) NA 2.5 [2.5-7.0] 19.4 [2.5-45.0]
Crohn’s disease localisation1
Ileal (L1) NA NA 0
Colonic (L2) NA NA 7
Ileocolonic (L3) NA NA 8
Proximal disease (L4) NA NA 2
Crohn’s disease behaviour1
B1 (NSNP) NA NA 6
B1p (NSNP+p) NA NA 1
B2 (S) NA NA 0
B2p (S + p) NA NA 1
B3 (P) NA NA 5
B3p (P + p) NA NA 1
Ulcerative Colitis1
Proctitis (E1) NA 3 NA
Left-sided (E2) NA 2 NA
Extensive (E3) NA 10 NA
All values were obtained at study inclusion. Localisation was obtained by ileocolonoscopy 
and esophagogastroduodenoscopy before treatment initiation, and magnetic resonance 
enteroclysis. Abbreviations: IQR, interquartile range; NA, not applicable; NSNP, non-
stricturing non-penetrating; S, stricturing; P, penetrating; p, peri-anal disease. 1Based on 
Paris classification for inflammatory bowel disease (24)






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3. Predictive value for the diagnosis of IBD and the UC and CD phenotypes
Amino acid AUC IBD AUC UC AUC CD
Histidine 0.868 0.909 0.827
Leucine 0.822 0.849 NA
Phenylalanine 0.836 0.853 0.818
Tryptophan 0.853 0.898 0.809
Tyrosine 0.778 NA NA
Valine 0.778 0.807 NA
Serine NA 0.836 NA
Predictive values were measured using a receiver operator curve. Abbreviations: AUC, area under the 
curve; IBD: inflammatory bowel disease; UC: ulcerative colitis; CD: Crohn’s disease; NA: not applicable. 
Levels of significance are similar to p-values in Table 2. 
DISCUSSION
 
In this study, we compared faecal amino acid profiles of de novo, treatment-naïve paediatric 
IBD patients with matched healthy controls, by means of targeted amino acid analysis. We 
observed that six faecal amino acid profiles of IBD patients could be discriminated from 
healthy controls with high accuracy. This high discriminative accuracy remained intact while 
focusing on the phenotypes UC and CD. However, UC could be discriminated from HC 
more accurately and based on a broader range of different amino acids compared to the 
CD subgroup. Lastly, the phenotypes UC and CD could not be discriminated based on their 
amino acid profiles. 
Novel techniques to diagnose de novo IBD in paediatric patients have recently been studied 
in an intention-to-diagnose cohort by analysis of faecal and serum metabolomic patterns 
of IBD patients (n=69) and endoscopically proven healthy controls (n=29) using liquid 
chromatography (LC)[22]. In line with our study, levels of the faecal amino acids tryptophan, 
glycine, citrulline and serine were increased in both UC and CD compared with HC, with 
the highest concentrations measured in UC patients. Histidine and phenylalanine were also 
elevated in IBD patients compared to healthy controls, though with a lower discriminative 
accuracy compared to the other amino acids. Tryptophan levels measured in serum were 
decreased in the IBD group, whereas levels of serine were increased, compared to healthy 
controls. Interestingly, concentrations of these two amino acids were elevated in faecal 
samples of IBD patients, suggesting both a role for a leaky gut and for metabolic alterations 
as potential causes for these differences. 
Other studies assessing the faecal human metabolome as biomarker for IBD have solely 
focused on adult IBD patients. Faecal amino acid profiles of 20 adult IBD patients (10 UC, 
10 CD) treated with prednisolone and 5-aminosalicylic acid as part of disease management, 
were compared to faecal samples of 13 healthy controls by means of nuclear magnetic 
resonance (NMR) spectroscopy[29]. In line with our study, levels of multiple amino acids were 
elevated in IBD patients compared to healthy controls. In contrast to our study outcome, 
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levels of amino acids were significantly increased in CD compared to UC. More specific, 
faecal concentrations of isoleucine, leucine, lysine and valine were significantly elevated, 
whereas levels of histidine, tryptophan and phenylalanine were undetectable. Interestingly, 
increased levels of especially the latter three amino acids (histidine, tryptophan and 
phenylalanine) were accurate for the differentiation of IBD versus HC in our study. One of 
the possible explanations for the undetectability of these amino acids in the previous study 
is the fact that NMR Spectroscopy is a less sensitive technique compared to AAA.  Bjerrum 
et al. assessed the global faecal metabolome of 92 adult IBD patients (48UC, 44CD) and 
21 controls by means of NMR spectroscopy[30]. Similar to our study, they found increased 
amino acid levels in IBD patients compared to healthy controls and related these metabolic 
changes to malabsorption and dysbiosis.      
Studies focusing on the serum metabolome as biomarker for IBD are scarce. In one study 
analyzing amino acid profiles of IBD patients in blood plasma using targeted AAA on 
22 amino acids similar to the ones assessed in our study, decreased plasma amino acid 
levels of IBD patients (n=387) compared to healthy controls (n=210) were observed[20]. 
Consistent with our study outcome, these differences were most pronounced for the amino 
acids histidine and tryptophan. In another study plasma amino acid levels of 43 IBD patients 
(24 UC, 19 CD) were compared to 17 healthy controls by means of NMR spectroscopy and 
showed increased levels of phenylalanine, leucine, isoleucine and glycine in IBD patients, 
whereas levels of histidine, creatine and choline decreased[19]. These studies are in line 
with the study outcome on paediatric serum amino acids levels in de novo IBD patients 
mentioned earlier.
Based on previous studies it could be hypothesised that the observed increases and 
decreases in concentration of specific serum amino acids, and increases in all faecal amino 
acids are due to decreased absorption in the intestines, a loss of amino acids caused by 
colonic leakage or a metabolic alteration (either by increased catabolism of proteins or by 
dysbiosis of intestinal microbiota)[25, 31, 32]. However, since levels of faecal amino acids 
in UC were higher compared to CD in this study, it is more likely that differences between 
a healthy gut and IBD result from a systemic loss of specific amino acids into the intestines, 
rather than from a decreased uptake in the jejunum. 
Interestingly, all of the significantly increased amino acids in this study are categorised 
lipophilic to very lipophilic, except for histidine. In addition, phenylalanine, tryptophan, 
tyrosine and histidine are all (unsaturated) aromatic amino acids. The chemical structure 
of histidine is also characterised by an electrically charged side chain (basic)[33]. All these 
chemical characteristics influence cell membrane diffusion and transportation. This might 
play a role in metabolic alterations due to dysbiosis of intestinal microbiota[34].
Recent evidence demonstrates that the human gut microbiota in the small and large 
intestine plays a role in dietary protein metabolism[35]. In a study performed by Davenport 
et al, paired colonic pinch biopsy samples of known inflammation sites were taken from 21 
CD and 23 UC patients and from 24 HC, on which PCR analysis of the variable region 4 of 
bacterial 16S ribosomal RNA was performed. They found that bacteria inhabiting inflamed 
tissue were related to the metabolism of amino acids[36]. For example, in a recent mice 
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model study on the CARD9 (caspase recruitment domain family member 9) gene, it was 
shown that tryptophan metabolism is altered in IBD[37]. Here, it was shown the microbiota of 
CARD negative mice failed to metabolize tryptophan into aryl hydrocarbon receptor (AHR) 
ligands. Inflammation decreased once the mice were treated with tryptophan metabolizing 
bacterial strains or AHR ligands. Based on these studies, it is not possible to address the 
differences in amino acid levels of faecal IBD samples directly to metabolic alterations. 
Whether these amino acids play an etiological role rather than reflecting inflamed intestines 
need to be elucidated in future (longitudinal) studies comparing levels of amino acids in 
blood plasma and faecal.
It has been shown that medication alters the composition of the faecal metabolome[30]. 
The strength of the current study is that potential bias by colonoscopy preparation and 
medication was circumvented by including only patients with de novo, treatment-naïve IBD, 
with samples collected prior to bowel preparation. Potential bias by differences in water 
content was circumvented by freeze-drying our samples according to a strict protocol. By 
strictly matching IBD subjects and controls, potential bias by age and sex was prevented. In 
addition, we were able to detect low concentrations of amino acids due to application of a 
highly sensitive and advanced technique to detect these metabolites. 
A limitation of this study is that clinical activity was assessed using the GPA, an activity 
scoring system based on a subjective physician’s observation with the possibility of inter- and 
intra-observer variance. However, each IBD subject underwent endoscopy upon inclusion, 
so we believe this may have only limited influence on the outcome. Second, we did not 
collect detailed information on dietary intake upon inclusion. The intake of dietary essential 
and non-essential amino acids possibly influences amino acids levels in the colon. It could 
be hypothesised that children with de novo IBD have a lower dietary intake compared 
to healthy controls due to dietary alterations linked to their illness, possibly influencing 
outcome. Therefore, differences in secretion or metabolism of certain amino acids between 
IBD patients and healthy controls could be masked due to differences in dietary intake. 
On the other hand, considering the increased amino acid levels of IBD patients compared 
to HC it is not likely this had a major influence on our study.  A third limitation of this 
study is the difference in duration of sample storage. The samples of IBD patients were 
stored for an average time of four years, whereas those of the control group were stored 
for just six months. Since storage time is of potential influence on metabolite degradation, 
it seems likely that more amino acids may have been degraded in the IBD group compared 
to the healthy group. However, since levels of amino acids were significantly higher in the 
IBD groups compared to the controls, metabolite degradation was thought not to be of 
substantial influence on the outcome of this study. 
In conclusion, in this explorative case-control study, faecal amino acid analysis allowed for 
discrimination between paediatric de novo, treatment-naïve IBD and controls. In particular, 
histidine, tryptophan and phenylalanine were strongly predictive for the discrimination of 
IBD patients and healthy controls. Since faecal amino acid analysis is a relatively fast, non-
invasive and inexpensive technique, it seems warranted to evaluate the potential of the 
aminogram as novel biomarker for IBD. 
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Supplementary figure 1. Box Whisker plots for all significantly different amino acids.
Box Whiskers plots with associated levels of significance. A: Histidine; B: Leucine; C: Phenylalanine; D: 
Tryptophan; E. Tyrosine; F. Valine; G. Serine. Abbreviations: HC, healthy controls; IBD, inflammatory 
bowel disease; UC, ulcerative colitis; CD, Crohn’s disease.
 
Supplementary figure 2A. Receiver operating characteristics curve for all significantly different amino 
acids between IBD and HC
A. Histidine IBD versus HC; B. Leucine IBD versus HC; C. Phenylalanine IBD versus HC; D. Tryptophan 
IBD versus HC; E. Tyrosine IBD versus HC; F. Valine IBD versus HC. Diagonal segments are produced 
by ties. Abbreviations: IBD, inflammatory bowel disease; HC, healthy controls. 
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Supplementary figure 2B. Receiver operating characteristics curve for all significantly different amino 
acids between UC and HC 
A. Histidine UC versus HC; B. Leucine UC versus HC; C. Phenylalanine UC versus HC; D. Tryptophan UC 
versus HC; E. Valine UC versus HC; F. Serine UC versus HC. Diagonal segments are produced by ties. 
Abbreviations: UC, ulcerative colitis; HC, healthy controls. 
 
Supplementary figure 2C. Receiver operating characteristics curve for all significantly different amino 
acids between CD and HC 
A. Histidine CD versus HC; B. Phenylalanine CD versus HC; C. Tryptophan CD versus HC. Diagonal 




Altered tryptophan levels in patients with 
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To the editor, 
With great interest we read the study by Nikolaus et. al. concluding that increased 
tryptophan (TRP) metabolism is associated with disease activity of inflammatory bowel 
disease (IBD)[1]. We agree with the authors that there still is an unmet need for non-invasive, 
cost-effective, reproducible and easy-to-perform tests for the diagnosis and risk assessment 
of IBD. Aromatic amino acids like TRP seem to be a promising candidate in this respect. We 
would, however, like to add some considerations regarding the underlying pathophysiologic 
mechanisms causing these differences in serum tryptophan levels. 
The authors hypothesised that the observed decreased serum levels of TRP in IBD might 
be explained by several mechanisms. First, serum TRP might be decreased due to down-
regulation of the expression of the neutral amino acid transporter solute carrier family 6 
member 19/system B(0) neutral amino acid transporter 1 (SLC6A19/B0AT1) found in their 
study, which is the main intestinal transporter involved in TRP absorption[2]. Unfortunately, 
faecal TRP levels were not assessed, hampering to exclude malabsorption as cause for 
decreased serum levels. In our recent publication on faecal amino acid levels in de novo, 
treatment-naïve paediatric IBD patients we have described that levels of TRP, amongst other 
amino acids, were elevated in stool samples of IBD patients[3]. Since we observed higher 
levels of faecal amino acids in UC subjects, in whom small intestines were by definition not 
affected, compared to CD, we hypothesised that jejunal malabsorption would be an unlikely 
explanation. However, Nikolaus et. al. reported stronger down-regulation of SLC6A19/
B0AT1 in UC compared to CD. This outcome, in combination with the elevated faecal TRP 
levels observed in our study, reinforces the possibility of malabsorption as a cause for the 
TRP level changes in IBD.
Another explanation given by the authors is the poorer nutritional state of CD patients 
compared to UC patients. While dietary intake of TRP was assessed in a subgroup of patients 
in their study, differences in nutritional status between the groups were not examined. We 
would like to add the consideration that, based on disease localisation, malabsorption 
would be expected to be more distinct in CD than in UC, while UC patients are expected 
to suffer more profoundly from protein loss trough colonic leakage. Our observations of 
higher faecal TRP levels in UC compared to CD, therefore underlines the hypothesis that 
colonic leakage might play a major role in causing TRP level differences in active IBD. In 
addition, 90% of TRP is used in the kynurine (KYN) pathway, which includes the production of 
quinolinic acid (QUI), picolinic acid (PIC) and kynurenic acid (KYA)[4]. The authors have shown 
an increased KYN/TRP ratio, increased levels of QUI and lower levels of PIC and KYA in IBD 
versus controls, illustrating the altered TRP metabolism in IBD. This alteration might have 
contributed to the decreased levels of serum TRP. However, one would expect decreased 
faecal TRP levels in upregulated TRP metabolism, and not to increased levels as observed 
in the IBD subjects in our study. We therefore think that both malabsorption and colonic 
leakage are more likely to be of influence on TRP levels than alterations in its metabolism. 
Furthermore, we would like to emphasize that despite the observed correlation between 
IBD and TRP, it remains yet unraveled whether this phenomenon is a consequence rather 
than cause of disease activity. Possibly, TRP plays a role in maintaining IBD activity. Previous 
177
10
mouse studies have shown that failure of TRP metabolism into aryl hydrocarbon receptor 
(AHR) ligands after stopping the expression of the caspase recruitment domain-containing 
protein 9 (CARD9) gene, induced colitis-like symptoms[5]. The gut microbiota metabolizes 
TRP into indole derivates, used for production of ARH ligands[6]. In addition, it is now 
known that ARH induces IL22 production, which plays a role in regeneration and protection 
of the intestinal mucosa[5,6]. We therefore hypothesize that lower levels of TRP, provoked 
by malabsorption or colonic leakage, could possibly influence IL22 secretion and maintain 
inflammatory symptoms. In line with this hypothesis, Nikolaus et. al. found increased IL22 
levels in IBD patients. 
Last, the authors emphasize the potential of tryptophan supplementation as a treatment 
option in IBD, based on mouse studies[5]. In line with our results, previous studies have 
shown alterations in serum and/or stool levels of aromatic amino acids in IBD patients 
[7]. We would therefore like to add the consideration that not only tryptophan, but also 
other (aromatic) amino acids, like phenylalanine and tyrosine, may hold potential for both 
diagnostic and treatment purposes in IBD.
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In this prospective intention-to-diagnose pilot study, we aimed to assess accuracy 
of serum and faecal amino-acids to discriminate de novo paediatric inflammatory 
bowel disease (IBD) and non-IBD children. Patients with suspected IBD were 
allocated the IBD (n=11) or non-IBD group (n=8) following laboratory testing 
or endoscopy according to the revised Porto-criteria. Faecal calprotectin levels 
were obtained, an addition blood and faecal sample were collected. Faecal 
and serum amino-acid profiles were analysed using High Performance-Liquid 
Chromatography. Nine faecal amino-acids (alanine (area under the curve 0.94), 
citrulline (0.94), glutamine (0.89), leucine (0.98), lysine (0.89), phenylalanine (0.99), 
serine (0.91), tyrosine (0.96) and valine (0.95) differed significantly between IBD 
and non-IBD. In serum, no significant differences were observed. This study 
underlines the potential of faecal amino-acids as novel, adjuvant non-invasive 




Inflammatory Bowel Disease (IBD) is a chronic gastrointestinal tract inflammation and 
comprises ulcerative colitis (UC) and Crohn’s disease (CD). Diagnosis and classification of 
paediatric IBD is primarily established by means of endoscopy and histopathology. This 
invasive procedure carries high burden on children, since endoscopy is performed under 
general anesthesia [1]. 
Faecal calprotectin (FCP) is the commonly used non-invasive biomarker in the diagnostic 
work-up of IBD because of its high sensitivity for mucosal inflammation (0.98, 95% CI 
0.95-0.99). This biomarker is, however, hampered by low specificity values, especially in 
paediatric patients (0.68, 95% CI 0.50-0.86)[2]. This leads to a large number of false positive 
tests and subsequently to unnecessary invasive procedures. 
Recent studies have demonstrated high sensitivity of amino acid (AA) composition in serum 
and faecal to discriminate (paediatric) IBD patients and healthy controls[3, 4]. Specificity 
values have not yet been addressed as no intention-to-diagnose population has been used 
as control group so far. We aimed to assess which biological sample holds the highest 
accuracy in the diagnostic work-up of paediatric IBD in an intention-to-diagnose population. 
METHODS
Study design 
This prospective intention-to-diagnose pilot study was performed between February 2018 
and February 2019 at the outpatient clinic of the paediatric gastroenterology department 
of the tertiary hospital Amsterdam UMC, The Netherlands. 
Participants 
Children aged 4-17 years, referred to the outpatient clinic because of suspected IBD, who 
were sent for routine laboratory blood tests after their first appointment, were asked to 
participate in this study. Exclusion criteria were proven infectious colitis one month prior 
to inclusion (defined by a positive stool culture for Salmonella spp., Shigella spp., Yersinia 
spp., Campylobacter spp. or Clostridium spp. Toxins), use of antibiotics, probiotics or 
immunosuppressive therapy three months prior to inclusion, co-morbidity with autoimmune 
diseases or other gastro-intestinal diseases (i.e. celiac disease, Hirschsprung’s disease), 
gastro-intestinal surgery except for appendectomy. According to the revised Porto-criteria, 
patients were allocated to the IBD group when IBD was proven based on endoscopic, 
radiologic and/or histologic findings[5]. Non-IBD patients were defined as children referred 
to our centre because of suspicion of IBD either based on medical history, laboratory 
testing, but in whom the diagnosis of IBD was not established after additional laboratory 
testing, radiological and/or endoscopic assessment. 
Sample and data collection 
All patients were asked to complete an online questionnaire including items on medical 
history and somatic symptoms. Clinical disease activity of the IBD-cases was determined 
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by the Paediatric Crohn’s Disease Activity Index (PCDAI) [6] or the Paediatric Ulcerative 
Colitis Activity Index (PUCAI) [7]. Localisation and behaviour of paediatric IBD were 
classified according to the Paris classification [8]. Blood samples were collected during 
routine laboratory tests, prior to initiation of therapy. Stool samples were collected and 
subsequently frozen at -20 degrees within 24 hours following blood sampling and before 
bowel cleansing was performed. From the obtained faecal samples, 500mg was freeze-
dried for further analysis.
Amino acid analysis
Faecal samples were measured using targeted High-Performance Liquid Chromatography 
(HPLC) conform our previously established standardised protocol[9]. Serum AA composition 
was determined by the Standard Operating Procedure of the Amsterdam UMC for routine 
serum AA analysis. Separation of AAs was done by ion-exchange chromatography followed 
by post-column derivatization with ninhydrin and detection by UV-absorbance.
Statistical analysis 
Statistical analysis was conducted conform our previous study[9]. On account of the small 
sample size, the Mann Whitney U test / Wilcoxon rank-sum test was used to calculate 
p-values and area under the curve (AUC) values to identify differences in aminograms 
between the IBD and non-IBD. To correct for multiple testing, a p-value of <0.005 was 
considered statistically significant. Kruskall wallis tests, followed by Mann-Whitney U tests in 
case of significance, were used to explore differences in  profiles between UC, CD and non-
IBD groups. Sensitivity and specificity of faecal AAs were compared to those of calprotectin. 
Spearman’s Rho test was used to calculate correlation coefficients between calprotectin and 
significantly different AAs. 
Ethical considerations
This study was approved by the Medical Ethical Review Committee (METc) of the VU 
University Medical Centre with file number 2015.393. Written informed consent was 
obtained from children and/or parents (only parents in case children <12 years). 
RESULTS
Baseline characteristics
Written informed consent was given by 20 participants. One patient was excluded as the 
faecal sample was not sufficiently collected. A total of 19 patients were consecutively 
included in this study of whom 11 were diagnosed with IBD (6 UC, 5 CD) and 8 were non-
IBD controls. Demographics are listed in Table 1. There were no significant differences in 
age, body-mass index (BMI), gender, symptoms duration, average stool consistency, sample 
storage time and levels of C-reactive protein between IBD and non-IBD. Calprotectin levels 
differed significantly between groups (median IBD 2050 µg/g vs. median 75.5 µg/g non-
IBD, p=0.001). Three out of eight non-IBD patients had elevated faecal calprotectin levels 
(202, 642 and 1300 µg/g). Non-IBD patients with high calprotectin levels were monitored at 












Sex, male (n [%]) 5 [83.3] 2 [40] 7 [63.6] 4 [50]
Age (median [IQR]), years) 10.4 [8.1-14.3] 15.9 [14.6 – 
17.2]
14.4 [9.2 – 16.6] 12.8 [9.4 – 
16.7]
Storage time (median 
[IQR], months)
3.5 [2.3 – 10.3] 5 [1.5 – 7] 4 [3 – 9] 8 [8 – 9]
BMI (median [IQR]) 15.6 [14.5 – 
19.2]
17.2 [15.0 – 
20.1]
16.1 [14.9 – 19.1] 19.1 [15.6 – 
24.2]
Bristol stool chart (n [%])
    Type 1
    Type 2
    Type 3
    Type 4
    Type 5
    Type 6





























Duration of symptoms 
(median [IQR], months)
3.5 [1.5 – 4.5] 4 [0.5 – 14.5] 4 [1 – 5] 6 [3 – 16.5]
Faecal calprotectin¥ (µg/g) 
(median[IQR])
3210 [850.5 – 
5739.8]
1312 [870.5 – 
2113.5]
2050 [1010 – 3680]¥ 75.5 [17.3 – 
532]¥
CRP (mg/l) (median[IQR]) 2.5 [2.5 – 3.4] 36 [22 – 43] 6 [2.5 – 36] 2.5 [2.5 -20.5]
Disease Activity Index1 
(median[IQR]) 
60 [46.3 – 
61.3]



















Ileal (L1) NA 2 [40] NA NA
Colonic (L2) NA 0 [0] NA NA
Ileocolonic (L3) NA 3 [60] NA NA
Proximal disease (L4) NA 1 [20] NA NA
Crohn’s disease behaviour2
B1 (NSNP) NA 3 [60] NA NA
B1p (NSNP+p) NA 2 [40] NA NA
B2 (S) NA 0 [0] NA NA
B2p (S + p) NA 0 [0] NA NA
B3 (P) 0 [0] NA NA
B3p (P + p) 0 [0] NA NA
Table continues











Proctitis (E1) NA NA NA
Left-sided (E2) NA NA NA
Extensive (E3) NA NA NA
All values were obtained at study inclusion. Localisation of IBD was obtained by ileocolonoscopy 
and esophagogastroduodenoscopy before treatment initiation, and MR enteroclysis. Abbreviations: 
IQR, interquartile range; NA, not applicable; NSNP, non-stricturing non-penetrating; S, stricturing; P, 
penetrating; p, peri-anal disease. 1 Based on Paediatric Crohn’s Disease Activity Index (PCDAI) and 
Ulcerative Colitis Activity Index (PUCAI). PCDAI defined as remission <10, mild 10-34, moderate 35-64, 
severe 65-85 points; PUCAI defined as remission <10, mild 10-27.5, moderate 30-37.5, severe ≥40. 
2Based on Paris classification for inflammatory bowel disease ¥Significant differences between IBD and 
controls p<0.001, analysed using the Mann-Whitney U test.
Amino acid composition
Inflammatory bowel disease versus controls
A total of 42 unique AAs were detected in all samples together of whom 20 could not 
be used of statistical analysis due to undetectable levels in more than 50% of the cases. 
From the 22 AAs included in the statistical analysis of faecal and serum, nine faecal AAs 
(alanine (AUC 0.94), citrulline (AUC 0.94), glutamine (AUC 0.89), leucine (AUC 0.98), lysine 
(AUC 0.89), phenylalanine (AUC 0.99), serine (AUC 0.91), tyrosine (AUC 0.96) and valine 
(AUC 0.95) differed significantly between IBD and non-IBD (Figure 1). Six faecal AAs were 
significantly different when comparing UC patients to the non-IBD group (alanine (AUC 
0.96), leucine (AUC 1.00), phenylalanine (AUC 1.00), serine (AUC 0.90), tyrosine (AUC 
0.98), valine (AUC 0.98). In CD patients versus non-IBD, these same faecal AAs had lowest 
p-values, though, none of them reached a level <0.005. No differences between subgroups 
of UC and CD were observed. In serum, no significant differences between IBD, subgroups 
of IBD and non-IBD were observed. We calculated cut-off values of faecal AAs to reach 
optimum specificity and sensitivity values. When aiming to obtain specificity levels of 100%, 
we observed high sensitivity of faecal alanine (80%; cut-off value 42.1 nmol/mg), leucine 
(90%; 24.1 nmol/mg), phenylalanine (90%; 12.9 nmol/mg), tyrosine (80%; 12.3 nmol/mg) 
and valine (80%; 25.9 nmol/mg). 
Comparison of faecal amino acids and calprotectin 
Based on the widely used cut-off value of 150 µg/g for calprotectin, all IBD children were 
classified correctly (sensitivity 100%) and three out of eight non-IBD children incorrectly 
(specificity 66.7%). Of these incorrectly classified non-IBD patients displaying elevated 
levels of calprotectin, only one displayed high levels of faecal AAs as well. This patient 
underwent a second endoscopic assessment a year after this study was closed, and is now 
treated for IBD-unclassified.  
Correlation between faecal amino acids and calprotectin
The faecal AAs citrulline (r=0.486, 95%CI 0.125 – 0.724), leucine (r=0.583, 95%CI 0.249 
– 0.788), phenylalanine (r=0.575, 95%CI 0.165 - 0.802) and valine (r=0.529, 95%CI 0.149 – 
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0.782) revealed a significant correlation to faecal calprotectin.  
DISCUSSION
We compared simultaneously collected faecal and serum AA profiles of de novo treatment-
naïve paediatric IBD patients and controls by means of targeted AA analysis and found 
statistically significant differences in nine faecal AAs. There were no differences in serum 
AA levels. 
In our previous study, faecal amino acid composition of 30 de novo treatment-naive 
paediatric IBD patients (15 UC, 15 CD) and 30 healthy controls (HC) were assessed using 
the same methodology. A significant increase in six faecal AAs was observed in IBD subjects 
when compared to HC(8). These AAs were amongst the most increased AAs in the current 
study, but were not all significantly altered in our current study. Contrary, our outcomes 
on serum AA composition were different to the currently available literature. In a previous 
study on assessment of serum AA levels, 387 adult IBD patients were compared to 210 
asymptomatic healthy controls[4]. A decrease in serum tryptophan and histidine were 
observed. In the current study, we did find negative z-scores for these AAs (-0.713 and 
-2.03, respectively), however, these differences were not significant. This may be due to 
our smaller sample size. We did find high AUC-values for faecal AAs, suggesting that these 
differences may be more explicit and therefore more useful as noninvasive biomarkers. 
The etiology and pathogenesis of IBD is still largely unknown. Studies focusing on 
metabolomics have contributed to a better understanding of IBD pathogenesis. Proteins, 
consisting of AAs, play an important regulatory role in metabolic pathways and maintaining 
intestinal health[10]. Current hypotheses on the underlying mechanisms of alterations in 
faecal AA levels in IBD patients include malabsorption, alterations in metabolism, gut 
dysbiosis and colonic leakage [11, 12]. As some AAs are essential, meaning they cannot be 
synthesized and must be obtained from the diet, IBD patients suffering from malabsorption 
would be expected to have decreased serum levels of essential amino acids. Since no 
differences in serum AA levels between IBD and controls were observed and nearly all 
serum values lay within the referency ranges of healthy children, malabsorption can be 
considered an unlikely explanation for the observed differences. The increase in faecal AA 
levels whilst sustaining normal levels in serum is possibly caused by a loss and degradation 
of proteins in infected and damaged enterocytes and colonocytes[13]. Another explanation 
may be a change in intestinal metabolism. Accumulating evidence shows a correlation 
between faecal AA levels and alterations in gut microbiota in IBD patients [14, 15]. 
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Figure 1. Box Whisker plots for faecal amino acids differentiating between inflammatory bowel 
disease patients and controls 
Faecal amino acid levels are given in µmol/L.  Levels were considered significant at a p-value of <0.005. 
Abbreviations: IBD inflammatory bowel disease, UC ulcerative colitis, CD crohn’s disease. C controls
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This study has several strengths. This was the first study in which simultaneous analysis of 
faecal and serum AA profiles in IBD patients was performed. We included participants in 
an intention-to-diagnose setting, which warranted inclusion of patients generalizable to the 
population presented at outpatient clinics. De novo treatment naïve paediatric IBD patients 
were included, avoiding potential bias by medication, colonoscopy preparation and long 
term disease activity. Furthermore, as we freeze-dried our faecal samples, potential bias 
by differences in stool consistency was circumvented. In addition, targeted AA analysis 
was done by a high sensitivity platform and based on standard operating protocols. As an 
explorative pilot study, we also encountered some limitations. Our sample size was small 
and therefore our study had low power. This may have resulted in false-negative results. In 
addition, we did not assess dietary intake so we were not able to correct for specific food 
products despite the knowledge of that lower protein intake negatively effects serum levels 
of specific AAs (e.g. tryptophan, phenylalanine, tyrosine)[16, 17]. As correction for dietary 
intake would lead to hundreds of variables, correction for this would not have been feasible 
based on the current sample size. However, as all children are residential in the same area 
in The Netherlands, we do not expect large differences in dietary intake. Last, the three 
non-IBD patients displaying high levels of faecal calprotectin were monitored for a median 
period of time of 3 months to exclude development of IBD later on. Only one non-IBD 
displayed high levels of faecal AAs upon inclusion. Remarkably, after closing the study, this 
patient underwent a sesecond endoscopic assessment because of persisting symptoms and 
is now treated for IBD-undetermined. This illustrated the high sensitivity of faecal AAs and 
their potential additional value as non-invasive biomarkers.   
We have planned a large intention-to-diagnose cohort study to validate faecal AAs as 
biomarkers,  since this test is cost-effective, reproducible and easy to perform[9]. Targeted 
AA analysis and calprotectin have comparable costs (approximately 28 [95% CI 15-50] 
American dollar), whereas endoscopy with biopsies cost approximately 1171 [700-2000] 
dollars, excluding anesthetics[18]. As demonstrated, high specificity values of faecal AAs 
may be reached whilst maintaining acceptable sensitivity values. Upon validation of faecal 
AAs, a diagnostic algorithm may be established combining calprotectin and multiple faecal 
AAs to improve test accuracy. The best performing AAs may be combined with calprotectin 
in a 2-step approach to lower the number of false-positive and false-negative tests and 
subsequently lower the number of unnecessary endoscopic assessments. Another subject 
of interest may be the correlation between faecal AAs and IBD localisation and to predict 
disease exacerbation or response to therapy using AAs allowing for development of 
personalised follow-up strategies. 
In conclusion, we observed that levels of nine faecal AAs were significantly increased in IBD 
versus intention-to-diagnose controls, while serum levels were comparable. This finding 
underlines the potential of faecal AA levels as additional non-invasive, low-cost biomarker 
in the diagnostic work-up of paediatric IBD. 
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The faecal volatolome, which is composed of faecal volatile organic compounds 
(VOCs), seems to hold potential as non-invasive biomarker for the detection of 
colorectal cancer (CRC) and its precursor lesions advanced adenomas (AA). The 
potential of the faecal volatolome has been subject of various studies using either 
chemical analytical or pattern-recognition techniques. The available literature on 
the potential of the faecal volatolome as CRC and AA biomarker was reviewed. 
Methods
A systematic literature search was conducted in PubMed, Embase, the 
Cochrane Library, Google Scholar and ResearchGate using the following 
keywords: Colorectal Cancer, Advanced Adenoma, Volatile Organic Compound, 
Metabolome, Gas Chromatrography-Mass Spectrometry, Selected-Ion Flow-Tube 
Mass-Spectrometry, eNose, and Faecal Biomarkers. 
Results
Eighty-eight titles or abstracts were identified from the search, of which eleven 
papers describing the potential of the faecal volatolome for CRC detection were 
selected. In these studies, different techniques were used for the headspace 
analyses of faecal VOCs, limiting the possibility to compare outcomes. Increased 
levels of amino acids and short chain fatty acids, and decreased levels of bile 
acids and polyol alcohols in the gas phase of faeces were observed repeatedly. 
All selected papers reported high diagnostic value for the detection of both CRC 
and AA based on faecal VOCs.
Conclusion
Based on the included studies, faecal VOC analysis seems promising for future 
screening of CRC and AA, with potentially improved test performances allowing 
for earlier detection of AA and CRC and consequently earlier initiation of 






Colorectal cancer (CRC) is the third most common malignancy with an incidence rate of 40.7 
per 100.000 in the US, and has the highest cancer-related mortality rate in the industrialised 
world [1-3]. The 5-year survival rate for colon cancer and rectum cancer are 64.4% and 
66.6%, respectively[3]. Early detection and treatment are critical factors in the course 
and prognosis of CRC, as the survival rate decreases with disease progression[4]. Most 
CRC develops from advanced adenomas (AA), and early detection and removal of these 
adenomas has been found to decrease CRC incidence and mortality [5, 6]. The most widely 
used screening modalities for CRC and its neoplastic precursors are faecal immunochemical 
testing (FIT) and endoscopic evaluation of the colon. Although this screening program has 
led to a decrease in mortality, the performance of this test is suboptimal, with a sensitivity 
and specificity for CRC of 56-89% and 94-97%, respectively, depending on used cut-off 
values [7]. This results in a substantial number of false negative tests, and as a consequence 
missed diagnosis of colorectal cancer in 11-44% of the cases. In addition, 3-6% of the 
healthy participants undergoing population based screening still receive false positive test 
results, which leads to the performance of unneeded colonoscopies. These colonoscopies 
carry a high burden on patients and create a small risk of complications (e.g. bleeding or 
perforation)[7]. Because of these limitations, a clear unmet need exists for a more accurate 
and non-invasive test to select high-risk individuals who need to undergo colonoscopy.
The use of gas molecules as noninvasive disease biomarkers stems from a long history of 
medicine in which Hippocrates characterised the distinct smell of melena as early as 400 
years BC, and patients with diabetes were described as have urine with a smell of rotten 
apples in ancient Chinese medicine [8]. Nowadays, gaseous molecules are analysed using 
highly sensitive techniques, resulting in smellprints comprised of over a thousand different 
gaseous molecules, referred to as volatile organic compounds (VOCs), or the ‘volatolome’. 
These VOCs are produced during metabolic processes such as inflammation, cancer 
degeneration and necrosis and can be measured in all conceivable bodily excrements 
including breath, urine and faecal dependent on their volatility and temperature of the 
sample. The faecal volatolome is also believed to reflect alterations in gut microbiota by 
a change in VOCs created during gut-microbiota interactions[9]. Multiple studies have 
focused on the use of the faecal volatolome as biomarker for CRC and AA with promising 
results[10, 11]. In this systematic review we have aimed to summarize the available literature 
on faecal volatolome analysis for the differentiation between CRC, AA and controls, and 
philosophize about the clinical implications for improved screening on colorectal cancer. 
METHODS
 
An electronic literature search was performed systematically, by using the electronic database 
of the National Centre for Biotechnology Information (PubMed), Embase, Cochrane Library, 
Google Scholar and ResearchGate to collect publications before June 2018. The following 
search terms for colorectal cancer and advanced adenoma, including synonyms and closely 
related words, were used as index terms and/or free words: ‘colorectal carcinoma’, ‘colon 
cancer’, ‘rectal cancer’, ‘colorectal neoplasia’, ‘colorectal tumor’, ‘advanced adenoma’, 
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‘high-risk adenoma’. These terms were combined with index terms and/or free words 
for VOC analyses (‘gas chromatography-mass spectrometry’, ‘ion mobility spectrometry’, 
‘selected-ion flow-tube mass-spectrometry’, ‘electronic nose’, ‘volatile organic compounds’, 
‘volatolome’, ‘gas molecules’, ‘metabolome’) and faecal biomarkers (‘faecal’, ‘faecal 
marker’, ‘faecal biomarker’). After the search, the collected literature was screened on title 
and abstract by two authors independently, and included in this study after selection by 
both of the authors (SB and NKHDB). The reference lists of identified papers were checked 
on additional studies missed during the original search. Full-text articles, abstracts and 
posters were only included if they focused on the faecal VOC composition, excluding other 
bodily fluids and metabolites. Non-original articles, reviews, duplicates and articles in other 
languages than English or Dutch were excluded from this review.
RESULTS
Eighty-six titles or abstracts were identified from the primary electronic search and reference 
lists after the literature search was performed in PubMed, Embase and the Cochrane Library 
and two articles were found using Google Scholar and ResearchGate (Figure 1). Of the 
identified records, 77 publications did not meet the criteria for inclusion for various reasons; 
a total of 11 publications could be included in this systematic review. Reasons for exclusion 
were the use of mucosal biopsies and other material rather than faecal, newly described 
methods without statistics provided, replies on papers or editorial comments and papers 
not relevant to the topic. Included literature consisted of nine full-texts original articles, one 
abstract and one poster presentation (Table 1). In six studies, gas chromatography (GC) was 
used for VOC identification, of which three used GC combined with mass spectrometry 
(GC-MS). Two studies made use of a self-made VOC sensor: SCENTA1. Other studies made 
use of selected-ion flow-tube mass spectrometry (SIFT-MS), electronic Nose (eNose) and 
dogs for scent detection. 
Volatolome analytical techniques
Analytical methods can be separated into chemical analytical techniques and pattern-
recognition technology. In chemical analytical techniques, alterations in the presence 
and concentrations of specific molecules can be detected, whereas pattern-recognition 
technologies focus on the discrimination of VOC profiles by differences in sensor resistance 
to specific VOCs. In this section of this review an overview of the  used analytical methods 
for faecal VOC analyses for the detection of CRC is given. In table 2, technical characteristics 
per analytical method are summarised.
Chemical analytical techniques
Gas-chromatography Mass-Spectrometry
This method has been proved to successfully analyse the VOC composition of various 
bodily fluids and is considered the gold standard for volatolome analyses[12]. Coupling 
chromatography to spectrometry allows for separation and quantification of individual 
VOCs. These analytes are transported through the chromatography column in a carrier 
gas and interact with the column surface. VOCs with different chemical characteristics 
have specific interactions with the column, resulting in a distinct transportation time for 
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sets of VOCs with comparable characteristics. VOCs are then ionised and pushed into 
the second (spectrometry) column, consisting of an electric field with varying voltage. 
The transportation time of the analytes is influenced by their electric charge, resulting in 
a distinct transportation time for sets of VOCs with comparable masses[13]. By combining 
separation on chemical characteristics and mass, the VOC composition can be measured 
very accurately which allows for biomarker recognition. 
Figure 1. PRISMA flow diagram
Selected Ion Flow Tube-Mass Spectrometry
Another technique used for faecal volatolome analyses for the detection of CRC is 
selected ion flow tube-mass spectrometry (SIFT-MS). This technique allows for real-time 
measurements and is therefore faster compared to the gold standard. Mass spectrometry 
is coupled to a selected ion flow tube, in which VOCs are ionised by precursor ions (H3O
+, 
NO+ and O2
+) in a defined order[14]. The precursor ions are generated using a microwave 
discharge and their order for the analysis is chosen using quadrupole mass spectrometry. 
Before the sample is injected, the selected precursor ions are introduced in the flow tube 
using helium as carrier gas. The precursor ions and VOCs interact in the flow tube and 
enter a second quadruple mass spectrometer where the product ions and precursors are 
separated. Real-time data analyses is done by scanning a specific spectrum of mass-to-
charge-ratios defined by the user. The absolute concentration can be calculated from the 
ratios using the precursor and product ion signals. This technique provides less detailed 
information on VOC composition compared to GC-MS, since VOCs remain less separated 
using this analysis, but allows for real-time measurements, has lower maintenance costs and 
does not require specialised personnel.
Pattern-recognition techniques
eNose technology
There are many sorts of different electronic nose (eNose) devices, which all have in 
common that VOC analysis is based on pattern-recognition. In eNose technology, VOCs 
are presented to an array of sensors made from specific material. Analytes interact with 
the individual sensors based on their chemical characteristics. This sensor-interaction is 
analysed with different techniques dependent on which eNose is used (e.g. conducting-
polymer sensors, electrochemical sensors, metal oxide sensors). The differences in sensor-
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interaction create a pattern which is called the VOC ‘smellprint’, and can be analysed with 
pattern recognition algorithms to identify specific diseases[15]. The main benefits of eNose 
technology are measurement speed and low costs and although disease-specific patterns 
can be recognised, individual VOC biomarkers cannot be identified on a molecular level. 
Furthermore, sensor drift over time may hamper reproducibility.
SCENT A1
A new eNose device for faecal VOC analyses which has solely been described by one 
research group so far, is the patented SCENT A1[16]. This is a device made of an array of five 
chemo resistive sensors which are capable of changing their resistance once in contact with 
specific VOCs, and can detect tumor biomarkers in low concentrations. The sensor material 
used in this device are SmFeO3 (Iron and samarium oxides), ST25 + Au (Tin and Titanium), 
ST20 (Tin and Titanium oxide 20%), TiTav (Titanium, Tantalum and Vanadium oxides) and 
In2O3 (Indium oxide). These sensors have been selected after thorough testing of 20 sensors 
composed of different material. The array of 5 sensors with the best diagnostic accuracy to 
differentiate between CRC and HC was selected for further development and validation[17]. 
Information on practicality, sensor stability and costs are lacking. 
Study characteristics and outcomes
Chemical analytical techniques 
Gas chromatography-mass spectrometry
The first study to explore the use of the faecal volatolome for the detection of CRC using 
GC-MS was conducted by Weir in 2013[10]. Stool samples were collected from 10 CRC 
patients prior to colon resection surgery and 11 healthy controls (HC). Global volatile 
metabolite profiling was performed on faecal samples of 9 CRC and 10 HC, and targeted 
short chain fatty acid (SCFA) profiling on 9 CRC and 11 HC,. The global volatolome of CRC 
patients showed increased levels of 11 amino acids (alanine, glutamate, glycine, aspartic 
acid, leucine, lysine, proline, serine, threonine, valine and phenylalanine), one carboxlylic 
acid (benzeneacetic acid), one SCFA (propionic acid) and one saturated fatty acid (myristic 
acid), one vitamin B5 derivate (pantothenic acid) and one steroid (cholesterol derivate). In 
addition, three unsaturated fatty acids  (oleic, linoleic and elaidic acid) as well as polyol and 
its derivates (glycerol and monooleoylglycerol), and one bile acid (ursodeoxycholic acid) 
were decreased. The SCFA profiles of CRC patients showed increased levels of acetic acid, 
valeric acid, isobutyric acid, isovaleric acid and decreased levels of butyric acid compared to 
profiles of HC. This study did not report any outcomes on accuracy, specificity and sensitivity 
for one (or a combination) of these metabolites as CRC biomarker. Another study applying 
GC-MS was reported by Bond, who analysed faecal samples from symptomatic patients 
and patients referred after they were tested positive during the UK Bowel Cancer Screening 
Program[18]. A total of 20 CRC patients and 60 HC were included. Four discriminating 
compounds were reported, of which compound A showed an area under the curve (AUC) of 
0.76 (P-value < 0.0001), and the combination of A and B increased the AUC to 0.82. After a 
10-fold cross validation, an AUC of 0.82 with a sensitivity of 87.9% and a specificity of 84.6% 
was found. During further logistic regression analyses a combination of three compounds 
(A, X and Y) was found, of which the AUC was 0.86 (P-value <0.0001). Unfortunately, no 
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Table 2. Overview of technical characteristics per volatolome analyses method
GC-MS SIFT-MS Cyranose 320 ® SCENT A1
Accuracy Very good 
separation of 
analytes using 







of VOCs is lost 













volatiles can be 
drawn









Speed 10 - 45 minutes 
per sample
A few seconds 









time of 1 hour 
per sample
Costs Expensive:
Mainly because of 






Machine is double 
the price of GC-


















Maintenance High maintenance Low maintenance Low 
maintenance
Sensor renewal 













Overview of technical characteristics per volatolome analyses method. Abbreviations: GC-MS, gas 
chromatography-mass spectrometry; SIFT-MS, Selected-ion Flow-tube Mass-Spectrometry; eNose, 
electronic Nose.
In 2017, Wang performed a study on the volatolome for CRC detection using GC-MS 
analyses on faecal samples of 15 CRC patients and 12 HC[19]. The levels of SCFAs acetic 
acid, valeric acid, butyric acid and isovaleric acid were increased in CRC patients, whereas 
isobutyric acid was decreased in this group. There was no difference in the level of propionic 
acid between CRC and HC. Furthermore, levels of 9 amino acids (glutamic acid, glycine, 
aspartic acid, leucine, glycerin, proline, serine, valine, phenylalanine), phenylacetic acid and 
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cholesterol derivates were significantly increased in the CRC group compared to HC, and 
the unsaturated fatty acids (oleic acid, elaidic acid and linoleic acid), two types of glycerin 
(glycerin and monoacyl glycerol), one saturated fatty acid (myristic acid), one vitamin B5 
derivate (pantothenic acid) and one bile acid (ursodeoxycholic acid) were decreased. 
In the most recent study on the use of GC-MS for faecal volatolome analyses, samples from 
26 newly diagnosed CRC patients were compared to 28 healthy individuals[20]. Analyses 
of long-chain fatty acids using GC-MS was combined with the analyses of SCFAs using GC 
coupled to a Mass Selective Detector (GC-MSD). In contrast to the previous studies, no 
significant differences were found in the levels of both these short and long-chain fatty acids 
when comparing CRC to HC. Interestingly, sub-analyses by gender did reveal an increase in 
faecal concentrations of both oleic acid and linoleic acids in male CRC patients whereas in 
previous studies decreased concentrations of these fatty acids were observed.
Other chemical analytical techniques
In 2015, selected ion flow tube linked to mass spectrometry (SIFT-MS) was used for the 
identification of individual faecal VOCs by Batty, who included 62 patients with a positive 
faecal occult blood test (FOBT)  resulting in a subsequent performed colonoscopy[21]. 
During endoscopy, at least one advanced adenoma (referred to as high grade adenoma) 
or adenocarcinoma was found in 31 of these participants (high risk group), while no 
abnormalities were observed in the residual of the participants (low risk group). In this article 
it is not noted how many patients included in the ‘high risk’ group had CRC or AA. Four 
analytes (m/z 35 and m/z 90 using H3O
+ as precursor ion, m/z 62 and m/z 94 using NO+ 
as precursor ion) were found to be significantly increased in the high risk group. Possible 
identities of these analytes were hydrogen sulphide, dimethyl sulphide and dimethyl 
disulphide. The compound with mass-to-charge ratio 90 remained unknown. Based on the 
whole dataset created by analyses of all three precursors, the researchers found an overall 
classification accuracy of 75%, with a specificity of 78% and a sensitivity of 72% for ‘high risk’ 
patients versus healthy controls.
Another study was conducted by Ishibe who included 30 CRC patients and 26 healthy 
volunteers. A gas sampling apparatus was built into a toilet which collected gas components 
during defecation.  Faecal gas was analysed on methyl marcaptan (MM) and hydrogen 
sulphide (H2S) using Gas Chromatography coupled to a Sulfur Chemiluminescence Detector 
(GC-SCD). Next Hydrogen (H2), methane (CH4) and carbon dioxide (CO2) were analysed by 
Gas Chromatography coupled to a Termal Conductivity Detector (GC-TCD). Levels of MM 
were found significantly increased in CRC patients, whereas levels of H2 were significantly 
decreased compared to HC. Using a logistic regression analyses, a discriminant formula was 




Dogs are renowned for their excellent sense of smell. Their olfactory capacities have 
been mainly used for hunting and protection of property, but trained dogs are also able 
to accurately detect drugs and explosives at borders, airplane fields or in prisons. For 
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disease detection, multiple studies have focused on the use of dogs for various carcinomas 
(e.g. prostate cancer, ovarian cancer, bladder cancer), all showing high accuracy to detect 
diseases[22-24]. A canine trial with a Labrador retriever aimed at identifying CRC was 
performed in 2013 and demonstrated a remarkable diagnostic accuracy. The sensitivity 
and specificity of faecal samples was high (97% and 99%, respectively)[25]. The correctness 
proved to be better than FOBT. 
Electronic Nose technology
Cyranose
In 2014, the VOC profiles, of faecal samples of 40 CRC patients, 60 patients with advanced 
adenomas (described as polyps sized >1.0cm or exposing villous features or high 
grade dysplasia) and 57 healthy controls were analysed and compared using an eNose 
(Cyranose 320®)[26]. The Cyranose 320® is a portable machine consisting of an array of 32 
nanocomposite carbon sensors. The interaction of specific VOCs with the sensor material 
causes swelling of the sensors, which induces a change in the electrical resistance. This 
change is measured and creates a specific ‘smellprint’. Faecal VOC profiles of CRC patients 
could be discriminated from controls based on their smellprint with a sensitivity of 85% and 
a specificity of 87% (AUC 0.92). Patients with advanced adenomas could be discriminated 
from controls with a sensitivity of 62% and specificity of 86% (AUC 0.79). Differentiation 
between CRC and AA was possible with a sensitivity and specificity of 75% and 73%, 
respectively (AUC 0.82).
SCENT A1
This fairly new eNose apparatus to discriminate CRC from HC has been described in two 
trials by the same research group. First, a total of 20 sensors composed of different material 
were tested in different arrays of 5 units, to find the best performing array for the detection 
of CRC[17]. Faecal samples of 6 CRC patients and 10 HC were used, of which all CRC 
patients and 9 out of 10 HCs were classified correctly using the best performing array. No 
statistics were described. In their following publication, a feasibility and validation study 
for this sensor array was performed[16]. In the feasibility study, the best performing array 
for the detection of CRC was again chosen after testing different combinations of sensors 
on a total of 157 samples in the laboratory (86 CRC, 71HC). An overall accuracy, sensitivity 
and specificity of 95% was computed when considering all the samples tested with all 
the sensor combinations tried. Then, the best performing array was validated in a new 
prospective case-control cohort including faecal occult blood test (FOBT) positive patients. 
A total of 6 CRC/AA patients, 20 low-risk adenoma patients and 60 healthy controls were 
included. Using this sensor-based eNose, all CRC and AA patients were classified correctly. 
Healthy controls were classified correctly in 58 out of 60 cases, 1 was classified in the low-
risk adenoma group and 1 was classified in the CRC and AA group. No values on sensitivity 
or specificity were given in this section of the paper.
Gas Chromatography coupled to Metal Oxide Gas Sensor
GC coupled to a Metal Oxide Gas sensor has been described in an abstract by Bond and 
is similar to eNose technology, in which resistance patterns are identified by computer 
algorithms. In their study performed in 2016, the VOC patterns of 18 CRC and 18 AA 
patients were compared to 78 healthy controls with a positive bowel screening[27]. 
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Advanced adenoma was described as any polyp sized >1.0 cm. High accuracy values of 
83.3% and 87.5%, were observed for the discrimination of CRC and AA patients compared 
to HC, respectively. Differentiation between CRC and AA patients was feasible with accuracy, 
sensitivity and specificity levels of 100%.
DISCUSSION
Analysis of the 11 selected papers demonstrated that the composition of the faecal 
volatolome is different in the presence of CRC and AA compared to a healthy state. In 
addition, the clinical value of the faecal volatolome as colonic neoplasia biomarker has been 
demonstrated in all published studies, with sensitivity values ranging between 75-97% for 
CRC and 62-100% for AA, and specificity values between 66.7-99% for CRC and 78-100% 
for AA. The metabolic ‘smellprint’ was analysed using multiple techniques, which limits the 
possibility of a detailed comparison of the papers. 
Three of the studies selected for this review used GC-MS, of which two investigated 
the global metabolic profile and one investigated only short-chain and long-chain fatty 
acids. Although research groups were small, ranging from 9 to 26 CRC cases, there are 
some interesting similarities in potential biomarkers found. For example, increased levels 
of similar amino acids (glycine, leucine, proline, serine and phenylalanine) were found in 
both studies evaluating the global metabolite profile, which could be caused by various 
reasons. First, an increase of the mucin-degrading bacteria Bacteriodes and Akkermansia 
muciniphila in CRC patients has been observed in various studies[10, 28]. These bacterial 
strains are known to break down mucin, which consists of glycoproteins built from amino 
acids. Enrichment of these mucin-degrading strains can cause an accumulation of free 
amino acids. In addition, both mucin degradation and colon cancer itself have been linked 
to intestinal inflammation[29-31]. Inflammation of the colon can cause a reduction in the 
absorption of amino acids, amongst other nutrients.  Last, autophagy is known to be 
activated in colorectal cancer cells, leading to the release of free amino acids[32]. 
Other similarities were the increased levels of the SCFAs valeric acid, isovaleric acid and 
acetic acid. Dissimilation of leucine by anaerobe bacteria results in the production of 
isovaleric acid, whereas valine dissimilation results in the production of isobutyic acid[33, 
34]. Both these amino acids have been found increased in stool of CRC patients. Therefore, 
the increase in isobutyric and isovaleric acid may be explained by the fact that they are final 
products of bacterial amino acid metabolism. Acetic acid may be used by colonic bacteria 
to produce butyric acid. Low levels of butyric acid producing bacteria have been found 
in CRC patients in multiple studies[10, 19]. High levels of acetic acid may be caused by a 
decrease in bacterial consumption. Another explanation given by Weir is the degradation 
of butyric acid to acetic acid in the colon[10]. Although these SCFAs may seem promising 
biomarker for CRC, it has to be noted that differences in levels of SCFAs were not shown 
by Song et al., who specifically focused on that section of the volatolome using the same 
analytical platform[20]. 
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In addition, the role of butyric acid is of importance. Butyric acid is a widely studied 
microbial metabolite, which is notorious for its prevention against colorectal cancer[11, 
35, 36]. Previous studies have shown decreased levels of butyric acid producing bacterial 
strains in faecal samples of CRC patients[10, 19]. It could be hypothesised that levels of 
butyric acid may also decrease in faecal of CRC patients, and that this compound may hold 
potential as CRC biomarker. Results of the publications included in this review are, however, 
inconclusive on this particular metabolite. One study has indeed shown decreased levels of 
butyric acid in faecal samples of CRC patients, whereas the other two studies focusing on 
SCFAs have either shown increased levels or no differences. These differences could at least 
partly be explained by differences in sampling methods, storage conditions and machine 
settings, underlining the need for the implementation of standardised protocols in faecal 
VOC analyses. Interestingly, the contradicting studies both found lower levels of butyric 
acid-producing bacterial strains in the faecal samples of their participants. 
Last, decreased levels of polyhydric alcohols (e.g. glycerol) and one bile acid (ursodeoxycholic 
acid) were found. Ursodeoxycholic acid is a secondary bile acid produced by colonic 
bacteria, and is considered to have a chemopreventive effect on colorectal cancer cells 
by inhibiting tumor development[37]. Polyhydric alcohols are used by human cancer cells, 
which possess a well-known transport system for increased glycerol absorption[38]. Uptake 
of these alcohols could explain the decreased levels in stool of CRC patients.
In colon cancer screening programs, the costs/quality ratio of biomarker detection is of 
great importance. Although there have been several studies published on the use of dogs 
for disease detection, all showing very high sensitivity, no studies have ever compared the 
accuracy of dogs and analytical techniques in a systematic manner. However, implementation 
of canine olfaction in daily practice is obviously hampered by obstacles as training is 
costly and laborious. It seems even more challenging to train sufficiently enough dogs for 
(nationwide) CRC screening programs[39]. The quality of the GC-MS technique is high, 
though it is expensive, time-consuming and needs specialised laboratory personnel for its 
operation and maintenance which limits its use for population based screening or large scale 
research[12, 15, 40]. Less expensive compared to GC-MS is SIFT-MS since it requires less 
maintenance and sample preparation, but this technique provides less detailed information 
on VOC composition. It is dependent of the chemical and mass characteristics of potential 
faecal CRC biomarkers, whether this technique could accurately differentiate between 
CRC and HC, and thus holds potential for population based screening. The publications 
on pattern-based techniques all report a high diagnostic value for the detection of both 
CRC and AA. The compact size, low costs, user-friendliness and speed of eNose analyses 
underline their potential for the high-throughput analyses required in population based 
screening. However, their main limitation is their inability to identify specific VOCs. 
To date, VOC tests for the detection of AA and CRC are still far from the use in a public 
health setting. For this, the number of subjects studied in the current available literature 
is rather small, and the use of various techniques for VOC analyses in combination with 
the use of different criteria used for advanced adenomas, hampers reliable comparison 
between studies. In addition, data on the VOC profiles of non-advanced polyps is lacking. 
It is well-known that the tendency of polyps to develop into malign neoplasia is dependent 
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of multiple characteristics as epithelial differentiation, size, basis and the presence of villous 
features. It would be of interest to assess whether these specific characteristics influence the 
VOC profile and whether there is similarity with the VOC profile of CRC patients. Another 
challenge to encounter before developing a disease specific eNose, is the correction for 
other factors influencing VOC profile. Though for breath analyses it is known that there is 
only small similarity in VOC profile when measured in a single individual at consecutive 
moments, information is lacking on the intraindividual stability of faecal VOC profiles[41]. In 
addition, it is known that lifestyle factors as smoking, dietary intake and use of medication 
have an effect on the faecal VOC composition [42-44]. Future studies should therefore 
take these variables into account by either matching of study participants or calculating 
correction factors per variable.  The next step for developing CRC specific VOC tests, is to 
combine measurements with a chemical analytical technique such as GC-MS and a pattern-
recognition based technique in a cohort including CRC, AA, non-advanced adenomas and 
healthy controls, to identify which disease specific molecules interact with which sensors. 
This allows for the development of a highly accurate, inexpensive, easy-to-use, CRC-
specific eNose. The CRC-specific eNose should then be tested on suitability for clinical 
implementation in mass screening programs, preferably by comparing the eNose to the 
presently used screening program test on performance characteristics, user friendliness and 
costs in a large population study. 
In conclusion, an increasing number of studies demonstrate the potential of the faecal 
volatolome as non-invasive biomarkers for the detection of CRC and advanced adenomas. 
The use of different techniques limits comparability, however, all studies demonstrated a 
high diagnostic value of the faecal volatolome for CRC detection. This holds promise for 
future screening on CRC and advanced adenoma, with potentially better test performances 
allowing for earlier detection of AA and CRC and consequently earlier initiation of treatment, 
possibly reducing morbidity and mortality rates next to lower rates of (unnecessary) 
colonoscopies. Future studies should focus on validation of previously found faecal VOC 
biomarkers in a large prospective  cohort linked to the population based screening, 
preferably by combining a chemical analytical technique with pattern-recognition, so CRC- 
and AA-specific biomarkers can be identified which can be used to develop tailor-made 
eNose sensors to be used in clinical practice. 
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Early detection and removal of colorectal cancer (CRC) and advanced adenomas 
(AA) decreases incidence and mortality. We aimed to evaluate potential of faecal 
volatile organic compounds (VOC) for colorectal adenomas detection and follow-
up using advanced electronic nose technology.
Methods
This was a prospective multi-centre case-control cohort including two district 
hospitals and one tertiary referral hospital. Patients undergoing colonoscopy were 
instructed to collect a faecal sample prior to bowel cleansing and were included 
when CRC, AA, large adenomas (LA; 0.5-1.0cm), small adenomas (SA; 0.1-0.5cm) 
or no endoscopic abnormalities (healthy controls; HC) were observed. Patients 
undergoing polypectomy and HC were asked for a second sample after three 
months. Faecal VOCs were measured with gas chromatography-ion mobility 
spectrometry. Random Forest, Support Vector Machine, Gaussian Process and 
Neural Net classification were used to evaluate accuracy. 
Results
In total, 14 CRC, 64 AA, 69 LA, 127 SA and 227 HC were included. Second 
sample was collected by 32 polypectomy patients and 32 HC. Faecal VOCs 
discriminated CRC and adenomas from HC (AUC(95%): CRC vs HC 0.96(0.89-1); 
AA vs HC 0.96(0.93-1); LA vs HC 0.96(0.92-0.99); SA vs HC 0.96(0.94-0.99)). There 
were no significant differences between CRC and adenoma groups. Patients 
with adenomas and HC were discriminated prior to polypectomy, whereas 
three months after polypectomy VOC profiles were similar (T0 adenoma vs HC 
0.98(0.95-1); T1 adenoma vs HC 0.55(0.40-0.69)). 
Conclusions
Faecal VOC profiles may be useful for early CRC and adenoma detection, and 





Colorectal cancer (CRC) is one of the three malignancies with the highest incidence in the 
industrialised world, with a 5-year survival rate of 64.4% and 66.6% for colon and rectum 
cancer, respectively[1]. Majority of CRC originates from dysplastic adenomatous polyps, so-
called advanced adenomas[2]. Early detection and removal of these precancerous polyps is 
essential for improvement of CRC course and prognosis, illustrated by a gradually decrease 
of survival rates with increasing cancer stage[3]. Faecal immunochemical test (FIT) is widely 
used for population-based screening but lacks sensitivity, indicated by the missed diagnosis 
of CRC in 1-47% and advanced adenomas in 43-61% of the tests[4]. In addition, specificity 
is suboptimal, as approximately 7% of the performed tests provide false-positive results 
leading to the performance of unneeded colonoscopies. This emphasizes the need for 
improvement of CRC/adenoma bowel screening tools. 
Endoscopic assessment is advised after FIT positivity, but also remains key for surveillance 
after removal of polyps (polypectomy) and following CRC treatment[3], as these patients 
remain at increased risk for development or recurrence of dysplastic lesions. Thus far, no 
non-invasive biomarkers have been validated for this purpose.
Analysis of the faecal volatolome is a novel approach within the field of biomarker 
exploration. The faecal volatolome consists of volatile organic compounds (VOCs), which 
are carbon-bound molecules. Composition of the faecal volatolome is considered to reflect 
metabolic processes in the human body, like inflammation, necrosis, change in dietary 
intake, gut microbial dysbiosis and cancer growth[5, 6]. Several studies have focused on 
the application of the faecal volatolome as a biomarker for detection of CRC and advanced 
adenoma, with promising results. However, none of the available studies have included 
patients with (low-risk) adenomas to explore the specificity of VOC analysis. Aim of this 
study was to assess the potential of faecal VOC as non-invasive biomarker to detect colonic 
neoplasia and precursor lesions. In addition, we aimed to explore its potential for secondary 
non-invasive surveillance following polypectomy.
METHODS
Study design
This multi-centre prospective case-control study was performed between February 2015 
and November 2017 at outpatient clinics of Gastroenterology and Hepatology departments 
in one tertiary referral hospital (Amsterdam UMC, location VUmc) and two district hospitals 
(OLVG West, Amsterdam and Spaarne Gasthuis, Hoofddorp and Haarlem), all located in 
The Netherlands. This study was approved on 04-09-2014 by the Medical Ethical Review 
Committee (METc) of Amsterdam UMC (2014.404), and by local METcs of OLVG West 
and Spaarne Gasthuis. The study protocol conforms to the ethical guidelines of the 1975 
Declaration of Helsinki as reflected in a priori approval by the institution’s human research 
committee. Written informed consent was obtained from all participants.
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Study participants and sample collection
Detection of colorectal adenomas and cancer
All patients aged  ≥18 years with a scheduled colonoscopy were asked to participate in 
this study, irrespective of endoscopy indication. Patients were divided into five subgroups 
based on observations during endoscopy, combined with histology reports in case 
biopsies or polypectomies were performed: (a) CRC, histologically confirmed carcinoma 
of the colon or rectum; (b) Advanced adenoma (AA), according to the European Society 
of Gastrointestinal Endoscopy (ESGE), that is, characterised by polyps ≥1cm in diameter, 
or with villous histology, or high grade dysplasia; (c) Large adenoma (LA), adenomas sized 
0.5-1.0cm in diameter without villous histology or high grade dysplasia; (d) Small adenoma 
(SA), adenomas sized <0.5cm in diameter without villous histology or high grade dysplasia; 
(e) Healthy controls (HC), characterised by no abnormalities observed during endoscopy 
(excluding small anal fibroma, haemorrhoids and/or diverticula), and in case of mucosal 
biopsies, no histopathological abnormalities[7]. Participants were asked to collect a faecal 
sample (Stuhlgefäß 10ml, Frickenhausen, Germany) prior to bowel preparation, store the 
sample in their own freezer at home within one hour following bowel movement and bring 
it to the hospital on the day of their endoscopic assessment. Samples were stored at -24°C 
directly upon arrival at the hospital. Participants were asked to complete a questionnaire 
on the day of sample collection, which included items on age, gender, body mass index 
(BMI), smoking habits, comorbidity and medication use. Exclusion criteria were presence 
of a known underlying gastrointestinal disease, incomplete endoscopic assessment due to 
various reasons (e.g. inadequate bowel cleansing, pain) and/or inability to collect or store 
sufficient faecal sample mass to perform VOC analysis. 
Monitoring of patients post-polypectomy
Between May and November 2017, patients who underwent a successful polypectomy 
during endoscopy were asked to participate in the follow-up part of this study. Participants 
were excluded from this group in case of incomplete removal of polyps. Remaining 
polypectomy patients were randomly matched to HC in a 1:1 ratio. All patients included in 
the second part of this study were asked to collect a follow-up faecal sample and complete 
a second questionnaire (same procedure as the first sample and questionnaire). These 
samples and questionnaires were collected by one of the researchers and transported to 
the hospital on dry ice where they were stored at -24°C upon arrival.
Endoscopic and histologic evaluation
Endoscopy reports and histologic outcome of mucosal biopsies and/or polypectomy were 
checked using electronic patient files. These outcomes were used as standard reference for 
localisation and total number of removed adenomas in this study. Endoscopies were either 
performed or supervised by trained gastroenterologists. Histopathological reports were 
used as the standard reference for size, differentiation grade (e.g. hyperplasia, dysplasia), 
villous histology and type of CRC in this study. Mucosal biopsies were noted as sized 0.2 
cm. The presence of sessile and/or serrated characteristics was noted for all non-advanced 
adenomas. When multiple polyps were present, classification was based on the most 
advanced or largest lesion.
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Sample preparation and faecal volatile organic compound analysis
One frozen subsample of 500 mg per participant was weighted and transferred into glass 
vials (20ml headspace vial, Thames Restek, Saunderton, UK). Samples were transported to 
the University of Warwick (Coventry, UK) for faecal VOC analysis. Gas chromatography-ion 
mobility spectrometer (GC-IMS, FlavourSpec®, G.A.S., Dortmund, Germany) was used to 
measure the faecal VOC patterns. In GC-IMS, analytes are pre-separated by retention time in 
a GC column (SE54 column) before entering the ion mobility spectrometer (IMS). Within the 
IMS system, soft chemical-ionization is performed using a low-radiation tritium (H3) source, 
subsequently creating reactant ions with injected gas. Ionised VOCs travel against flow of 
an inert drift gas. Drift time of each substance is determined by ions mass and geometrical 
structure due to interactions with the drift gas. In general, the larger the molecule, the more 
it loses its momentum and thus, the longer it takes to travel along the tube. Resulting ion 
current is measured as a function of time[8]. Prior to analysis, the samples were heated to 
80°C for 8 minutes. After this, GC was performed at 40°C using nitrogen 99∙9% (3∙5 bar) 
as carrier gas and IMS was performed at 45°C using nitrogen 99∙9% as drift gas. Flow rates 
were set at 150ml/min (0∙364 kPa) (IMS), and 20 ml/minute (34,175 kPa) for 6 minutes (GC). 
A schematic overview of the setup is depicted in Figure 1.
Figure 1. Gas Chromatography Ion Mobility Spectrometry. Samples are heated to 80°C for 8 minutes 
prior to analyses. Headspace of sample is injected into GC-IMS. VOCs enter the GC column where 
they are separated based on their interaction with carrier gas. VOCs with similar retention times enter 
the IMS column simultaneously and are ionised using a soft-chemical ionization. Ionised VOCs travel 
against flow of inert gas. Drift time of VOCs is determined by ion’s mass and geometrical structure. The 
resulting ion current is measured by electrometer as function of time. 
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Statistical analysis
Using IBM SPSS Statistics (version 22), demographic data of each group were calculated 
and compared. One way ANOVA or Kruskall Wallis tests were used to compute differences 
in baseline demographics between groups. For the secondary part of this study, t-tests, 
Fisher’s exact test, chi-square and Mann-Whitney U tests were used to compute differences 
between groups. Raw GC-IMS data were pre-processed to crop areas that contained 
chemical information. A threshold was applied to remove background noise. Then, a 
correction for instrumental disturbances was performed by baseline correction, where 
reactive ion peaks were aligned on all samples. Data were split into three sets, 70% for 
training and validation and 30% as a test set. Wilcoxon rank-sum test was used to find the 
20, 50 and 100 most discriminatory features and subsequently Sparse Logistic Regression, 
Random Forest, Gaussian Process, Support Vector Machine and Neural Net classification 
were used to provide statistical results. In the case of small subgroups of interest, subsets of 
HC were chosen randomly to avoid skewed analyses.
RESULTS
Baseline characteristics
In total, 1039 patients collected a faecal sample prior to colonoscopy of which samples 
from 14 CRC patients, 64 AA, 69 LA and 127 SA were included in this study. 227 HC were 
included as they did not have any mucosal abnormalities during endoscopy. Baseline 
demographics of all study participants are depicted in Table 1. Age differed significantly 
between groups (p<0.001), with HC displaying the lowest mean age (60 ± 11.8) and 
advanced adenoma the highest (68.8 ± 6.7). Gender differed significantly between HC, 
SA, LA and advanced adenoma (p<0.0001) but not between HC and CRC or any of the 
adenoma groups. There were no significant differences in BMI, smoking status and use of 
antibiotics between groups. For the follow-up part of this study, all 32 patients undergoing 
a complete polypectomy and 32 HC subjects were included and collected a second faecal 
sample three months after endoscopy. Baseline demographics of the follow-up study are 
given in Table 2. There were no significant differences in BMI, smoking status and use of AB 
three months prior to sample collected. Gender and age did differ significantly between 
groups (p<0.014, p<0.001, respectively).
Faecal volatile organic compound analysis
Results of VOC analyses by means of GC-IMS are shown in Table 3. Results from the 
Random Forest classifier based on the 20 most discriminative features are presented. Data 
generated based on all five classifiers using the 20, 50 and 100 most discriminative features 
are given in Supplemental Table 1-3. 
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Age (mean, ± s∙d∙) 66∙6 ± 8∙7 68∙8 ± 6∙7 68∙7 ± 7∙2 63∙7 ± 10∙0 60 ± 11∙8
Gender, f (n, [%]) 6 [42∙9] 17 [26∙3] 21 [30∙4] 44 [34∙6] 129 [56∙8]
BMI* (mean, ± s∙d∙) 25∙9 ± 5∙3 27∙0 ± 4∙1 26∙6 ± 3∙9 27∙3 ± 6∙5 26∙6 ± 7∙0
ABx 3 months prior to inclusion 
(n, [%])
0 [0] 6 [9∙4] 3 [4∙3] 21 [16∙5] 31 [13∙7]
Smoking Status (n, [%])
Active 2 [14∙3] 9 [14∙1] 15 [21∙7] 23 [18∙1] 37 [16∙3]
Quit 10 [71∙4] 37 [57∙8] 36 [52∙2] 64 [50∙4] 92 [40∙5]
Never 2 [14∙3] 18 [28∙1] 17 [24∙6] 40 [31∙5] 98 [43∙2]
Size largest adenoma (mean, ± 
s∙d∙)
0∙7 ± 0∙63 1∙4 ± 0∙64 0∙7 ± 0∙26 0∙4 ± 0∙32 NA
Localisation of Largest adenoma† (n, [%])
Caecum 0 [0] 4 [6∙3] 7 [10∙1] 12 [9∙4] NA
Colon Ascendens 1 [7∙1] 8 [12∙5] 12 [17∙4] 32 [25∙2] NA
Flexura Hepatica 1 [7∙1] 2 [3∙1] 0 [0] 1 [0∙8] NA
Colon Transversum 0 [0] 3 [4∙7] 15 [21∙7] 18 [14∙2] NA
Flexura Lienalis 0 [0] 1 [1∙6] 0 [0] 1 [0∙8] NA
Colon Descendens 1 [7∙1] 4 [6∙3] 6 [8∙7] 9 [7∙1] NA
Sigmoid 5 [35∙7] 30 [46∙9] 19 [27∙5] 24 [18∙9] NA
Rectosigmoid 2 [14∙3] 3 [4∙7] 1 [1∙4] 4 [3∙1] NA
Rectum 2 [14∙3] 6 [9∙4] 6 [8∙7] 14 [11∙0] NA
Terminal ileum 1 [7∙1] 0 [0] 0 [0] 1 [0∙8] NA
CRC type (n, [%])
Adenocarcinoma 12 NA NA NA NA
Neuroendocrine 2 NA NA NA NA
Advanced adenoma characteristics (largest adenoma) (n, [%])
≥ 10 mm NA 54 [84∙4] NA NA NA
Villous histology NA 31 [48∙4] NA NA NA
HGD NA 6 [9∙4] NA NA NA
Polyp characteristics (largest adenoma) (n, [%])
No dysplasia NA 1 [1∙6] 9 [13∙0] 9 [7∙1] NA
Hyperplasia NA 2 [3∙1] 4 [5∙8] 14 [11∙0] NA
LGD NA 55 [85∙9] 55 [79∙7] 100 [78∙7] NA
Sessile/serrated NA NA 8 [11∙6] 10 [7∙9] NA
Table continues

















Total number adenomas removed (n, [%])
1 6 [42∙8] 11 [17∙2] 18 [26∙1] 59 [46∙5] NA
2 1 [7∙1] 14 [21∙9] 20 [29∙0] 34 [26∙8] NA
3 3 [21∙4] 11 [17∙2] 14 [20∙3] 14 [11∙0] NA
4-5 2 [14∙3] 14 [21∙9] 8 [11∙6] 15 [11∙8] NA
6-10 1 [7∙1] 13 [20∙3] 9 [13∙0] 4 [3∙2] NA
>10 0 [0] 1 [1∙6] 0 [0] 0 [0] NA
Baseline characteristics. Abbreviations: CRC, colorectal cancer; AA, advanced adenoma, LA, large 
adenomas; SA, small adenomas; HC, healthy controls; BMI, body mass index; NA, not applicable; 
HGD: high grade dysplasia; LGD: low-grade dysplasia; AB: antibiotics. *Insufficient documentation of 
2CRC,  6AA, 6LA, 10SA; 11 HC.





Age (mean, ±SD) 71∙0 ± 5∙9 60∙5 ± 11∙3
Gender (n females, %) 5 [15∙6] 15 [46∙9]
BMI (mean, ±SD) 26∙8 ± 4∙2 26∙3 ± 3∙4
Smoking status (n, %)
Active 6 [18∙8] 4 [12∙5]
Quit 18 [56∙3] 19 [59∙4]
Never 8 [25∙0] 9 [28∙1]
Indication for endoscopic assessment (n, %)
Positive FIT 10 [31∙3] 4 [12∙5]
Rectal blood loss 4 [12∙5] 1 [3∙1]
Change in bowel habits 2 [6∙3] 3 [9∙4]
Surveillance 5 [15∙6] 3 [9∙4]
Abdominal Pain 2 [6∙3] 11 [34∙4]
Diarrhea 3 [9∙4] 1 [3∙1]
Weight Loss 1 [3∙1] 0 [0]
Anaemia 0 [0] 2 [6∙3]
Constipation 0 [0] 2 [6∙3]
Family history CRC+ 1 [3∙1] 8 [25]
Monitoring previous diverticulitis/abscess 0 [0] 2 [6∙3]
Other 4 [12∙5] 5 [15∙7]
ABx 3 months prior to inclusion (n, %) 2 [6∙3] 6 [18∙8]








Size adenoma (mean, ±SD) 1∙1 ± 0∙5 NA
Localisation of adenoma (n, %)
Caecum 3 [9∙4] NA
Colon Ascendens 6 [18∙8] NA
Flexura Hepatica 0 [0] NA
Colon Transversum 2 [6∙3] NA
Flexura Lienalis 1 [3∙1] NA
Colon Descendens 2 [6∙3] NA
Sigmoid 11 [34∙4] NA
Rectosigmoid 1 [3∙1] NA
Rectum 4 [12∙5] NA
Ileocecal valve 1 [3∙1] NA
Adenoma characteristics (largest adenoma) (n, [%])
≥ 10 mm 13 [40∙6] NA
Villous histology 9 [28∙1] NA
HGD 0 [0] NA
No dysplasia 3 [9∙4] NA
Hyperplasia 0 [0] NA
LGD 29 [90∙6] NA
Sessile/serrated 3 [9∙4] NA
Total number adenomas removed (n, [%])
1 7 [21∙9] NA
2 11 [34∙4] NA
3 7 [21∙9] NA
4-5 3 [9∙4] NA
6-10 4 [12∙6] NA
Baseline characteristics of participants in polypectomy follow-up study. Abbreviations: HC, healthy 
controls; BMI, body mass index; ABx: antibiotics. 
Detection of colorectal cancer, advanced adenomas and non-advanced 
adenomas
Based on faecal VOC profiles, CRC was discriminated from HC with high diagnostic 
accuracy (AUC ± 95%CI: 0∙96(0∙89 – 1)(Table 3, Supplementary table 1-3). Likewise, high 
diagnostic accuracy was observed for discrimination of AA, LA and SA when compared to 
HC (Advanced adenoma 0∙96(0∙93 –1); LA 0∙96(0∙92 – 0∙99); SA 0∙96(0∙94-0∙99))(Table 3, 
Supplementary tables 1-3). There were no significant differences between any of the CRC, 
AA, LA and SA groups based on faecal VOCs (Table 3, Supplementary table 1-3). Receiver 
operator characteristic (ROC) curves are constructed in Figure 2. 
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Faecal volatile organic compounds for surveillance after polypectomy
Faecal VOC profiles of patients with adenomas differed significantly from HC before polyp 
removal (AUC ± 95%CI: 0∙98(0∙95-1)). Remarkably, there was no difference between the 
faecal VOC profiles of patients who underwent a polypectomy and HC three months after 
endoscopic intervention (AUC ± 95%CI: 0∙55(0∙40-0∙66)). There was a highly significant 
difference in the profiles of patients with adenomas before and after polypectomy, whereas 
no significant differences were present in faecal VOC profiles of HC before and three months 
after endoscopy (T0 vs T1 polyps 0∙94(0∙88-1); T0 vs T1 HC 0∙58(0∙44-0∙73)). ROC-curves for 
the follow-up study are depicted in Figure 3. 
Figure 2. Receiver operator characteristic curves for the comparison between colorectal cancer, 
advanced adenoma, large adenoma and small adenoma and healthy controls. Abbreviations: CRC, 
colorectal cancer; AA, advanced adenomas; LA, large adenoma; SA, small adenoma; HC, healthy 
controls; AUC, area under the curve.
221
13
Figure 3. Receiver operator characteristic curves for the polypectomy follow-up. Abbreviations: AUC, 
area under the curve; HC, healthy controls.
DISCUSSION
We observed high diagnostic accuracies for faecal VOC-based differentiation between CRC 
and HC and between adenomas and HC. Faecal VOC profiles of patients with adenomas 
converted towards those of HC after polypectomy. VOC profiles of CRC could not be 
discriminated from different adenoma types. These results demonstrate the potential of 
faecal VOC analysis for both colonic neoplasia screening and surveillance.
This is the first study to assess faecal VOC profiles for CRC and advanced adenoma detection, 
which included patients with non-advanced adenomas as unique control groups. No previous 
studies have been performed on the potential of faecal VOC profiles for surveillance after 
polypectomy. Surveillance of patients after polypectomy using FIT has been subject of 
a previous study comparing stool haemoglobin levels with colonoscopy outcomes[9]. A 
total of 5225 participants completed a first FIT one year after polypectomy, demonstrating 
sensitivity and specificity values of 27∙6% and 94∙1% at 40 µg/g, and 51∙7% and 86∙2% at 10 
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µg/g for CRC, respectively. For AA, sensitivity and specificity values were 17∙0% and 95∙1% 
for 40 µg/g and 33∙0% and 88∙0% for 10 µg/g, respectively. Replacing colonoscopy with 
FIT would reduce colonoscopies by 71%, but would lead 30-40% missed CRC cases and 
40-70% missed cases of advanced adenomas. Observed discriminative accuracies for CRC 
and advanced adenoma detection based on faecal VOC analysis exceed these reported 
accuracies[4, 10]. In addition, accuracy to distinguish patients with adenomas from HC was 
high prior to polypectomy, whereas intra-individual profiles changed to physiological state 
three months following polypectomy, indicating the potential of faecal VOCs as biomarker 
for timing of polyp surveillance, and tight control in high risk populations (e.g. Lynch 
syndrome). 
Table 3. Differences between all subgroups of colorectal neoplasia, polyps and healthy controls based 
on faecal volatile organic compounds
Comparison AUC (95% CI) Sensitivity Specificity PPV NPV P-value
Colorectal cancer vs 
healthy controls
0∙961 (0∙891-1) 1 1 0∙889 1 <0∙001
Advanced adenoma 
vs healthy controls
0∙964 (0∙932-0∙996) 0∙969 0∙938 0∙939 0∙968 <0∙001
Large adenomas vs 
healthy controls
0∙957 (0∙923-0∙992) 0∙985 0∙912 0∙918 0∙984 <0∙001
Small adenomas vs 
healthy controls
0∙964 (0∙940-0∙987) 0∙960 0∙929 0∙931 0∙959 <0∙001
Colorectal cancer vs 
advanced adenomas
0∙541 (0∙382-0∙700) 0∙984 0∙188 0∙829 0∙75 0∙294
Colorectal cancer vs 
large adenomas
0∙41 (0∙31 - 0∙51) 0∙06 0∙96 0∙25 0∙81 0∙920 
Colorectal cancer vs 
small adenomas
0∙413 (0∙379-0∙446) 1 0 0∙113 NA 0∙965
Advanced adenomas 
vs large adenomas
0∙53 (0∙43 - 0∙63) 0∙75 0∙36 0∙55 0∙58 0∙278
Advanced adenomas 
vs small adenomas
0∙578 (0∙495-0∙662) 0∙719 0∙444 0∙397 0∙757 0∙039
T0 Healthy controls vs 
T0 pre-polypectomy
0∙982 (0∙946-1) 1 0∙967 0∙970 1 <0∙001
T1 Healthy controls vs 
T1 post-polypectomy
0∙548 (0∙404-0∙691) 0∙906 0∙25 0∙547 0∙828 0∙256
T0 vs T1 pre- and 
post-polypectomy
0∙936 (0∙875-0∙996) 0∙906 0∙906 0∙906 0∙906 <0∙001
T0 vs T1 Healthy 
controls
0∙581 (0∙436-0∙726) 0∙938 0∙267 0∙577 0∙8 0∙139
Outcomes obtained using Random Forest analyses based on 20 most discriminating features. 
Abbreviations: AUC, area under the curve; CI, confidence interval; PPV, positive predictive value; NPV, 
negative predictive value; CRC, colorectal cancer; AA advanced adenoma; LA, large adenomas; SA, 
small adenomas; LGD, low-grade dysplasia; HC healthy controls.
223
13
Few studies have demonstrated the potential to discriminate CRC and advanced adenomas 
from HC based on faecal VOC analysis. Current study outcomes are in line with this 
literature. However, reliable comparison with other studies is restricted due to the small 
number of included subjects, lack of knowledge on VOC profiles of advanced adenomas 
and non-advanced adenomas, and the use of various different techniques and sampling 
protocols. Four previous studies have focused on detection of CRC using the analytical 
platform gas chromatography—mass spectrometry (GC-MS), which is considered the gold 
standard for the detection of specific metabolites [11-14]. In the most recent publication, a 
group of adenomatous polyps patients (n=56) was included in addition to CRC (n=21) and 
no neoplasia as HC (n=60). Multiple differences in metabolite levels were found. Highest 
diagnostic accuracy was found for the combination of Propan-2-ol and 3-methylbutanioc 
acid discriminating CRC samples from polyps and HC (AUC 0.82). These differences 
specifically provided discrimination between CRC patients and other groups, whereas in 
the current study, VOC profiles differed between CRC and adenoma groups compared to 
HC. Possible explanations for this are the differences in faecal VOC analysis technique, and 
in inclusion criteria per subgroup. In the publication by Bond et. al., polyp characteristics 
are not reported, which hampers reliable comparison to our study groups. All other studies 
using GC-MS reported relatively small groups of subjects, ranging from n=9-26 CRC and 
n=10-60 HC. There were interesting similarities in study outcomes (e.g. increased levels 
of amino acids and short-chain fatty acids and decreased levels of polyhydric alcohols 
and bile acid), though, none of these metabolite levels were consequently altered. In one 
previous publication, VOC profiles of 40 CRC, 60 advanced adenoma and 57 endoscopy 
controlled HC were compared using pattern-recognition (eNose, Cyranose 320 ®)[15]. 
Based on faecal VOC patterns, CRC and advanced adenomas were discriminated from 
HC with sensitivity of 85% and 62%, and specificity of 87% and 86%, respectively. These 
test characteristics were below characteristics found in the current study, however, using 
the Cyranose 320®, subgroups of CRC and advanced adenomas were discriminated with 
moderate accuracy (sensitivity 75% and specificity 73%). A possibility for this apparent 
discrepancy is the number of CRC patients included in the study by de Meij et al., increasing 
power to find differences between groups. Another possibility is the instrumental difference 
between the Cyranose 320® and the GC-IMS system. The Cyranose 320® uses an array of 
nanocomposite sensors, whereas the GC-IMS system is using drift time. Although GC-IMS 
is more sensitive and repeatable, it cannot measure molecules with low proton affinities. 
Should differentiation between CRC and advanced adenomas be based on these type of 
molecules they could not have been detected in the current study.
Alterations in faecal VOC patterns represent metabolic shifts that may be explained by 
various mechanisms (e.g. alterations in dietary intake, microbial dysbiosis, inflammatory 
processes, cancer degeneration). In a recent study, metabolic waste was retrieved from 
benign cells, colon cancer cells and breast cancer cells that were grown in vitro. It was 
observed that dogs were able to differentiate cancer cells from benign cells, but not the 
cell waste of breast from colon cancer, implying that both cancers phenotypes seem to 
share a common smell print[16]. This may also apply for different phenotypes of adenomas; 
adenoma and eventually CRC degeneration are possibly based on a shared (metabolic) 
pathway, explaining the similarities in VOC patterns observed in the current study. Apart 
from excretion of metabolic end-products, our findings may be explained by the presence of 
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intestinal dysbiosis. Faecal microbiota has important function in protection against invading 
pathogens and strong evidence exists for the association between microbial dysbiosis and 
polyp-associated tissue and colonic neoplasia[17]. Causality remains unclear; it is unknown 
whether this phenomenon is triggered or maintained by carcinogenesis. Intriguingly, 
in the present study it was found that faecal VOC profiles of patients three months after 
polypectomy were altered to normalcy following this intervention, suggesting that the 
alleged faecal microbial dysbiosis returns to physiological state after polyp removal. 
Design of this large, multi-centre prospective cohort contributed to generalizability of the 
outcomes. Bias by colonic abnormalities was avoided by including an endoscopy controlled 
HC subgroup. This study also had some limitations. Most importantly, CRC subgroup 
was relatively small which may have contributed to the inability to discriminate CRC and 
adenoma profiles. In addition, even though most variables expected to influence faecal 
VOC profiles were evenly present in the subgroups (i.e. smoking status, BMI and use of 
antibiotics), gender and age did differ between groups. Data on the influence of age and 
gender on faecal VOC profiles are lacking and we were therefore not able to exclude this 
possible bias. 
Future research aimed at creating a disease-specific faecal VOC algorithms for CRC and 
adenoma detection may focus either on pattern-recognition or on metabolite specific 
analytical platforms. The use of pattern-recognition may be favourable for this purpose since 
this allows for fast, easy-to-perform, high-throughput and low-cost analyses, underlining its 
suitability for application in clinical practice. Using machine learning, algorithms may be 
built for the detection of CRC and its precursor lesions, which improve continuously with 
increasing numbers of samples measured. Once the algorithm reaches satisfactory accuracy, 
the device may be implemented not only for population based screening but also for intra-
individual surveillance after polyp or CRC removal. For surveillance, the device should be 
validated coupled to endoscopy outcomes in the surveillance program. Last, our data have 
raised the hypothesis that faecal VOCs associated with CRC and advanced adenoma may 
be a consequence rather than the cause of adenoma presence. It would be interesting 
from a pathophysiological and therapeutic point of view to unravel the underlying entities 
causing the faecal VOC differences pre- and post-polypectomy. 
In conclusion, because of its high sensitivity, this study highlights the potential faecal VOC 
analysis for population based screening. Additionally, intra-individual faecal VOC profiles 
of patients with adenomas altered towards a physiological state following polypectomy, 
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CHAPTER 14
Data integration of stool microbiota, proteome 
and amino acid profiles to discriminate patients 
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Screening for colorectal cancer (CRC) reduces its mortality but has limited 
sensitivity. We aimed to explore potential biomarker panels for CRC and adenoma 
detection and to gain insight into the interaction between gut microbiota 
and human metabolism in the presence of these lesions by integrating faecal 
microbiota, proteome and amino acid profiles.
Methods
Between February 2016 and November 2019, patients ≥18 years with a scheduled 
colonoscopy in two district hospitals and one tertiary referral hospital were eligible 
for this multi-centre cohort. Participants were divided into subgroups of CRC 
(n=12), adenomas (n=21) and controls without endoscopic abnormalities (n=20) 
and collected faecal samples for proteome (LC-MS/MS), microbiota (16S rRNA 
profiling) and amino acid (HPLC) assessment. Feature selection was performed to 
obtain best predictive biomarker panels. Pearson correlation was used to create 
networks of all omics platforms.
Results
Maximum area under the curve (AUC) for individual markers were 0.95 for CRC 
versus controls (HBA1), 0.89 for adenoma versus controls (ethanolamine) and 0.86 
for CRC versus adenoma (sulfo-l-cystine). Integration of data sets revealed markers 
associated with increased blood excretion, stress- and inflammatory responses 
and pointed towards downregulation of epithelial integrity. Combining omics 
platforms led to selection of new panels which outperformed AUC of hemoglobin 
in this cohort, which is currently used in FIT (AUC 0.98, 0.95 and 0.87 for CRC vs 
controls, adenoma vs controls and CRC vs adenoma, respectively). 
Conclusions
Integrating faecal microbiota, proteome and amino acids platforms provides for 
new biomarker panels that may improve non-invasive screening for adenomas 







































Detection and surveillance of adenoma patients 
undergoing polypectomy using faecal microbiota 
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The risk of recurrent dysplastic colonic lesions is increased following polypectomy. 
Yield of endoscopic surveillance after adenoma removal is low whilst interval 
colorectal cancers occur. Aim of this study was to longitudinally assess dynamics 
of faecal microbiota and amino acids in the presence of adenomatous lesions and 
after their endoscopic removal.
Methods
In this prospective multicentre case–control cohort study, patients undergoing 
colonoscopy, irrespective of indication, were instructed to collect a faecal sample 
prior to bowel preparation. Patients with advanced adenomas and non-advanced 
adenomas (0.5-1.0cm) who underwent polypectomy during endoscopy (n=19) 
were strictly matched on age, body-mass index and smoking habits to controls 
without endoscopic abnormalities (n=19). All subjects collected a follow-up faecal 
sample 3 months after adenoma removal. On all paired samples, microbial taxa 
were measured by 16S RNA sequencing and using linear discriminant analysis 
effect size (LEfSe), amino acids (AA) were measured by High Performance Liquid 
Chromatography (HPLC). 
Results
Adenoma patients could be discriminated from controls based on AA and 
microbial composition. Levels of proline (p=0.001), ornithine (p=0.02) and serine 
(p=0.02) were upregulated in adenoma patients compared to controls, but 
expressed levels similar to those of controls after adenoma removal. These AAs 
were combined as potential adenoma specific panel and area under the curve 
(AUC) value of 0.84 (95%CI 0.81 - 0.89) and 0.79 (0.64 – 0.94) were found for 
the training and test set, respectively. For bacterial taxa, differences between 
patients with adenomas and controls were found, (Bifidobacterium↓, Sutterella ↑ 
and Catenibacterium ↑), independently on performance of  polypectomy. 
Conclusion
We were able to describe an amino acids panel specifically increased only in the 
presence of adenomas and a microbial signature present in adenoma patients, 
irrespective of polypectomy. Upon validation, the amino acid panel may serve as 
non-invasive marker to determine timing of surveillance endoscopy. The microbial 
signature may be of help for the detection of high-risk individuals. These panels 
may both improve effectiveness of the surveillance program, leading to less 




























This thesis focused on the exploration and development of non-invasive biomarkers for 
the detection and follow-up of inflammatory bowel disease and colorectal neoplasia. 
To this end, we made use of faecal bacterial composition (microbiota), protein spectra 
(proteomics) as well as metabolite spectra (metabolomics), in specific amino acid profiles 
and faecal volatile organic compounds (VOC), which are referred to as ‘omics’ platforms. 
Throughout this thesis, deep phenotyping of study participants based on these omics 
strategies has led to the exploration of potential tools for novel, accurate and non-invasive 
disease detection, surveillance and prediction of disease course at an early stage, which, 
if clinically implemented, may lead to earlier initiation of treatment and consequently 
decreased numbers of complications, surgery and hospital admission. In addition, detailed 
characteristics of metabolic end-products are essential to enlarge knowledge on pathological 
pathways and to develop scientifically based therapeutic interventions linked to the gut 
microbiota and human metabolism. Within this thesis we used various analytical techniques 
for the omics measurements. For faecal VOC measurements, pattern-recognition was 
assessed based on different electronic nose (eNose) techniques: sensor resistance (Cyranose 
320©), field asymmetric ion mobility spectrometry (FAIMS) and gas chromatography – ion 
mobility spectrometry (GC-IMS). In addition, the faecal microbiota was assessed using 16S 
ribosomal DNA Sequencing, the human faecal proteome was investigated using Liquid 
Chromatography-Mass Spectrometry/Mass Spectrometry (LC-MS/MS) and the amino acid 
profiles were assessed using High Performance Liquid Chromatography (HPLC). 
PART I 
Optimizing volatile organic compound analysis
In the first part of this thesis we assessed the influence of methodological variables and 
environmental factors on composition and dynamics of faecal volatile organic compound 
analysis for different gastro-intestinal diseases. In Chapter two, the influence of sampling 
conditions on diagnostic accuracy of VOC measurements was assessed in a cohort of de 
novo treatment-naïve paediatric IBD patients and asymptomatic healthy controls and 
measured using FAIMS. Here, we defined sampling conditions to reach the optimum 
accuracy of faecal VOC as diagnostic biomarker. We observed that faecal sample mass, 
as well as number of thaw-freeze cycles and time-interval between sample preparation 
and VOC analysis all significantly influenced outcome. Comparable variations in VOC 
composition after different sampling procedures have previously been described[1]. We 
also observed that prolonged sample storage in frozen condition, up to 20 months did not 
affect accuracy of faecal VOCs to discriminate IBD from controls. A larger faecal sample 
mass resulted in an increased diagnostic accuracy, with 500mg providing optimum test 
characteristics. In addition, we observed that an increase in thaw-freeze cycles negatively 
influenced diagnostic accuracy, with a loss of 20% after one cycle and even a complete 
loss of discriminative value after two thaw-freeze cycles. Another severe loss in diagnostic 
accuracy was presented when a delay in analysis of 180 minutes had taken place after 
sample thawing. These findings underlined the importance of a standardised and strict 
operating procedure for faecal VOC measurements and formed the basis of our sampling 
protocol of the VOC studies throughout this manuscript.  
The aim of chapter three was to assess the stability of faecal VOC composition under 
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different inter-individual variations in a cohort of healthy individuals, defined as individuals 
with no gastrointestinal diseases and mucosal abnormalities as by the Cyranose 320©. Here, 
we described variations in VOC profiles based on age, gender, body-mass index, smoking 
status, dietary preferences, medication use and co-morbidity. Similar to these outcomes, 
the influence of smoking on faecal VOC profiles has previously been described. In the 
current study, we also presented that the factors ‘low BMI’ (<18.5), ’younger age’ (18-35) 
and a vegetarian or other specific diets strongly influenced VOC profiles, whereas the least 
influence was found for the variables gender, age > 51 years, previous smoking and use of 
antibiotics within three months before measurements. The importance of correction for these 
‘lifestyle’ variations when performing faecal VOC analysis was underlined by this study. We 
proposed methodological correction models  for future research as for example matching 
on the most important variables or the calculation of correction factors within a clinical 
study. In addition, we presented that most sensors of the Cyranose 320© demonstrated 
similar changes in electrical resistance when measuring one singular faecal sample. As 
the sensor outcomes were illustrated by a common tendency per sample to either have 
outcomes above or below their mean sensor outcome across samples, the question was 
raised whether the sensors react differently to specific VOCs or whether short-term sensor 
drift may affect sample outcomes. This finding was the basis for the next chapter. 
Although short-term sensor drift over time is a limitation of eNose technology, for which 
correction may be needed, its high diagnostic accuracy presented in previous studies, 
combined with its low costs and fast measurements are appealing for routine testing in 
clinics[2]. In chapter four, we therefore investigated the effects of sensor drift on faecal 
VOC profiles as measured using the Cyranose 320© in a cohort of adult patients with 
IBD. Mucosal IBD disease activity was assessed based on endoscopic evaluation and the 
control group consisted of age, gender, smoking habits and hospital matched patients who 
underwent colonoscopy for various reasons and had no endoscopic abnormalities. In this 
study, we presented that short-term sensor drift more profoundly influenced VOC patterns 
than any other clinical variable, such as dietary intake, and disease state of interest, in 
this case IBD, irrespective of disease activity and localisation. Most correction methods 
for sensor drift are solely reported once and are mostly based on available, public and 
mostly artificial online environments, whereas in this study, the effects of eNose sensor drift 
on diagnostic accuracy were illustrated in a real-life cohort. In addition, we proposed a 
correction method for this sensor drift which led to improved diagnostic accuracy of faecal 
VOC profiles to detect IBD. Furthermore, various methodological methods to avoid bias 
by sensor drift were proposed. These outcomes emphasize the importance of sensor drift 
correction to improve reliable eNose measurements. Raising awareness amongst clinicians 
on this phenomenon and how to deal with it in a standardised manner is important as 
correction for drift improves reliability and repeatability of eNose study outcomes, both 
within and across studies.
In part one of this thesis, the possible confounding effects of environmental factors, inter- 
and intraindividual variations and sensor drift have been assessed. Based on these studies, 
we have developed a standard operating procedure and have proposed correction methods 
for confounding lifestyle and sensor drift factors. Awareness of these effects and how 
to adjust study protocols accordingly is important amongst clinicians performing eNose 
293
16
measurements, as this improves consistency, as well as repeatability and reliable comparison 
between studies. Standardization of protocols may facilitate future implementation of 
eNose technology in clinical practice.
PART II 
Volatile organic compound analysis as biomarker for inflammatory bowel 
disease
Both paediatric and adult Inflammatory bowel disease (IBD) are diagnosed and monitored 
using endoscopic assessment, which are invasive and costly. The differentiation between 
paediatric IBS and IBD is often challenging in daily practice and faecal calprotectin testing 
is characterised by a low specificity of IBD, leading to a significant number of (unnecessary) 
invasive endoscopic procedures performed. Previous studies have highlighted the potential 
of faecal VOCs to differentiate between paediatric IBD patients and controls[3, 4]. Studies 
on its discriminative value when including symptomatic paediatric IBS patients were 
lacking in the available literature, limiting to reliably explore the specificity of VOC analysis 
to discriminate IBD from an intention to diagnose population. In chapter five, a proof of 
principle study is described in which we were able to differentiate paediatric patients with 
inflammatory bowel disease from symptomatic irritable bowel syndrome (IBS) patients and 
asymptomatic controls based on faecal VOC profiles, as measured with FAIMS. In addition, 
it was concluded that the faecal VOC profiles of IBS patients were similar to those of 
asymptomatic controls. This latter finding suggested that these faecal profiles may possibly 
serve as additional non-invasive biomarker to differentiate between paediatric IBS and IBD 
patients, which would subsequently lead to less unnecessary endoscopic procedures. As 
this was a proof of principle study with limited number of inclusions, a larger endoscopy-
controlled intention-to-diagnose cohort needs to be performed in the future, including 
study groups with low and high faecal calprotectin values to reliably compare accuracy of 
the currently used markers to faecal VOC profiles and to assess the value of VOC profiling 
as (additional) diagnostic biomarker for IBD in clinical practice. 
In the literature, urinary VOC profiles have been described to evaporate within few hours 
and after nine months of storage in the freezer[5]. Therefore, collection of urinary samples 
for VOC study purposes may, although possibly more patient-friendy to collect and store, 
be less reliable compared to faecal samples. In a previous (unpublished) study, we provided 
questionnaires to participants including items on their experience with faecal sample 
collection. We observed that for most children, the collection of a faecal sample caused 
a level of embarrassment, whereas they indicated that sampling of urine would be less 
of an issue. As on-demand collection of urinary samples during clinical appointments has 
practical advantages over faecal samples, we conducted a study to assess the differences 
in diagnostic accuracy between faecal and urinary volatile organic compound profiles for 
IBD. In Chapter six, the potential of these urinary and faecal VOC profiles were compared 
in an intention-to-diagnose cohort of patients aged 4–17 years, referred to the outpatient 
clinic of a tertiary centre under suspicion of IBD. Here, we assessed urinary and faecal VOC 
profiles as measured with gas chromatography–ion mobility spectrometry and found that 
both bodily excrements performed similarly for the detection paediatric IBD diagnosis. 
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Although faecal VOC samples are considered to be more robust and stable over time and 
would therefore be more suitable for large-batch measurements and less urgent matters, 
the development of disease-specific VOC algorithm based on urine samples may be a 
valuable addition for bed-side, on demand analysis. 
In chapter seven, we assessed the potential of faecal VOC profiles to detect adult IBD 
patients in a large multi-centre cohort, using an advanced eNose technology system for 
pattern-recognition (GC-IMS). We were able to compose and internally validate a diagnostic 
algorithm based on faecal VOC data that discriminated IBD patients from controls, 
irrespective of their disease activity, with similar sensitivity and higher specificity to that of 
faecal calprotectin levels. An algorithm for the discrimination between active disease and 
remission could, however, not be established based on faecal VOC profiles. Faecal VOC 
profiles are thought to partly reflect the gut microbiota[6]. Consistent patterns for specific 
IBD-related bacterial species have not yet been validated due to differences of methodology 
used to describe microbiota composition in the available literature[7]. However, in multiple 
studies, the microbial stability has been found higher in healthy individuals compared to 
IBD patients, who are characterised by a decreased diversity and higher variability over 
time[8-13]. Remarkably, this variability of microbial composition in IBD patients does not 
correlate with disease activity and as fluctuations in microbiota composition have been 
observed both during exacerbation and clinical remission, no typical microbial signatures 
related to flare-ups have been identified [8, 9, 14]. This may well explain the high diagnostic 
accuracy of faecal VOC profiles to discriminate between IBD patients and HC, as well as 
the inability to discriminate between active and quiescent disease in the current study. In a 
previous study on breath VOC profiling, differences between active IBD and remission were 
presented based on metabolites related to inflammatory processes[15]. These findings 
combined implicate that faecal VOCs may serve as valuable biomarker for IBD detection. 
As the course of IBD is characterised by periods of relapse and remission and insufficient 
control of (sub)clinical mucosal inflammation leads to irreversible bowel damage, early 
prediction of changes in disease state adds to timely management adjustment which 
subsequently improves disease outcome and prevents drug-related side effects[16, 17]. 
Gut microbial markers and faecal calprotectin (FCP) have been presented as predictive 
markers for IBD course, however, validation of these markers is lacking for this purpose[18]. 
In chapter eight, we conducted a follow-up cohort study of IBD patients in which we aimed 
to predict biochemical disease course (based upon faecal calprotectin levels) and clinical 
disease course (based on clinical activity scores) using faecal VOC profiles. We observed 
differences in faecal VOC profiles of IBD patients preceding a change in disease activity 
based upon faecal calprotectin levels, both prior to going into exacerbation and going 
into remission. There were no differences preceding a change in the clinical disease course 
as based upon disease activity scores. In this study, the groups were too small to draw 
firm conclusions regarding the potential of VOC profiling to monitor IBD, however, the 
suggestion is made that faecal VOC profiles may be useful to predict disease course and 
optimize treatment an early stage. A larger cohort is required to validate our findings and 
may further improve the predictive algorithm. 
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In conclusion, part two of this thesis presents the potential of faecal VOC profiles to detect 
and monitor IBD patients. Some of the newly obtained algorithms have already been 
internally validated. To implement these algorithms in a clinical setting, external validation 
needs to be performed. For this, it is important to choose one or more specific eNose 
technologie(s) for further implementation steps, as pattern-recognition algorithms will vary 
upon the technology and device used and this will influence outcome of external validation. 
Alongside this, faecal VOC profiles should be assessed next to faecal calprotectin and 
endoscopy outcomes in an intention-to-diagnose setting, to investigate their additional 
value and to conduct a reliable cost/benefit analysis for clinical implementation. Once 
these aspects have been addressed, the results are externally validated and VOC profiles 
appear to be cost-effective, measurements may be performed for clinical purposes whilst 
simultaneously adding to a growing pattern-recognition database further improving 
diagnostic accuracy. 
PART III
The liquid faecal metabolome as biomarker for paediatric inflammatory bowel 
disease
Metabolomics is a branch of chemistry that studies all molecules with a low molecular 
weight within cells, fluids, tissues or organisms and their interaction with metabolic 
processes. Similar to faecal VOC profiles, in which gaseous metabolites are measured, 
these liquid metabolites are believed to directly reflect the underlying biochemical state of 
the medium measured. The metabolite composition of any medium changes continuously 
and rapidly over time as the composition is dependent of numerous processes such as 
synthesis, degradation, absorption, transportation and excretion. Still, it is believed that in 
the event of predominant pathophysiologic processes, changes in the overall composition 
of the metabolome may be useful for disease detection. In the third part of this thesis, we 
illustrated the potential of metabolomic methods for detection of children with inflammatory 
bowel disease and their additional value to unravel pathophysiological processes. 
In chapter nine, the potential of the faecal amino acid composition for IBD detection was 
explored in a cohort of de novo paediatric IBD patients. IBD patients were distinguished 
from controls based on six specific amino acids varying between the phenotypes UC and 
CD. The faecal and serum metabolomic patterns of paediatric IBD patients have recently 
been subject to another study assessing both the serum and faecal metabolome[19]. In line 
with our study, levels of the faecal amino acid tryptophan were increased in both UC and CD 
compared to HC. We additionally found elevated faecal levels of histidine, phenylalanine, 
leucine, tyrosine and valine in paediatric IBD patients. Based on these outcomes, faecal 
amino acids do seem to hold potential as diagnostic biomarker, which may be more 
disease-specific and personalised compared to FCP. Since only small study groups were 
used for this explorative study, larger intention-to-diagnose studies should be performed 
in a longitudinal setting before firm conclusions can be drawn on the clinical potential of 
faecal amino acids for IBD detection and for monitoring of disease activity. 
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In chapter ten, we hypothesised on the underlying pathophysiology causative for the 
change in faecal amino acid composition in a letter to the editor. Based on the available 
literature, we opted that colonic leakage may be the most likely cause for the increased 
faecal amino acid levels, though, other contributing factors as downregulation of absorption 
transporters, a poor nutritional state and a change in metabolism were described. 
In chapter eleven, we presented a pilot study including de novo paediatric IBD children and 
symptomatic children without IBD to validate our previous results in an intention-to-diagnose 
setting, whilst simultaneously comparing amino acid composition of both faeces and serum 
to levels of faecal calprotectin. We presented significantly increased levels of nine amino 
acids in paediatric IBD children when compared to the non-IBD children, whereas there were 
no differences in serum amino acid levels. This latter finding was contrary to the available 
literature on adult IBD patients, in which a decrease of tryptophan and histidine have been 
described[20]. We did present negative z-values for these AAs. These were, however, non-
significant. We demonstrated that high specificity values of faecal AAs may be reached 
whilst maintaining acceptable sensitivity values. Based on calprotectin, all IBD children 
were classified correctly and three out of eight non-IBD children were classified incorrectly. 
Of these incorrectly classified non-IBD patients displaying elevated levels of calprotectin, 
only one displayed high levels of faecal AAs. Remarkably, this patient underwent a second 
endoscopic assessment a year after this study was closed, and is currently being treated 
for IBD-unclassified. Though this pilot study was small, these outcomes illustrate the high 
specificity of faecal AAs and their potential additional value as non-invasive biomarkers.   
In conclusion, we repeatedly presented elevated levels of faecal amino acids in IBD patients, 
irrespective of their phenotype. The etiology and pathogenesis of this phenomenon is still 
largely unknown. Current hypotheses on the underlying mechanisms of alterations in faecal 
AA levels in IBD patients include malabsorption, alterations in metabolism, gut dysbiosis 
and colonic leakage [21, 22]. In addition, accumulating evidence shows a correlation 
between faecal AA levels and alterations in gut microbiota in IBD patients [23, 24].  Since 
testing for faecal AA composition seems reproducible, is easy-to-perform and has low costs, 
this technology would be suitable for clinical use. We have planned a large intention-to-
diagnose cohort study to validate faecal AAs as biomarkers. Upon validation, a diagnostic 
algorithm may be established combining calprotectin and multiple faecal AAs to improve 
test accuracy. 
PART IV
Using multi-omics strategies to our advantage in the search for early stage 
colorectal cancer biomarkers
Early detection and treatment are critical factors in the course and prognosis of CRC, as 
the survival rate decreases with disease progression[25]. Most of the CRC lesions develop 
from adenomas in the so-called adenoma-carcinoma sequence, in which it is thought that 
a sequence of mutations result in carcinogenic development. Identification and removal of 
high-risk adenomas (advanced adenomas) has been described to decrease CRC incidence 
and mortality [26, 27]. To date, the most widely used screening test for CRC and its precursor 
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lesions is the faecal immunochemical test (FIT). Although this screening program has led 
to a decrease in mortality, the performance of this test has suboptimal sensitivity, indicated 
by the missed diagnosis of CRC in 1-47% and AA in 43-61% of the tests[28]. In addition, 
specificity is suboptimal, as approximately 7% of the performed tests provide false-positive 
results leading to the performance of unneeded colonoscopies. Endoscopic assessment 
is advised after FIT positivity, but also remains key for surveillance after removal of polyps 
(polypectomy) and following CRC treatment, as these patients remain at increased risk for 
development or recurrence of dysplastic lesions[25]. In the fourth part of this thesis we 
describe the potential of faecal volatolomics as well as metabolomics, proteomics and 
microbial profiling as diagnostic tool for CRC and adenomas and for polyp surveillance. 
In chapter twelve we have provided a review of the available literature on the evidence of 
faecal VOCs as biomarker for CRC and its precursor lesions. In all studies, promising results 
for future screening of adenomas and CRC based on faecal VOC analyses were described, 
yet, the lack of standardised sampling procedures, the use of various analytical techniques 
and the lack of correction for participant variables as smoking and diet hampered a reliable 
comparison of results. 
In chapter thirteen, we demonstrated differences between well-characterised patients 
with CRC, advanced adenomas, large adenomas and small adenomas when compared to 
healthy controls (defined as patients with no colonic abnormalities) based on faecal VOC 
profiles in a large cohort, measured with a GC-IMS system. Additionally, we described 
that patients with adenomas and controls can be discriminated prior to polypectomy, 
however, three months after polypectomy faecal VOC profiles are similar. This suggests that 
the faecal VOC profiles of patients three months after polypectomy alter to more closely 
resemble healthy controls following this intervention and is substantiated by the fact that 
faecal VOC profiles of controls did not  differ pre- and post-endoscopy, whereas profiles of 
polypectomy patients did differ pre- and post-polypectomy. This study implied that faecal 
VOC profiles may be useful for early CRC and adenoma detection when added to the 
currently available screening methods, but it should not be used for screening as single 
marker, as large numbers of false positive results will be obtained, leading to a large number 
of unnecessary endoscopies. Furthermore, this study highlighted that faecal VOC profiles 
may be used for timing of polyp surveillance as polypectomy led to a normalization of 
VOC profile. Strong evidence exists for the association between microbial dysbiosis and 
polyp-associated tissue and colonic neoplasia[29]. As faecal VOC profiles partly reflect the 
gut microbiota composition, alterations in the microbial composition may be underlying 
the differences in VOC profiles. So far, causality of the association between gut microbial 
composition and polyp-associated tissue remains unclear. It is unknown whether microbial 
changes trigger carcinogenesis, or, whether specific species are attracted to the gut 
when malignant processes are evolving. As in chapter thirteen, faecal VOC profiles were 
described to return to normal state after polyp removal, the suggestion is raised that the 
alleged faecal microbial dysbiosis returns to physiological state after polyp removal. Based 
on these findings, it could be hypothesised that gut microbial changes may rather result 
from the underlying adenoma-carcinoma sequence than being the  causative factor. This 
study formed the basis of the next two chapters, in which the metabolomic, proteomic 
and microbial profiles are more closely assessed to further investigate the  change in VOC 
patterns. 
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In chapter fourteen, we integrated data on faecal microbiota, human faecal proteome and 
faecal amino acid profiles in a multi-centre cohort of CRC-patients, adenoma-patients and 
controls who underwent colonoscopy (for various reasons) without endoscopic abnormalities. 
We presented potential diagnostic biomarkers within the proteomic, microbial and amino 
acid platforms. In addition, we presented that a combination of markers from the proteomic 
and amino acid platforms outperformed accuracy of the (proteomic) haemoglobin markers 
in discriminating both CRC and adenomas from controls, and in discriminating CRC 
from adenomas. As these haemoglobin markers are currently used for population based 
screening, we believe that after validation in a new cohort, the above mentioned new 
panels may improve screening for adenomas and CRC. This would subsequently lead to 
lower incidence and mortality of bowel cancer. Furthermore, we demonstrated new insights 
into the complex interplay of human metabolism and gut microbial composition in the 
presence of adenomas and CRC. In line with the available literature, we revealed markers 
associated with increased blood excretion in the presence of adenomas and CRC. In 
addition, we presented an upregulation of end-products associated with inflammatory- and 
stress responses and a downregulation of epithelial integrity. We described associations 
between these end-products and specific anti- and pro-carcinogenic microbial taxa and 
hypothesised on the aetiology of these associations based on the available literature. 
In chapter fifteen, we assessed the adenoma-associated gut microbiota and amino acid 
profile and investigated their regulation prior to and after adenoma removal in a prospective 
cohort, including adenoma patients undergoing polypectomy and controls undergoing 
colonoscopy. Patients with adenomas and controls were distinguished prior to intervention 
both based on microbial taxa and amino acid profiles. Overall, amino acids returned to 
physiological state after adenoma removal, whereas the adenoma-associated alterations 
in bacterial taxa remained largely similar, irrespective of polypectomy. Adenoma-specific 
amino acids were combined into one biomarker panel which outperformed diagnostic 
accuracy of the currently used population based FIT test. Based on these study findings, 
the suggestion was made that amino acids may serve as biomarkers to determine the 
right timing of surveillance endoscopy, whereas the microbial signature may be used to 
select high-risk individuals. Upon validation of these panels, these findings may improve 
effectiveness of the surveillance program, leading to less unnecessary endoscopies and less 
interval-cancer.
In conclusion, in part four of this thesis, we presented that the use and integration of 
various omics platforms as faecal VOC profiles, microbiota, metabolome and proteome 
hold potential to improve both our currently used CRC screening program and timing of 
our post polypectomy endoscopic surveillance program. Similar to part two of this thesis, 
some of the newly obtained algorithms have already been internally validated, however, 
to implement these algorithms in a clinical setting, external validation needs to take place. 
In the future, we therefore intend the enrollment of a validation cohort in which we aim to 
repeat measurements and validate currently established algorithms. After validation, these 
markers should be tested next to the currently used gold standards to provide for a reliable 
cost/benefit analysis setting and to choose the best available omics strategy. Improvement 
of the screening and surveillance program may then lead to lower CRC incidence and 




It has now become evident that profiling of faecal metabolic end products holds 
tremendous potential as biomarker for disease detection, disease course prediction and 
disease surveillance. Apart from the need for a high diagnostic accuracy, for a screening test 
to be valuable, a high level of reproducibility is warranted. Therefore, a biomarker should 
be stable and detectable against changes in environmental circumstances. Moreover, it 
should be cost-effective and easy to use. Third, in case of population based screening, 
a test that can be transported via regular mail would be preferred. With regards to the 
omics platforms used in this thesis, especially protein analysis, has been proven to remain 
unaffected by circumstances such as storage, transport and dietary intake, hereby meeting 
up to the criterion of robustness. For microbial composition, it is known that dietary intake, 
storage time and temperature all influence outcomes, however, various studies on CRC 
have shown comparable outcomes for some specific bacterial strains, making it unlikely that 
environmental differences significantly affect these CRC-specific bacteria. The influence of 
storage temperature on microbiota composition, for which minus 80 degrees seems to be 
preferred, brings along logistic challenges for transportation via regular mail. Amino acid 
analysis seems to hold high potential as non-invasive CRC and adenoma biomarker. Costs 
of these analysis are low compared to both microbial and protein profiling, underlining its 
potential for large-batch population-based screening. However, this platform is at the early 
stage of development for faecal analysis. The influence of diet and variations in storage and 
transportation have not yet been elucidated. 
A downside of the above mentioned metabolite specific analytical platforms is, however, that 
measurements are relatively time-consuming, and usually require expensive equipment and 
expertise. Electronic nose technology may overcome these limitations, as, once a diagnostic 
algorithm is developed, results can be obtained within minutes after collection. In addition, 
the use of pattern-recognition may be favourable for diagnostic purposes since this allows 
for easy-to-perform, high-throughput and low-cost analysis, underlining its suitability for 
application in clinical practice. Non-invasive testing for the detection and monitoring of 
IBD, advanced adenomas or CRC based on faecal VOC profiles is, however, still far from 
the use in a public health setting. The use of various techniques between different studies 
for faecal VOC analyses in combination with the use of different criteria used for specific 
diseases, hampers reliable comparison between studies. In addition, as alterations in VOC 
profiles have been presented for sampling circumstances, lifestyle variations and sensor 
drift during measurements, collaboration to establish standardization of methodology 
and technique should be given priority in future studies. Using machine learning, we have 
presented algorithms specific for the detection of IBD, CRC and precancerous polypous 
lesions. The accuracy of these algorithms will improve continuously with increasing numbers 
of samples measured. Once the disease-specific algorithm reaches satisfactory accuracy, it 
should be validated in a new cohort of patients and compared to the currently used gold 
standard, to calculate a cost-benefit ratio. The device and corresponding disease-specific 
algorithms may then be implemented not only for population based screening but also for 
intra-individual surveillance or follow-up. For population based screening or large batches 
of samples, it would be preferable to analyse all samples at one central collection point 
where the VOC profiles may be measured and based on the existing algorithm, chance 
of disease may be calculated. For smaller numbers of samples, eNose devices may even 
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allow for bedside analysis. Though, the limitation of sensor drift first needs to be addressed 
by standardizing correction methodology before reliable diagnostic algorithms can be 
developed for these smaller devices. 
Development of a reliable cost/benefit analysis is limited in this early phase of biomarker 
development, as  targeted analysis and batch measurements change the costs of each 
omics strategy dramatically and increasing specificity and sensitivity of the proposed test 
will subsequently alter the costs of the following health care steps. In the future, presented 
biomarker panels and algorithms should be validated in new datasets, covering all omics 
platforms. In addition, the new biomarker panels should be tested separately and in 
combination with the currently used gold standards for screening and surveillance. This 
may lead to a selection and development of a set of optimal, diagnostic biomarkers to be 
used as clinical tools. 
CONCLUSION
In conclusion, this thesis highlights the potential of faecal VOC analysis for the detection of 
IBD and the prediction of its disease course. In addition, its potential for CRC and adenoma 
detection is presented and proposed to be a reliable tool for intra-individual surveillance 
and to estimate the timing endoscopy after polyp removal. We have described combined 
omics panels to increase diagnostic accuracy for detection of both CRC and adenomas 
compared to the use of solely one omics platform. Future studies should focus on the 
following aspects: a standardised method for VOC measurements, robustness assessment of 
amino acid profiles, a prospective validation study comparing all biomarkers and algorithms 
to the gold standard and a cost/benefit assessment. This way the best biomarker(s) and/or 
algorithms may be selected for further development as clinical tools, improving detection 
of disease at an early stage which subsequently leads to earlier treatment, lower numbers 
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In dit proefschrift worden biomarkers onderzocht voor de niet-invasieve vroegdetectie en het 
monitoren van inflammatoir darmlijden (IBD), dikke darmkanker (CRC) en poliepen. Hiervoor 
wordt gekeken naar faecale eindproducten van ons metabolisme. Deze eindproducten, 
ookwel biomarkers, bestaan onder andere uit vluchtige organische componenten (VOCs), 
de bacteriële samenstelling (faecale microbioom), de eiwitsamenstelling (het faecale 
proteoom) en hiervan de bouwstenen, de aminozuur profielen, welke behoren bij het 
faecale metaboloom. De overkoepelende term voor deze biomarkers wordt ‘omics’ 
genoemd. In dit proefschrift hebben deze omics strategieën gezorgd voor nieuwe manieren 
om darmaandoeningen op een niet-invasieve manier in een vroeg stadium te detecteren, 
te monitoren en het beloop van ziekte te voorspellen. Dit is van belang omdat dit in de 
kliniek kan leiden tot vroegtijdige behandeling, vermindering van complicaties, operaties 
en opnames in het ziekenhuis. Daarnaast is gedetailleerde ziekte-specifieke informatie over 
de eindproducten van het metabolisme essentieel om ons begrip van de pathologie te 
vergroten en om wetenschappelijk onderbouwde therapeutische interventies te ontwikkelen, 
gelinkt aan metabolisme en het faecale microbioom. Hiertoe wordt in dit proefschrift 
gebruik gemaakt van verscheidene technieken. Allereerst, VOCs zijn gasvormige organische 
moleculen waarvan wordt gedacht dat zij zowel de samenstelling en functie van het 
microbioom als de interactie met het humane metabolisme reflecteren. Om de faecale VOC 
profielen te meten wordt in deze thesis gebruikt gemaakt van patroonherkenning op basis 
van machine learning algoritmes met verscheidene electronische neus (eNose) technieken: 
sensor resistentie (Cyranose 320©), asymmetrische veld - ionmobiliteitsspectrometrie 
(FAIMS) en gas chromatrografie - ionmobiliteitsspectrometrie (GC-IMS). De faecale 
bacteriële samenstelling wordt geanalyseerd met 16S ribosomale DNA sequencing, 
het humane proteoom middels vloeistof chromatografie – massa spectrometrie / massa 
spectrometrie (LC-MS/MS) en de aminozuurprofielen met hogedrukvloeistofchromatografie 
(HPLC). 
DEEL I
Het optimaliseren van de vluchtige organische componenten analyse
In het eerste deel van dit proefschrift wordt de methodologie en de stabiliteit van de VOC 
analyse voor de detectie van gastro-intestinale aandoeningen onderzocht. In hoofdstuk 
twee wordt onderzocht wat het effect is van verschillende onderzoeksprotocollen 
op de diagnostische accuratesse van VOC profielen voor het detecteren van nieuw-
gediagnosticeerde, nog onbehandelde kinderen met IBD. Zij worden vergeleken met 
een groep klachtenvrije gezonde kinderen. De faecale VOC profielen worden gemeten 
met gebruik van FAIMS. Het werd duidelijk dat de accuratesse toeneemt bij het verhogen 
van de massa van het faecale monster. Hierbij gaf een massa van 500mg een zeer hoge 
diagnostische nauwkeurigheid. Een toename van de hoeveelheid dooi-vries cycli had 
een drastisch effect op de accuratesse, waarbij een verlies van 20% werd gezien na één 
dooi-vries cyclus en een totaal verlies van discriminatieve waarde na twee dooi-vries cycli. 
Een vertraging in de meting van 180 minuten na ontdooien van het faecale monster gaf 
tevens drastisch verlies van diagnostische mogelijkheden. Het  bevroren bewaren van de 
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samples voor 20 maanden had geen duidelijk effect op de diagnostische waarde van de 
VOC profielen. Gebaseerd op deze studie resultaten hebben we een strikt studie protocol 
ontwikkeld dat een optimale diagnostische accuratesse bewerkstelligt bij het gebruik van 
faecale VOC profielen als diagnosticum. Dit protocol vormde de basis voor de rest van dit 
manuscript. 
Het doel van hoofdstuk drie was om de stabiliteit van faecale VOC profielen te onderzoeken 
bij verschillen in de leefstijl. Dit werd onderzocht in een cohort van gezonde individuen, 
welke in deze studie zijn gedefinieerd als asymptomatische individuen die om verschillende 
redenen een endoscopie kregen, waarbij geen afwijkingen aanwezig waren. Faecale 
geurprofielen zijn in deze studie onderzocht met gebruik van de Cyranose 320© gebaseerd 
op sensor resistentie. De invloed van variabelen als leeftijd, geslacht, BMI, rookgedrag, 
dieet, gebruik van medicatie en co-morbiditeit op faecale VOC samenstelling werd 
onderzocht. We vonden dat zowel roken als een laag BMI (<18), een lage leeftijd (18-35 
jaar), een vegetarisch of ander specifiek dieet en het gebruik van antibiotica in de drie 
maanden voorafgaand aan de meting allen van invloed waren op het faecale geurprofiel. 
In deze studie werd het belang van de correctie voor deze ‘leefstijl’ variaties bij het doen 
van faecale VOC analyses duidelijk. Tevens werden verschillende correctie methodes 
voor toekomstig onderzoek voorgesteld, zoals het matchen van cases en controles op de 
meest belangrijke leefstijl variaties of het berekenen van correctie factoren binnen een 
studie. Daarnaast werd aangetoond dat de sensor uitslagen van de Cyranose 320© allen 
een soortgelijke verandering in elektrische resistentie hadden wanneer zij aan een fecaal 
monster werden blootgesteld, terwijl de 32 sensoren op verschillende VOCs een andere 
reactie behoren te hebben. Hierdoor werd de mogelijke invloed van zogenaamde ‘sensor 
drift’, het tijdelijk afdrijven van sensor uitslagen, op de VOC profielen blootgelegd. Deze 
bevinding vormde de basis van de volgende studie. 
Ondanks dat het verschuiven van sensoruitslagen een bekende beperking is van de eNose, 
is de diagnostische accuratesse van deze techniek in verscheidene studies aangetoond. 
Gecombineerd met de lage kosten en snelheid van de metingen is dit een aantrekkelijke 
techniek om te gebruiken in de kliniek. In hoofdstuk vier wordt het effect van sensor afdrijving 
op de diagnostische accuratesse van faecale VOC profielen onderzocht, gemeten met de 
Cyranose 320©. Dit wordt gedaan op basis van een cohort met volwassen IBD patiënten 
waarbij de ziekte activiteit gescoord wordt op basis van de endoscopie afbeeldingen. 
Hierbij hebben wij ons gehouden aan het eerdere protocol en zijn de cases en controles 
voorafgaand aan de analyse gematcht op leeftijd, geslacht, rookgedrag en ziekenhuis van 
inclusie. In dit hoofdstuk wordt aangetoond dat, wanneer er niet gecorrigeerd wordt voor 
sensor drift, deze variabele een grotere invloed heeft op de faecale VOC patronen dan 
IBD zelf, ongeacht de ziekteactiviteit en lokalisatie van de ziekte. In de literatuur zijn de 
meeste sensor drift correctie methoden maar eenmalig gerapporteerd, en deze zijn vaak 
gebaseerd op publiekelijk beschikbare, artificiële online databases. In de huidige studie 
wordt dit effect onderzocht op een levensecht cohort. Tevens wordt een correctie methode 
voorgesteld en uitgevoerd, waarbij de accuratesse om IBD te detecteren verbetert. De 
uitkomsten van de huidige studie benadrukken het belang van sensor drift correctie bij 
eNose metingen om de betrouwbaarheid van de uitkomsten te verbeteren.
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In deel een van dit proefschift worden mogelijke confounders van faecal VOC profielen 
gezocht in onderzoeksprotocollen, inter-individuele variaties en eNose technieken zelf. 
Gebaseerd op de studies uit deel I hebben we een standaard bedrijfsprotocol ontwikkeld 
voor faecale VOC profielen en hebben we mogelijke correctie methoden voorgesteld voor 
sensor drift. Wetenschap van deze mogelijke confounders en hoe met deze om te gaan is 
belangrijk onder artsen en onderzoekers die gebruik maken van eNose metingen, omdat 
dit de consistentie, herhaalbaarheid en betrouwbaarheid van de metingen bevorderd. 
DEEL II
De vluchtige organische componenten analyse als biomarker voor inflammatoir 
darmlijden
Inflammatoir darmlijden is een chronische ontstekingsziekte van het maag/darmstelsel. Er 
zijn twee vormen waarin IBD voorkomt, dit zijn de ziekte van Crohn (CD) en colitis ulcerosa 
(CU). De ziekte wordt bij zowel kinderen als volwassenen gediagnostiseerd en gemonitord 
door middel van endoscopische onderzoeken. In de kliniek is het soms een uitdaging om 
het onderscheid te maken tussen patiënten met een prikkelbaar darmsyndroom (IBS) en 
met IBD. Fecaal calprotectine wordt in de kliniek gebruikt om een actieve darmontsteking 
op te sporen, en kan daarmee de aannemelijkheid dat er IBD speelt vergroten. Het 
calprotectine is echter een marker voor alle vormen van mucosale darmontstekingen en 
heeft daarom een lage specificiteit voor IBD. Dit leidt tot een aantal onnodig uitgevoerde 
endoscopische onderzoeken. Deze zijn niet alleen invasief en duur, maar zijn ook zwaar 
voor kinderen omdat zij moeten worden opgenomen in het ziekenhuis en laxatie middelen 
krijgen toegediend via een neusmaag sonde. In eerdere studies is de toepasbaarheid van 
faecale VOC profielen voor de detectie van IBD patiënten aangetoond. Echter, dit is steeds 
gedaan in vergelijking met asymptomatische kinderen. In hoofdstuk vijf wordt aangetoond 
dat kinderen met IBD kunnen worden onderscheiden van symptomatische kinderen met IBS 
gebaseerd op faecale VOC profielen gemeten met de FAIMS techniek. Daarnaast wordt 
aangetoond dat er geen onderscheid is tussen de faecale VOC profielen van kinderen 
met IBS en asymptomatische (gezonde) kinderen. Deze bevindingen benadrukken dat de 
geurprofielen van toegevoegde waarde zijn voor het differentiëren tussen symptomatische 
kinderen met IBD en zonder IBD. Dit kan in de toekomst leiden tot het verrichten van 
minder (onnodige) invasieve endoscopische onderzoeken bij kinderen met buikklachten. 
In de literatuur wordt beschreven dat de VOC profielen van urine binnen enkele uren 
diffunderen. Het verzamelen van urine monsters lijkt daarom minder geschikt dan faecale 
samples. Echter, in een eerdere (ongepubliceerde) vragenlijst studie bleek dat er met 
name voor kinderen schaamte speelt bij het verzamelen van faecale monsters. Zij gaven 
aan dat dit een minder grote rol speelt bij het verzamelen van urine. Omdat het ‘op 
aanvraag’ verzamelen van een urine monster tijdens een afspraak op de polikliniek tevens 
praktische voordelen heeft, ontwikkelden we een studie om de verschillen in diagnostische 
accuratesse te onderzoeken tussen urine monsters en faecale monsters voor het detecteren 
van kinder-IBD. In hoofdstuk zes werd deze accuratesse vergeleken in een ‘intention-to-
diagnose’ cohort van patiënten tussen de 4 en 17 jaar oud. Deze patiënten werden allen 
verwezen naar een tertiair centrum vanwege verdenking op IBD. Kinderen met symptomen, 
Appendix. Dutch summary
310
maar waarbij geen IBD gediagnosticeerd werd, vormden de controle groep. Faecale 
geurprofielen werden gemeten met een geavanceerde, zeer stabiele eNose techniek: 
GC-IMS. Voor zowel ontlasting als urine werd hetzelfde protocol gevolgd, waarbij tevens 
bewaartijd van samples in de vriezer gelijk was. Er werden geen verschillen aangetoond in 
de diagnostische accuratesse tussen faecale en urinaire VOC profielen voor IBD. Ondanks 
dat er wordt gedacht dat faecale VOC profielen stabieler en meer robust zijn over de tijd en 
hierdoor meer geschikt zijn voor het doormeten van grote partijen monsters, zou een ziekte-
specifiek VOC algoritme voor urine een goede optie zijn voor snelle ‘bed-side’ metingen. 
In hoofdstuk zeven is onderzocht of faecale geurprofielen het onderscheid kunnen maken 
tussen volwassenen met IBD en gezonde controles in een groot multi-centrum onderzoek 
waarbij we gebruik maakten van de GC-IMS techniek. In deze studie werd een hoge 
diagnostische accuratesse aangetoond voor de vergelijking tussen IBD patiënten en 
controles, ongeacht de ziekteactiviteit van deze patiënten. Onze bevindingen toonden 
aan dat de geurprofielen mogelijk behulpzaam zijn bij het opsporen van IBD. De detectie 
van de mate van ziekteactiviteit op basis van faecale geurprofielen was matig. Omdat een 
opvlamming progressief verloopt, werd de hypothese gesteld dat geurprofielen mogelijk 
wel een rol kunnen spelen bij de vroeg detectie van een verandering in ziekteactiviteit. 
Dit is belangrijk omdat periodes van (sub)klinische mucosale ontsteking kunnen leiden 
tot onomkeerbare darmschade en complicaties. In hoofdstuk acht onderzochten we dit 
vraagstuk in een follow-up studie van IBD patiënten die op gezette momenten faecale 
samples en vragenlijsten verzamelden voor de klinische activiteit score, het fecaal 
calprotectine en faecale geurprofielen. In deze studie werd ontdekt dat de faecale 
geurprofielen van patiënten voorafgaand aan een verandering in ziekteactiviteit, gebaseerd 
op het fecaal calprotectine, verschillend zijn dan patiënten waarvan de ziekteactiviteit stabiel 
blijft.  Dit gold voor patiënten die van een exacerbatie in remissie gingen als voor patiënten 
in remissie die een exacerbatie kregen. De onderzoeksgroepen geïncludeerd in deze studie 
waren te klein om uitspraken te doen over het gebruik van faecale geurprofielen met als 
doel het voorspellen van het ziektebeloop van IBD in de kliniek. Echter suggereren de 
bevindingen van deze studie wel dat faecale geurprofielen mogelijk een bijdrage zouden 
kunnen leveren aan de optimalisatie van IBD behandeling. Een groter cohort is echter 
nodig om deze bevindingen te valideren. 
Concluderend, in deel twee van dit proefschrift wordt beschreven hoe faecale 
geurprofielen kunnen bijdragen aan de klinische zorg voor kinderen en volwassenen 
met IBD. Sommige van de voorgestelde algoritmes zijn al intern gevalideerd. Voordat 
verdere implementatiestappen gezet worden, is het van groot belang om allereerst 
een keuze te maken welke de eNose techniek het meest geschikt is voor het beoogde 
doeleinde, omdat patroonherkenning algoritmes specifiek zijn voor het bijbehorende 
meetinstrument. Wanneer deze keuze is gemaakt, zal het verkregen algoritme gevalideerd 
moeten worden in een extern prospectief cohort, waar het vergeleken moet worden met 
het fecaal calprotectine en de gouden standaard, de endoscopie. Op deze manier kan de 
toegevoegde waarde van faecale VOC profielen als biomarkers berekend worden en een 
betrouwbare kosten/baten analyse verricht worden. 
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Deel III Het faecale metaboloom als biomarker voor inflammatoir darmlijden bij kinderen
Het metaboloom omvat alle moleculen met een laag moleculair gewicht binnen cellen, 
vloeistoffen, weefsels of organismen en diens interactie met metabole processen. 
Vergelijkbaar met faecale VOC profielen, waarin gasmoleculen gemeten worden, wordt 
gedacht dat deze vloeibare moleculen een directe reflectie zijn van de onderliggende 
biochemische status van het medium dat gemeten wordt. Het metaboloom van een medium 
verandert continue, vaak en snel omdat de samenstelling afhankelijk is van verscheidene 
processen zoals synthese, degradatie, absorptie, transport en excretie. Toch wordt er 
gedacht dat, in het geval van predominante (patho)fysiologische processen, globale 
veranderingen in deze samenstelling bruikbaar kunnen zijn voor ziekte-detectie. In dit 
derde deel illustreren we de potentiële toegevoegde waarde van het faecale metaboloom 
voor het vaststellen van inflammatoir darmlijden bij kinderen. 
In hoofdstuk negen wordt de accuratesse van faecale aminozuren voor de detectie van 
IBD onderzocht in een cohort van nieuw gediagnosticeerde kinderen. We tonen aan 
dat IBD van controles kan worden onderscheiden met een hoge accuratesse op basis 
van zes aminozuren, welke verschillen tussen de fenotypes CD en UC. Gelijk aan de 
eerdere literatuur was een van deze verhoogde aminozuren het molecuul tryptofaan. Wij 
vonden daarnaast een verhoging van histidine, phenylalanine, leucine, tyrosine an valine 
in kinderen met IBD. In een brief worden in hoofdstuk tien hypotheses uitgewerkt over 
de onderliggende pathofysiologie die ten grondslag ligt aan de verschillen in faecale 
aminozuur profielen tussen kinderen met IBD en hun gezonde leeftijdsgenoten. Gebaseerd 
op onze eerdere studie en de beschikbare literatuur, stellen we dat lekkage uit het colon 
de meest waarschijnlijke oorzaak is voor de verhoging van faecale aminozuren bij IBD 
patiënten. Andere mogelijke bijdragende factoren als de verminderde expressie van 
absorptie-transporters, een verminderde voedingsstatus en een veranderd metabolisme 
worden tevens beschreven. In hoofdstuk elf wordt een kleine pilot studie gepresenteerd 
waarbij de faecale en serum aminozuren van een groep nieuw-gediagnosticeerde IBD 
kinderen worden vergeleken de profielen met symptomatische kinderen zonder IBD in 
een ‘intention-to-diagnose’ setting. We presenteren wederom significante verhogingen 
van, dit keer negen, verschillende faecale aminozuren bij IBD patiënten, terwijl er geen 
verschillen worden aangetoond in de aminozuurprofielen van het serum. Deze laatste 
bevinding is anders dan eerder gepubliceerde literatuur, waarbij een vermindering van 
tryptofaan en histidine werd beschreven in het serum. In onze studie werden negatieve 
Z-waarden gevonden voor deze specifieke aminozuren in het serum, echter waren onze 
bevindingen niet significant. Gedemonstreerd wordt dat de hoge specificiteit van faecale 
aminozuren behaald wordt terwijl een acceptabele sensitiviteit behouden blijft. Gebaseerd 
op het faecale calprotectine, een veelgebruikte biomarker, werden 3 van 8 niet-IBD 
kinderen verkeerd gediagnosticeerd. Van deze patiënten had maar één kind verhoogde 
aminozuren. Deze patiënt is een half jaar na de studie een tweede endoscopie ondergaan 
vanwege aanhoudende klachten en is alsnog gediagnosticeerd met IBD. Ondanks dat dit 
een kleine pilot studie was, illustreren deze uitkomsten de hoge specificiteit en hiermee de 
toegevoegde waarde van faecale aminozuren als niet-invasieve IBD biomarkers. 
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In deel III zijn herhaaldelijk verhoogde faecale aminozuurprofielen gevonden bij kinderen 
met IBD, onafhankelijk van het fenotype. De etiologie en pathogenese van dit fenomeen is 
nog onduidelijk. Huidige hypotheses zijn lekkage uit het colon, malabsorptie, ondervoeding, 
een veranderd metabolisme of een veranderde microbiële samenstelling van de ontlasting. 
Omdat het testen van aminozuren reproduceerbaar lijkt, makkelijk te verrichten is en weinig 
kosten met zich mee brengt, is deze technologie uitermate geschikt voor klinisch gebruik. 
We zijn voornemens een grote, prospectieve, ‘intention-to-diagnose’ cohort studie op 
te zetten om deze faecale aminozuurprofielen te valideren als biomarkers voor kinderen 
met inflammatoir darmlijden. Een combinatie met het faecale calprotectine zou dan in 
de toekomst gebruikt kunnen worden om niet-invasieve risico inschatting te verbeteren 
hiermee en minder (onnodige) endoscopieën uit te voeren. 
DEEL IV
Multi-omics strategieën als biomarkers voor de vroege opsporing van 
colorectaal kanker en risicopoliepen
De vroegdetectie en behandeling van colorectaal kanker (CRC) zijn belangrijke factoren voor 
het verloop en de prognose, omdat de overlevingskans vermindert bij een toegenomen 
ziekteprogressie. De meeste CRC lesies ontstaan vanuit adenomateuze poliepen in de 
zogenoemde adenoom-carcinoom reeks. Hierbij wordt gedacht dat een serie van mutaties 
resulteert in CRC. Het identificeren en verwijderen van hoog-risico adenomen (advanced 
adenomen) leidt tot een verlaging van CRC incidentie en mortaliteit. Momenteel wordt er 
in Nederland gebruikt gemaakt van het bevolkingsonderzoek, waarbij er wordt gescreend 
op CRC en hoog-risico adenomen op basis van de faecale immunochemische test (FIT). Dit 
screeningprogramma heeft tot een verlaging van CRC mortaliteit geleid, maar de test heeft 
een suboptimale sensitiviteit en specificiteit. Op basis van de FIT test wordt CRC in 1-47% 
van de gevallen gemist, afhankelijk van de afkapwaarde die gebruikt wordt. Daarnaast 
worden hoog-risico poliepen in 43-61% van de gevallen gemist door deze test. Ook is 7% 
van de uitslagen fout-positief, wat ertoe leidt dat er veel onnodige coloscopieën worden 
uitgevoerd. Endoscopie wordt niet alleen uitgevoerd na een positieve FIT test, maar blijft 
ook de standaard interventie voor surveillance na het verwijderen van adenomen en CRC. 
In het vierde deel van deze thesis wordt onderzocht of patiënten met CRC en poliepen 
kunnen worden opgespoord met behulp van verscheidene omics platforms. Daarnaast 
wordt onderzocht of faecale geurprofielen, het microbiota en faecal aminogrammen van 
toegevoegde waarde kunnen zijn in het huidige surveillance programma. In hoofdstuk 
twaalf geven we een overzicht van de bestaande literatuur over faecale geurprofielen als 
biomarker voor CRC en voorstadium adenomen. Ondanks dat het niet mogelijk was een 
goede vergelijking te maken tussen de studies door een gebrek aan gestandardiseerde 
methoden en gebruik van verschillende technieken, beschreven al deze studies allen 
veelbelovende resultaten. In hoofdstuk dertien wordt de diagnostische waarde van faecale 
geurprofielen beschreven voor de detectie en monitoring van CRC en adenomen, waarbij 
gebruik is gemaakt van onze gestandardiseerde methodologie. In deze studie wordt gebruik 
gemaakt van patroon-herkenning met een geavanceerde electronische neus, een GC-IMS 
systeem. Op basis van de geurprofielen worden patiënten met CRC, voorloper adenomen, 
grote goedaardige adenomen en kleine adenomen met hoge accuratesse gekarakteriseerd 
313
en onderscheiden van gezonde controles. Daarnaast wordt beschreven dat de faecale 
geurprofielen van patiënten met adenomen die een radicale poliepectomie ondergaan, 
3 maanden na het verwijderen van het adenoom een geurprofiel hebben dat gelijk is aan 
die van controlepatiënten terwijl de geurprofielen van controlepatiënten niet veranderen 
pre- en post endoscopie. Op basis van deze bevindingen kan gesuggereerd worden 
dat er een adenoom-specifiek geurprofiel bestaat, welke mogelijk gebruikt kan worden 
voor screening en surveillance doeleinden. Omdat de faecale bacteriële samenstelling 
deels gereflecteerd wordt door faecale VOC profielen, kan het zijn dat dit geassocieerde 
microbioom ten grondslag ligt aan de uitkomsten van hoofdstuk dertien. Eerdere studies 
hebben een associatie aangetoond tussen bacteriële dysbiose en poliep-geassocieerd 
weefsel / CRC. De causaliteit van deze associatie is tot op heden nog onduidelijk. Enerzijds 
kunnen de microbiële veranderingen carcinogenese in het colon stimuleren, anderzijds is 
het mogelijk dat specifieke bacteriën zich nestelen in het colon in de aanwezigheid van 
neoplastische laesies. Omdat in dit hoofdstuk wordt beschreven dat de faecale VOC 
profielen normaliseren na een radicale poliepverwijdering, is de suggestie gewekt dat het 
faecale microbiota tevens normaliseert. Op basis van deze bevinding kan gesuggereerd 
worden dat de microbiële dysbalans in de aanwezigheid van adenomen meer waarschijnlijk 
een resultaat is van de onderliggende adenoom-carcinoom reeks dan een oorzaak. Deze 
studie vormt de basis van de opvolgende twee hoofdstukken, waarin het metaboloom, 
proteoom en microbiota nader onderzocht worden. 
In hoofdstuk veertien wordt data van de faecale microbiota, het proteoom en de 
aminogrammen geintegreerd in een multi-centrum cohort van patienten met CRC, 
adenomen en controles zonder afwijkingen bij endoscopie. Potentiële biomarkers voor 
ziekte detectie worden gepresenteerd binnen elk van deze platforms. Daarnaast worden 
deze geselecteerde biomarkers gecombineerd tot potentiële ‘diagnostische panels’. Deze 
overschreiden de accuratesse van het huidige gebruikte FIT zowel voor de detectie van 
CRC patienten als van patienten met adenomen. Na validatie van deze zogenoemde 
panels zouden deze het bevolkingsonderzoek naar CRC kunnen verbeteren. Tevens 
worden nieuwe inzichten gepresenteerd betreffende de interactie tussen het humane 
metabolisme en het microbiota in de aanwezigheid van neoplastische lesies. Vergelijkbaar 
met eerdere literatuur worden markers gepresenteerd welke een associatie hebben met 
verhoogde bloed excretie en afbraak. Daarnaast presenteren we markers geassocieerd met 
een verhoogde inflammatoire status, verhoogde stress reactie en een vermindering van 
epitheliale integriteit. Associaties worden beschreven met zowel pro- als anticarcinogene 
microbiële taxa. 
In hoofdstuk vijftien onderzoeken we het adenoom-geassocieerde aminozuurprofiel en 
microbiota voorafgaand en na poliepectomie in een prospectief cohort van adenoma 
patienten en controle patiënten zonder afwijkingen bij endoscopie. Patiënten met adenomen 
werden onderscheiden van controles op zowel op basis van het aminozuurprofiel als op 
basis van de microbiota. Er werd een adenoom specifiek aminozuur profiel gevonden, dat 
na verwijderen van de adenomen terugkeerde naar de ‘normale staat’, terwijl de bacteriële 
samenstelling van de ontlasting onveranderd bleef na de interventie. De adenoom-specifieke 
aminozuren werden gecombineerd tot één biomarker panel waarvan de accuratesse die 
van de huidig gebruikte FIT test overschreedt. Gebaseerd op deze resultaten suggereren 
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we dat het faecale aminogram kan dienen als biomarker voor adenomen, waarbij de juiste 
timing van een surveillance endoscopie bepaald kan worden. Klinisch betekent dit een 
verbetering van de efficiëntie van het surveillance programma met een vermindering van 
onnodige coloscopiën, een vermindering van interval kanker en een verlaging van de 
zorgkosten. 
Concluderen, in deel IV van deze thesis presenteren we dat het gebruik en de integratie van 
verscheide omics platforms zoals het faecale VOC profiel, de microbiota, het metaboloom 
en proteoom van toegevoegde waarde kunnen zijn voor ons huidige bevolkingsonderzoek 
darmkanker en het surveillance programma post-poliectomie. Sommige van deze algoritmes 
zijn reeds intern gevalideerd. Voordat implementatie in de kliniek kan plaatsvinden moet 
externe validatie worden bewerkstelligt. Een doel voor de komst is daarom om een 
validatiecohort uit te rollen waarin niet alleen de huidige bevindingen gevalideerd kunnen 
worden, maar ook naast de huidige gouden standaard kan worden gelegd voor een gedegen 
kosten-baten analyse. Na validatie kan de implementatie van deze nieuwe biomarkers een 
verbetering van zowel het screening als het surveillance programma opleveren, met een 
vermindering vsan onnodige coloscopiën, een vermindering van interval kanker en een 
verlaging van de zorgkosten.
Toekomstperspectief
Faecale metabole eindproducten hebben de potentie om gebruikt te worden als gastro-
intestinale biomarkers, zo is duidelijk geworden uit de studies in dit proefschrift. Zowel 
voor het diagnosticeren als voor vervolgen van darmziekten. Zowel voor inflammatoir 
darmlijden als voor colorectaal kanker en zijn voorloper poliepen. Echter zijn er een aantal 
voorwaarden waaraan deze biomarkers moeten voldoen, voordat dit kan resulteren in 
een gebruiksklare, klinische test. Ten eerste moeten de ontwikkelde algoritmes uit dit 
proefschrift ofwel nog intern en extern, ofwel alleen extern gevalideerd worden. Ten 
tweede, om een screeningtest of surveillancetest grootschalig te kunnen implementeren 
zijn er een aantal karakteristieken vereist. Zo moeten de uitkomsten van een test stabiel zijn, 
ongeacht de omgevingsomstandigheden. Daarnaast moet een test kosteneffectief zijn en 
is de mogelijkheid om materiaal per post te versturen een pre- bij het verwerken van grote 
hoeveelheden monsters. 
Met het oog op de omics strategieën in deze huidige thesis, is met name de stabiliteit van 
de eiwitspectra reeds aangetoond. Transport, opslagtemperatuur en voedselinname lijken 
geen effect te hebben op de uitkomsten van deze test. Deze omgevingsfactoren zijn wel 
van invloed op de bacteriële samenstelling van de ontlasting. Belangrijk is daarom om te 
onderzoeken of deze factoren een invloed hebben op de specifieke bacteriële stammen 
die als biomarker kunnen dienen voor de beoogde aandoening. Omdat verscheidene 
studies naar het colorectaal kanker-geassocieerde microbiota dezelfde bacteriële stammen 
aanwijzen, lijkt een verschil in dieet en transportwijze geen grote invloed te hebben. Wel 
is aangetoond dat een bewaartemperatuur van -80 graden nodig is, om de bacteriële 
samenstelling betrouwbaar te kunnen meten. Een grote hoeveelheid materiaal per 
post versturen is hierdoor niet mogelijk. Aminozuur profielen hebben in tegenstelling 
tot de hiervoor benoemde methoden relatief zeer lage kosten. Hiermee lijken faecale 
aminozuurprofielen geschikt om te fungeren als diagnosticum. Echter, deze strategie staat 
315
nog in de kinderschoenen van biomarker exploratie en robuustheid van uitkomsten moet 
nog onderzocht worden. 
Een nadeel van bovengenoemde metaboliet-specifieke analytische platforms is dat de 
materiaal voorbereiding en metingen relatief veel tijd kosten, de techniek kostbaar is 
en speciaal getrainde laboranten nodig zijn voor het analyseren van het materiaal. De 
elektronische neus techniek kan dit soort limitaties ondervangen. Nadat een diagnostisch 
algoritme is ontwikkeld, kunnen metingen binnen enkele minuten worden gedaan, zonder 
dat het faecale materiaal voorbereid hoeft te worden voor de analyse. Daarnaast kan 
patroonherkenning voordeliger zijn voor diagnostische doeleinden omdat de metingen 
makkelijk uitvoerbaar zijn, er grote hoeveelheden in een keer gemeten kunnen worden 
en de analyses relatief goedkoop zijn. Toch zijn faecale VOC profielen voor diagnostische 
doeleinden nog niet klaar voor klinisch gebruik. Door het toepassen van de vele verschillende 
technieken zijn de voor- en nadelen van eNose technologie onderzocht, maar wordt de 
mogelijkheid om verschillende studies van verschillende onderzoeksgroepen met elkaar 
te vergelijken bemoeilijkt. Daarnaast zijn veranderingen in VOC profielen aangetoond 
bij sensor variaties, leefstijl variaties en het gebruik van verschillende studieprotocollen. 
Samenwerking om tot standaardisatie van de methodologie en gebruikte eNose techniek 
te komen, zou daarom prioriteit moeten hebben bij toekomstige studies. 
Gebaseerd op ‘machine-learning’ hebben we in deze thesis een aantal VOC algoritmes 
getoond, specifiek voor de detectie van IBD, CRC en poliepen. De accuratesse van deze 
algoritmes verbetert naarmate er een groter aantal ontlastingsmonsters gemeten wordt. 
Zodra een algoritme voldoende accuratesse bereikt, kan deze gevalideerd worden in een 
extern cohort van patiënten, naast de huidige gouden standaard, om een kosten-baten 
analyse op te maken. Het apparaat en bijbehorende ziekte-specifieke algoritme kan daarna 
worden geïmplementeerd als klinische tool, zowel voor screening als voor surveillance. Voor 
het uitvoeren van bevolkingsonderzoek zou het voordelig zijn om het ontlastingsmateriaal 
te verzamelen op centrale punten in Nederland. De kans op specifieke ziekten kan dan 
berekend worden aan de hand van de ziekte-specifieke algoritmen. Voor kleinere patiënt 
aantallen kan een kleinere en gebruiksvriendelijkere eNose gekozen worden welke ‘aan het 
bed’ ingezet kan worden. Echter, voor deze kleinere eNose apparaten moet de sensor drift in 
de gaten worden gehouden en moet er een goede, gestandaardiseerde correctiemethode 
ontwikkeld worden alvorens betrouwbare algoritmes kunnen worden ontwikkeld. 
Het berekenen van een goede kosten-baten analyse is moeilijk in deze vroege fase van 
biomarker exploratie. Gerichte metingen kunnen ontwikkeld worden voor metaboliet-
specifieke technieken wanneer bepaald is welke metabolieten interessant zijn. Grote 
hoeveelheden metingen kunnen de kosten van een techniek drastisch veranderen. Een 
verbeterde accuratesse van een test kan de kosten voor de gezondheidszorg op de lange 
termijn verminderen. Deze factoren zullen allemaal van invloed zijn op de uiteindelijke 
waarde van een nieuwe biomarker. Om een goede vergelijking van de diagnostische 
waarde te maken is het van belang de geselecteerde biomarkers en algoritmes tezamen te 
valideren in een nieuwe dataset en te vergelijken met de huidige gouden standaard. Op 
deze manier kan (een combinatie van) de beste biomarker(s) gekozen worden voor verdere 




In deze thesis wordt de potentiële waarde getoond van faecale VOC profielen voor 
de detectie van inflammatoir darmlijden en het voorspellen van veranderingen in het 
ziektebeloop. Daarnaast wordt getoond dat faecale VOC profielen waardevol kunnen zijn 
voor de detectie van colorectaal kanker en wordt de patroonherkenning voorgesteld als 
techniek voor het bepalen van de surveillance timing na het verwijderen van poliepen. 
We beschrijven dat verscheidene omics platforms gecombineerd kunnen worden om 
de diagnostische accuratesse voor de detectie van colorectaal kanker en poliepen te 
verbeteren. In de toekomst zullen studies zich moeten focussen op een aantal aspecten: de 
standaardisatie van VOC metingen, robuustheid van aminozuur metingen, een prospectieve 
gezamenlijke validatie van de biomarkers en algoritmes gecombineerd met de huidige 
gouden standaard en een kosten/baten analyse. Op deze manier kunnen de beste 
biomarker(s) en/of algoritmes geselecteerd worden voor de verbetering van ziekte detectie 
en monitoring, wat leidt tot vroegere behandelingen, een verminderd aantal complicaties, 
operaties, ziekenhuisopnames en uiteindelijk morbiditeit.
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DANKWOORD
Zo. En toen was het opeens al tijd om het dankwoord te schrijven. Het idee was om hier eens 
rustig de tijd voor te nemen vanuit een ligstoel in een vissersdorpje van Cù Lao Chàm, een 
duikeilandje gelegen aan de Oostkust van Vietnam. De coronacrisis gooide (gelukkig wel 
net op tijd) roet in het eten, waardoor dit deel nu geschreven wordt vanaf een balkonnetje 
gelegen aan de Oostkant van Amsterdam. Omdat het glas altijd half vol is zal ik dan 
maar zeggen dat deze quarantaine in ieder geval genoeg tijd geeft voor reflectie. Tijdens 
de opleiding geneeskunde werd ik, in tegenstelling tot veel van mijn medestudenten, 
nogal enthousiast van de blokken biostatistiek. Niemand in mijn omgeving was dan ook 
verrast dat ik direct voor een onderzoeksplek wilde solliciteren na het afronden van mijn 
studie. Inmiddels heb ik drie jaar en zes maanden aan dit proefschrift gewerkt en kan ik 
met zekerheid zeggen dat ik er iedere dag ontzettend van heb genoten. Van dwars door 
Nederland rijden in de poepmobiel om mensen thuis te verlossen van het bruine goedje 
in hun vriezer tot het heerlijke gevoel als je eindeloos verzamelde studie resultaten bij 
elkaar komen in een manuscript (en dat hetgeen wat je had verzonnen ook nog eens lijkt 
te werken), het was me allemaal een genoegen. Ondanks dat dit boek op mijn naam staat 
kan ik de eer voor al deze ideeën en resultaten zeker niet in mijn eentje opstrijken. Zonder 
de hulp van alle patiënten die welwillend waren om hun ontlasting af te staan voor deze, 
toch wat afwijkende, hypotheses, was dit proefschrift nooit tot stand gekomen. Daarnaast 
wil ik graag iedereen in mijn omgeving bedanken die een steentje heeft bijgedragen aan 
het ontstaan van dit proefschrift: mijn promotor, copromotor, collega’s, vrienden en familie.
Ten eerste wil ik mijn promotor, Nanne de Boer, bedanken voor de kans die je me gaf om 
dit promotietraject op te pakken. Ik kan mij ons eerste gesprek nog vrij levendig herinneren. 
Ik was halsoverkop naar het VUmc gefietst omdat ik had vernomen dat er een eNose 
onderzoeksplek vrij was genomen. Zonder spatbord en daarom onder de modder arriveerde 
ik bij Chris, die mij direct doorstuurde voor een audiëntie bij jou. Dat viel niet tegen. In een 
mum van tijd was de stress weg, de sfeer goed en wist je me te enthousiasmeren over de 
geurprofielen van je zogenoemde bruine goud. En zo ging het eigenlijk ook de rest van 
mijn promotietraject. Jouw enthousiasme is altijd aanwezig geweest als ik weer met een 
nieuw voorstel voor een studie je kamer binnen stapte. Je hebt me altijd gestimuleerd 
om deze ideeën van de grond te krijgen. Ik ben er trots op dat ik dit proefschrift mag 
verdedigen met jou als mijn promotor en hoop dan ook dat ik in de toekomst nog steeds 
veel van je mag leren, zowel op wetenschappelijk als op klinisch vlak. Ik durf wel te stellen 
dat ik mijn MDL carrière grotendeels aan jou te danken heb. Jij hebt écht je uiterste best 
gedaan om mij te helpen waar nodig en waar mogelijk, en dat heeft ertoe geleid dat ik een 
fantastische PhD-tijd heb gehad. 
Mijn copromotor, Tim de Meij, ook jij hebt me tijdens mijn promotietraject steeds weer 
geënthousiasmeerd om nieuwe ideeën uit te werken en met jouw goede gevoel voor taal 
werd het woordaantal van menigeen manuscript ineens gehalveerd (had je misschien ook 
even bij dit dankwoord kunnen doen). Ik begrijp niet hoe jij het doet met al die promovendi, 
wetenschappelijke stagestudenten, patiënten, ouders én een telefoon die ongeveer iedere 
3 minuten af gaat, maar op de een of andere manier is er bij jou altijd nog wel even tijd 
voor een koffietje om mee te denken over een studie of om de laatste levensplannen te 
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bespreken. Ik heb dat altijd heel erg op prijs gesteld. Veel dank hiervoor. Onderzoek doen 
onder het toeziend oog van jou en Nanne gaat gepaard met een hoop gezelligheid en 
veel humor. De onderzoeksbesprekingen op vrijdagmiddag waar de standaard grappen op 
Bassie-en-Adriaanse wijze werden herhaald, waardoor we steeds om 5 voor 5 aanvingen met 
de daadwerkelijke stand van zaken, waren een wekelijks hoogtepunt. Ook de weekendjes 
Birmingham met als topper de karaoketent en als dieptepunt de treinrit naar Coventry 
zullen me altijd bijblijven, alsmede jouw gezichtsuitdrukking bij het zien van het bed dat ik 
jou en Nanne had gereserveerd.  
Dear members of the reading committee, dear prof. dr. Dekker, prof. dr. Arasaradnam, prof. 
dr. Bouma, prof. dr. Weersma, prof. dr. Sterk and prof. dr. van Rheenen. I would like to thank 
you for your willingness to read and evaluate this thesis. 
De bewaking over het koud houden van de faecescontainers heb ik te danken aan alle 
medewerksters van de frontdesk, Nelleke, Patty, Anne, Anna, Debby, Natasha, Mariam, 
Georgette, Carolina, Jennifer en Nasrin. Van een losse bolus in een zakje tot een compleet 
ingevroren potje in een fles cola, de ingeleverde faecescontainers moesten altijd per direct 
van balie naar vriezer en ik besef me dat dit niet altijd de schoonste klus is geweest voor 
jullie. Dank hiervoor. 
Jessica en Cynthia, bedankt voor al jullie hulp bij het verwerken van alle bestellingen, 
facturen, verzendingen en contracten (het waren er best wel veel), mapjes die het niet 
deden, spoedaanvragen en ga zo maar door. De MDL-afdeling heeft twee organisatorische 
toppers aan jullie en ik hoop jullie dan ook weer tegen te komen tijdens het UMC-deel van 
de MDL opleiding.
De verzameling van alle samples en de patiëntinclusies zijn mede gelukt door de inzet 
van alle wetenschappelijke stage studenten. Roy, Eva, Jesse, Rianne, Edo, Mehdjebien, 
Ibhrahim en Marina, hartstikke bedankt voor alle hulp en moeite. 
Ook aan alle co-auteurs heel veel dank voor alle hulp en input bij de studies uit dit 
manuscript. Gerd, René, Johan, Pieter, Maarten, Marc, dank voor de hulp en mogelijkheid 
om alle 1000+ patiënten bij jullie te includeren, voor het scoren van de endoscopie beelden 
en voor de kritische reviews van de manuscripten. Renée Menezes, veel dank voor alle hulp 
bij de statistiek van de Cyranose metingen. Eduard, wat per toeval begon bij de beoordeling 
van het stageverslag van Roy, eindigde in een heuse faecale aminozuren onderzoekslijn. 
Heel veel dank voor het vertrouwen en het openstellen van het laboratorium. Ik heb goede 
hoop dat we elkaar in de toekomst weer gaan tegenkomen! Ook Abdellatif en Erwin, veel 
dank voor jullie hulp bij het maken van de protocollen, het verrichten van de metingen en 
het analyseren van de resultaten. Marieke, dank voor de fijne samenwerking in het MUMC+. 
De treinritjes naar Maastricht in de vroege uurtjes, om vervolgens uren met Dion in de 
zuurkast te zitten om poepsamples te hakken zal ik niet gauw meer vergeten. Dion, jij tilde 
het poepscheppen naar een geheel nieuw niveau waarna woorden als de plokkelaar en de 
bungeejumper nooit meer hetzelfde zullen zijn. Connie en Irene, jullie moet ik natuurlijk ook 
bedanken voor jullie hulp en input bij het verrichten van de proteomics metingen voor de 
laatste stukken van dit proefschrift.
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Dear co-authors from the other side of the canal, thank you all for your input, help, hard 
work and critical review of the studies we have performed together! James, Andrew and 
George, thank you all  for the opportunity to work in your laboratories. All visits truly have 
been pleasant and educational experiences. Emma, thank you for helping me with all those 
stinky samples. Alfian, a lot of thank for all the last minute figures, night work on extra 
comparisons and skype meetings to figure out whether we are talking about the same 
thing. Siavash, Sam, Akira, Reece, thank you for the warm welcome at the lab! Nabil, thank 
you for teaching me how to do prepare the samples for the 16S RNA sequence and helping 
me along the way with this project. Animesh, thank you so much for all of the scheduled and 
unscheduled meetings and for having the patience to explain the statistical methods step 
by step to me. I have never met anyone so enthusiastic and motivated and it is contagious! 
Patricia, thank you for helping out with the microbial statistics. 
Daarnaast wil ik de Maag Lever Darm Stichting en het KNGF Geleidenhonden bedanken 
voor de fijne samenwerking. 
Beste MDL collega’s, zowel staf als AIOS, dank jullie voor al jullie hulp en inzet voor de 
studies uit dit proefschrift en voor de fijne samenwerking op de MDL poli. Speciale dank 
aan Chris Mulder, omdat je me naar Engeland hebt verwezen voor mijn keuzestage, waar 
ik niet alleen een fantastische en leerzame tijd heb gehad, maar waar ook de grondslag ligt 
van een heel aantal samenwerkingen waaruit dit proefschrift is ontstaan. 
Collega’s van de MDL- en kinderMDL-onderzoekskamers. Nora, jou moet ik natuurlijk 
bedanken voor de timing van je appje voor deze baan en voor de ongelofelijk goed 
georganiseerde overdracht. Daan, jij was al ver op weg met je promotietraject toen ik 
aansloot bij de eNose groep en was al helemaal ingeburgerd in de kunst van het opa&opa 
belachelijk maken. Met een goede portie zelfspot, een uitstekende Engelse tongval, een 
tamelijk sceptische kijk op het leven en een groot verlangen om presentaties te geven op 
congressen bracht jij jouw promotietraject tot een prachtig eind. Ik zal aan je denken als ik 
ook met zichtbare palpitaties sta te wachten tot ik mag verdedigen. Sofia, ik had de eer om 
jouw wetenschappelijke stage te begeleiden waarbij je fanatiek begon met poepsnuffelen 
en inmiddels heb je mij geloof ik ingehaald met je promotietraject. Respect voor jouw 
buffeltempo! Ik ben blij dat wij collega’s zijn geworden en hoop dat we in de toekomst nog 
vaker mensen mogen verwarren met onze samenwerkingen. Elsa, we hebben elkaar helaas 
nog niet veel kunnen zien in het ziekenhuis vanwege de corona-toestanden maar ik wens je 
veel plezier en succes toe in het eNose team! Margreet, dank voor je vrolijke aanwezigheid 
en luisterend oor. Inge, hartstikke bedankt voor je hulp bij de soms onbegrijpelijke logistiek 
van het regelen van contracten en facturen. Louis, wat een taak heb jij gehad om het 
testosteron in de onderzoekskamer te vertegenwoordigen! Dank voor je nuchterheid, je 
toeziend ook op de privacyreglementen en natuurlijk voor de droppastilles. Petra, bedankt 
voor jouw bijdrage aan alle IBD studies, uitleg over Epic en het onderhoud van de kamer. 
Jij bent absoluut onmisbaar bij de IBD-zorg van de afdeling. Renee, deel 1 van de terrible 
triad, dankjewel voor het warme welkom in de onderzoeksgroep, de vele ijsjes met 
spikkels, de koffietjes van beneden, de avonturen in kinderland, de fantastische feestjes, de 
aanmoediging tijdens de sollicitaties en het gezellige weekendje in Birmingham. Maxine, 
deel 2 van de terrible triad, jij ook bedankt voor al het voorgaande met toevoeging van je 
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heerlijke kookkunsten, het bieden van een thuiswerkplek en alle wijntjes en borrelplankjes 
in de zon. Onze samenwerking is uitgegroeid tot een fijne vriendschap waar ik veel waarde 
aan hecht. De uitspraak ‘de eerste pannenkoek mislukt altijd’ zal ik nog vaak gebruiken. 
Berrie, jij staat áltijd klaar om goed advies of hulp te geven en om je gerust te stellen 
als dat nodig is. Zowel in het VUmc als in Alkmaar wist jij me altijd weer even met beide 
voeten op de grond te parkeren als ik het even niet meer wist. Heel erg veel dank hiervoor. 
Melek, laten we snel weer een tripje naar een congres doen met een hostelovernachting 
er achteraan geplakt, dat was echt een groot succes. Yvette, Tom, met jullie heb ik niet 
lang samengewerkt maar heel veel dank voor al jullie wijze adviezen. Floris, dank voor het 
creëren van het leukste oppaskind ooit. Paul, die Engelse curry komt nog een keer, beloofd! 
Roog, hopelijk zijn we nog niet uitgebakkeleid of het nut van het microbioom (ik hoor je nu 
al OTA roepen). Tess en Sara, pendelend tussen de afdelingen maar altijd gezellig als jullie 
er waren! Tess, wat een ontzettende dijk van een follow-up cohort, ik zal mijn best doen op 
inclusies komende tijd. Floor, ik kom graag nog een keer voor die chips-dipsaus bij je langs 
en Femke, heel veel succes de komende jaren!
Nog een speciale dank aan mijn nicht Tonnie, die direct in een labjas klaar stond toen mijn 
poephak schema wat krap begon te worden en die haar huis beschikbaar heeft gesteld 
voor idiote projecten zoals ‘de geur uit het dopje van de faecescontainer koken’. Ook dank 
mijn neef Tim, die meteen een mini-studio van zijn appartement maakte en een filmpje in 
elkaar draaide toen een tijdschrift me vroeg een video-abstract in te dienen (ook voor de 
legendarische autocue, was niet te zien)!
 
In Juli van 2019 startte ik als ANIOS MDL in het NWZ in Alkmaar om alvast klinische ervaring 
op te doen voorafgaand aan de start van de opleiding. Michael, Thijs, Annemarie, Esmerij, 
Maria, Dimitri, Liesbeth, Willem, Emma, Dirk, Sietze, Sjoerd, Arnoud, Bas, Peter en Sabri, 
bij jullie heb ik mijn eerste kilometers gemaakt binnen de MDL, graag wil ik jullie bedanken 
voor de leuke en leerzame tijd. 
Dan wil ik graag een aantal van mijn vrienden bedanken. Allereerst: Eva. Super. Duper. De. 
Beste. Sinds het MFVU bestuursjaar zijn de ‘waar zijn we nu weer beland’ momenten al niet 
meer weg te denken. Of het nu in de Filipijnen, Indonesië of in Nederland is, ik hoop dat de 
oneindige lijst met vreemdsoortige activiteiten als brandnetels rood schilderen en 5-stemmig 
Harry Potter zingen blijft groeien. Dank aan de glitterpoezen, voor zo’n lieve vriendengroep, 
waarmee iedere dag een feestje is zowel in als buiten het ziekenhuis. Marjolein, dank voor 
je luisterend oor en eindeloze telefoontjes, ik oefen vast voor je verjaardag. Saskia aka 
Kakkie, dank voor je grappen die soms zo bot zijn dat ik mijn idealen maar direct overboord 
gooi als ik de deur binnen stap. Misschien kun je voor vanavond nog een aantal loempia’s 
bestellen. Nina, dank voor je eindeloze nuchterheid die deze chaos maar mooi bij elkaar 
houdt. Febe, dank voor je verrassende opmerkingen en bloembollencadeautjes, jij mag er 
zijn. Carolien, bedankt voor je jaarlijkse pie-pie en andere nerdengrapjes. 
Dit boek was er zeker niet geweest zonder Alwine. Een liftwedstrijd naar de Ardennen 
werd het begin van een ongekende band en heeft mij als persoon behoorlijk gevormd. Van 
Indonesië tot Nicaragua, van snowboarden tot diepzee duiken, het blijft een avontuur met 
jou en ik ben heel blij dat wij nog steeds af en toe samen mogen reizen. Ik ben je ontzettend 
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bij Eefje, als klein kuiken kwam ik aanzetten bij jullie vriendengroep waarin ik met open 
armen door je werd ontvangen. Heel erg veel dank voor je fantastische kookkunsten, de 
leuke feestjes, fijne gesprekken en je hulp bij het oefenen voor de opleidingssollicitaties. 
Dank aan Fleur, waaraan iedereen een voorbeeld kan nemen als het gaat om de kunst 
van het ‘volgen van je hart’. Ik hoop dat de muzikale uitlaatklep die jij me geeft nog vele 
jaren doorgaat. Hopelijk kom je nog vaak terug uit het verre Zuuje zodat we hier in het 
Amsterdamse weer kunnen genieten van je ambachtelijke zuurdesems. 
Jelle, dankjewel voor al onze avonturen. Onze reis in Marokko met als (letterlijk) hoogtepunt 
de klim naar de besneeuwde top van Mount Toubkal (4100m) in spijkerbroek (min 17 
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huurwandelschoen zal me altijd bij blijven. Al zijn de koppel-hammam en kamelenrace toch 
ook moeilijk te vergeten. 
Hannelies, ik begin steeds meer argwaan te krijgen over die combinatiebestellingstactiek. 
Hopelijk gaan onze sportsessies nog lang door (die coronakilo’s moeten er toch echt weer 
af)!
Luce, thank you for showing me that Coventry is just as fun outside the engineering 
laboratory as it is inside. I wouldn’t want to have missed that Lady Godiva statue for the 
world. Dank aan mijn co-groep, Jiska, Carmen, Coco, Jennifer en Tishelle – aan het zebra 
thema zal ik nooit wennen maar het totale kippenhok tijdens de winterweekendjes doen 
me altijd goed. 
Dan hebben we nog Nusman. Elloelloello. Mijn hospitalwifey (sorry Roos). Het beste 
dienstblok ooit heb ik dus nu al gehad, en het blok aftoppen met een publicatie en pils ga 
ik niet meer vergeten. Als ‘ie nog op tijd geaccepteerd wordt beloof ik dat ik hem ongezien 
als supplement in dit boekje schuif. En Roos, jouw blije triatlonkoppie was dé reden dat ik 
daar het jaar erna stond (weliswaar niet voor zo een buffelafstand als jij) maar wat ben ik blij 
dat we samen konden ‘trainen’. Dankjewel voor de fijne gesprekken en dankjewel dat jullie 
deur altijd wagenwijd openstaat! Wordt zeer gewaardeerd.
Isabelle en Jennifer, jullie gaan al zo lang mee! Bedankt dat jullie er nog steeds zijn (Isabelle 
het wordt nu toch wel echt tijd om de wisseltrofee door te geven, mijn suggestie is om deze 
aan mij te overhandigen tijdens het promotiefeest). 
To Jenny and Dion, thank you for giving me the best start in Birmingham I could have wished for. 
The (accidental) changes in my internship upon arrival at the QE have led to half of this book! 
To Shri, my interest in ERCPs was already existing when I arrived in the UK, but thanks to 
you this has now become an end-goal (pre-cut! pre-cut!). Thank you for all the good hospital 
and non-hospital related conversations. Your endless curiosity, optimism and faith in people 
are things to look up to. Trish, thank you for the warm welcome into your family, for making 
me familiar with the phenomena ‘banoffee’ and ‘sticky toffee pudding’ and for making me 
feel at home in Birmingham. I really appreciate all the things I have learnt from you and your 
family. To Tara and Nasen, thank you for allowing me into the house as your temporary Dutch 
sister and for playing difficult Irish games with me even though I don’t understand them. 
Dan nog mijn eigen familie. Oma, dankjewel voor alle oude studieboeken van opa die 
je me hebt gegeven. Het is jammer dat ik niet op tijd was om hem nog al mijn medische 
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vragen te kunnen stellen, maar de boeken gebruik ik nog bijna iedere dag. Lieve Julie, 
mijn grote zus. Wie ons heeft zien ruziën als pubers voor de spiegel in de badkamer had 
niet kunnen bedenken hóe onmisbaar je zou worden voor mij. Ik ben heel trots op de kaft 
van mijn proefschrift en dat komt vooral omdat jij die zelf hebt gemaakt. Ik ben blij dat jij 
ook tijdens de verdediging van dit boekje naast mij wilt staan (meer waarschijnlijk is zitten 
met die +1). Mam, Pap en Cathy. Het zal jullie na mijn veel te enthousiaste spreekbeurt 
over poep in groep 7 niet verrast hebben dat ik besloot te gaan promoveren op ditzelfde 
onderwerp. De leus ‘alles wat je wil bereiken kan, als je het maar graag genoeg wilt’ is me 
met de paplepel ingegoten en heeft zeker een bijdrage geleverd aan het ontstaan van dit 
proefschrift. Dank jullie wel voor alle steun en zekerheid die ik altijd heb gekregen om te 
gaan voor wat ik wilde bereiken.
En last but not least, my Lydia from the Bakery, Diewertje, ik hou van jou.
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